
<html lang="en"     class="pb-page"  data-request-id="479f186f-dfb2-41f4-8685-690fb195f601"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b01295;issue:issue:10.1021/jmcmar.2019.62.issue-24;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)" /></meta><meta name="dc.Creator" content="Richard A.  Ward" /></meta><meta name="dc.Creator" content="Mark J.  Anderton" /></meta><meta name="dc.Creator" content="Paul  Bethel" /></meta><meta name="dc.Creator" content="Jason  Breed" /></meta><meta name="dc.Creator" content="Calum  Cook" /></meta><meta name="dc.Creator" content="Emma J.  Davies" /></meta><meta name="dc.Creator" content="Andrew  Dobson" /></meta><meta name="dc.Creator" content="Zhiqiang  Dong" /></meta><meta name="dc.Creator" content="Gary  Fairley" /></meta><meta name="dc.Creator" content="Paul  Farrington" /></meta><meta name="dc.Creator" content="Lyman  Feron" /></meta><meta name="dc.Creator" content="Vikki  Flemington" /></meta><meta name="dc.Creator" content="Francis D.  Gibbons" /></meta><meta name="dc.Creator" content="Mark A.  Graham" /></meta><meta name="dc.Creator" content="Ryan  Greenwood" /></meta><meta name="dc.Creator" content="Lyndsey  Hanson" /></meta><meta name="dc.Creator" content="Philip  Hopcroft" /></meta><meta name="dc.Creator" content="Rachel  Howells" /></meta><meta name="dc.Creator" content="Julian  Hudson" /></meta><meta name="dc.Creator" content="Michael  James" /></meta><meta name="dc.Creator" content="Clifford D.  Jones" /></meta><meta name="dc.Creator" content="Christopher R.  Jones" /></meta><meta name="dc.Creator" content="Yongchao  Li" /></meta><meta name="dc.Creator" content="Scott  Lamont" /></meta><meta name="dc.Creator" content="Richard  Lewis" /></meta><meta name="dc.Creator" content="Nicola  Lindsay" /></meta><meta name="dc.Creator" content="James  McCabe" /></meta><meta name="dc.Creator" content="Thomas  McGuire" /></meta><meta name="dc.Creator" content="Philip  Rawlins" /></meta><meta name="dc.Creator" content="Karen  Roberts" /></meta><meta name="dc.Creator" content="Linda  Sandin" /></meta><meta name="dc.Creator" content="Iain  Simpson" /></meta><meta name="dc.Creator" content="Steve  Swallow" /></meta><meta name="dc.Creator" content="Jia  Tang" /></meta><meta name="dc.Creator" content="Gary  Tomkinson" /></meta><meta name="dc.Creator" content="Michael  Tonge" /></meta><meta name="dc.Creator" content="Zhenhua  Wang" /></meta><meta name="dc.Creator" content="Baochang  Zhai" /></meta><meta name="dc.Description" content="The RAS/MAPK pathway is a major driver of oncogenesis and is dysregulated in approximately 30% of human cancers, primarily by mutations in the BRAF or RAS genes. The extracellular-signal-regulated ..." /></meta><meta name="Description" content="The RAS/MAPK pathway is a major driver of oncogenesis and is dysregulated in approximately 30% of human cancers, primarily by mutations in the BRAF or RAS genes. The extracellular-signal-regulated ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 11, 2019" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01295" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01295" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01295" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01295" /></link>
        
    
    

<title>Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01295" /></meta><meta property="og:title" content="Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0013.jpeg" /></meta><meta property="og:description" content="The RAS/MAPK pathway is a major driver of oncogenesis and is dysregulated in approximately 30% of human cancers, primarily by mutations in the BRAF or RAS genes. The extracellular-signal-regulated kinases (ERK1 and ERK2) serve as central nodes within this pathway. The feasibility of targeting the RAS/MAPK pathway has been demonstrated by the clinical responses observed through the use of BRAF and MEK inhibitors in BRAF V600E/K metastatic melanoma; however, resistance frequently develops. Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors, where RAS/MAPK pathway reactivation has occurred, such as relapsed BRAF V600E/K melanoma. We describe our structure-based design approach leading to the discovery of AZD0364, a potent and selective inhibitor of ERK1 and ERK2. AZD0364 exhibits high cellular potency (IC50 = 6 nM) as well as excellent physicochemical and absorption, distribution, metabolism, and excretion (ADME) properties and has demonstrated encouraging antitumor activity in preclinical models." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01295"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01295">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01295&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01295&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01295&amp;href=/doi/10.1021/acs.jmedchem.9b01295" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 11004-11018</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00885" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.9b01753" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Richard A. Ward</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard A. Ward</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#92e0fbf1faf3e0f6bcf3bce5f3e0f6d2f3e1e6e0f3e8f7fcf7f1f3bcf1fdff"><span class="__cf_email__" data-cfemail="cab8a3a9a2abb8aee4abe4bdabb8ae8aabb9beb8abb0afa4afa9abe4a9a5a7">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+A.++Ward">Richard A. Ward</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2310-9477" title="Orcid link">http://orcid.org/0000-0002-2310-9477</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark J. Anderton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark J. Anderton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+J.++Anderton">Mark J. Anderton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Bethel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Bethel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Bethel">Paul Bethel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason Breed</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason Breed</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Breed">Jason Breed</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Calum Cook</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Calum Cook</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Calum++Cook">Calum Cook</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emma J. Davies</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emma J. Davies</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emma+J.++Davies">Emma J. Davies</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew Dobson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew Dobson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Dobson">Andrew Dobson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhiqiang Dong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiqiang Dong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiqiang++Dong">Zhiqiang Dong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gary Fairley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gary Fairley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gary++Fairley">Gary Fairley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Farrington</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Farrington</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Farrington">Paul Farrington</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lyman Feron</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lyman Feron</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lyman++Feron">Lyman Feron</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vikki Flemington</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vikki Flemington</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vikki++Flemington">Vikki Flemington</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Francis D. Gibbons</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francis D. Gibbons</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">DMPK, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francis+D.++Gibbons">Francis D. Gibbons</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark A. Graham</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark A. Graham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Graham">Mark A. Graham</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ryan Greenwood</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ryan Greenwood</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ryan++Greenwood">Ryan Greenwood</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lyndsey Hanson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lyndsey Hanson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lyndsey++Hanson">Lyndsey Hanson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philip Hopcroft</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip Hopcroft</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Hopcroft">Philip Hopcroft</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rachel Howells</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rachel Howells</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rachel++Howells">Rachel Howells</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julian Hudson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julian Hudson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</div><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div><div class="loa-info-affiliations-info">DMPK, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</div><div class="loa-info-affiliations-info">Medicinal Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julian++Hudson">Julian Hudson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael James</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael James</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</div><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div><div class="loa-info-affiliations-info">DMPK, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</div><div class="loa-info-affiliations-info">Medicinal Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++James">Michael James</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Clifford D. Jones</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Clifford D. Jones</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</div><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div><div class="loa-info-affiliations-info">DMPK, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</div><div class="loa-info-affiliations-info">Medicinal Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Clifford+D.++Jones">Clifford D. Jones</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher R. Jones</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher R. Jones</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</div><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div><div class="loa-info-affiliations-info">DMPK, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</div><div class="loa-info-affiliations-info">Medicinal Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+R.++Jones">Christopher R. Jones</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yongchao Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongchao Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongchao++Li">Yongchao Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott Lamont</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott Lamont</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Lamont">Scott Lamont</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Lewis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Lewis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Lewis">Richard Lewis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicola Lindsay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicola Lindsay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicola++Lindsay">Nicola Lindsay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James McCabe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James McCabe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++McCabe">James McCabe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas McGuire</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas McGuire</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++McGuire">Thomas McGuire</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philip Rawlins</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip Rawlins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Rawlins">Philip Rawlins</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karen Roberts</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen Roberts</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Roberts">Karen Roberts</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linda Sandin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linda Sandin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</div><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div><div class="loa-info-affiliations-info">DMPK, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</div><div class="loa-info-affiliations-info">Medicinal Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linda++Sandin">Linda Sandin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Iain Simpson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Iain Simpson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div><div class="loa-info-affiliations-info">Bioscience, Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</div><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div><div class="loa-info-affiliations-info">DMPK, Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</div><div class="loa-info-affiliations-info">Medicinal Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Iain++Simpson">Iain Simpson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steve Swallow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steve Swallow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Swallow">Steve Swallow</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jia Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jia Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Tang">Jia Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gary Tomkinson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gary Tomkinson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10 2NA, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gary++Tomkinson">Gary Tomkinson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Tonge</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Tonge</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Tonge">Michael Tonge</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhenhua Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenhua Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenhua++Wang">Zhenhua Wang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Baochang Zhai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Baochang Zhai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Baochang++Zhai">Baochang Zhai</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01295&amp;href=/doi/10.1021%2Facs.jmedchem.9b01295" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 11004–11018</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 11, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 August 2019</li><li><span class="item_label"><b>Published</b> online</span>11 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 December 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01295" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01295</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11004%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRichard%2BA.%2BWard%252C%2BMark%2BJ.%2BAnderton%252C%2BPaul%2BBethel%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D24%26contentID%3Dacs.jmedchem.9b01295%26title%3DDiscovery%2Bof%2Ba%2BPotent%2Band%2BSelective%2BOral%2BInhibitor%2Bof%2BERK1%252F2%2B%2528AZD0364%2529%2BThat%2BIs%2BEfficacious%2Bin%2BBoth%2BMonotherapy%2Band%2BCombination%2BTherapy%2Bin%2BModels%2Bof%2BNonsmall%2BCell%2BLung%2BCancer%2B%2528NSCLC%2529%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11018%26publicationDate%3DDecember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01295"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6222</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01295" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;A. Ward&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;J. Anderton&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Bethel&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Breed&quot;},{&quot;first_name&quot;:&quot;Calum&quot;,&quot;last_name&quot;:&quot;Cook&quot;},{&quot;first_name&quot;:&quot;Emma&quot;,&quot;last_name&quot;:&quot;J. Davies&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Dobson&quot;},{&quot;first_name&quot;:&quot;Zhiqiang&quot;,&quot;last_name&quot;:&quot;Dong&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;Fairley&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Farrington&quot;},{&quot;first_name&quot;:&quot;Lyman&quot;,&quot;last_name&quot;:&quot;Feron&quot;},{&quot;first_name&quot;:&quot;Vikki&quot;,&quot;last_name&quot;:&quot;Flemington&quot;},{&quot;first_name&quot;:&quot;Francis&quot;,&quot;last_name&quot;:&quot;D. Gibbons&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Graham&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;Greenwood&quot;},{&quot;first_name&quot;:&quot;Lyndsey&quot;,&quot;last_name&quot;:&quot;Hanson&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Hopcroft&quot;},{&quot;first_name&quot;:&quot;Rachel&quot;,&quot;last_name&quot;:&quot;Howells&quot;},{&quot;first_name&quot;:&quot;Julian&quot;,&quot;last_name&quot;:&quot;Hudson&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;James&quot;},{&quot;first_name&quot;:&quot;Clifford&quot;,&quot;last_name&quot;:&quot;D. Jones&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;R. Jones&quot;},{&quot;first_name&quot;:&quot;Yongchao&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Lamont&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Lewis&quot;},{&quot;first_name&quot;:&quot;Nicola&quot;,&quot;last_name&quot;:&quot;Lindsay&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;McCabe&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;McGuire&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Rawlins&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Roberts&quot;},{&quot;first_name&quot;:&quot;Linda&quot;,&quot;last_name&quot;:&quot;Sandin&quot;},{&quot;first_name&quot;:&quot;Iain&quot;,&quot;last_name&quot;:&quot;Simpson&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Swallow&quot;},{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;Tomkinson&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Tonge&quot;},{&quot;first_name&quot;:&quot;Zhenhua&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Baochang&quot;,&quot;last_name&quot;:&quot;Zhai&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;11004-11018&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01295&quot;},&quot;abstract&quot;:&quot;The RAS/MAPK pathway is a major driver of oncogenesis and is dysregulated in approximately 30% of human cancers, primarily by mutations in the BRAF or RAS genes. The extracellular-signal-regulated kinases (ERK1 and ERK2) serve as central nodes within this pathway. The feasibility of targeting the RAS/MAPK pathway has been demonstrated by the clinical responses observed through the use of BRAF and MEK inhibitors in BRAF V600E/K metastatic melanoma; however, resistance frequently develops. Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors, where RAS/MAPK pathway reactivation has occurred, such as relapsed BRAF V600E/K melanoma. We describe our structure-based design approach leading to the discovery of AZD0364, a potent and selective inhibitor of ERK1 and ERK2. AZD0364 exhibits high cellular potency (IC50 = 6 nM) as well as excellent physicochemical and absorption, distribution, metabolism, and excretion (ADME) properties and has demonstrated en&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01295&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01295" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01295&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01295" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01295&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01295" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01295&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01295&amp;href=/doi/10.1021/acs.jmedchem.9b01295" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01295" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01295" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01295%26sid%3Dliteratum%253Aachs%26pmid%3D31710489%26genre%3Darticle%26aulast%3DWard%26date%3D2019%26atitle%3DDiscovery%2Bof%2Ba%2BPotent%2Band%2BSelective%2BOral%2BInhibitor%2Bof%2BERK1%252F2%2B%2528AZD0364%2529%2BThat%2BIs%2BEfficacious%2Bin%2BBoth%2BMonotherapy%2Band%2BCombination%2BTherapy%2Bin%2BModels%2Bof%2BNonsmall%2BCell%2BLung%2BCancer%2B%2528NSCLC%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D24%26spage%3D11004%26epage%3D11018%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/jmcmar.2019.62.issue-24/20191226/jmcmar.2019.62.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The RAS/MAPK pathway is a major driver of oncogenesis and is dysregulated in approximately 30% of human cancers, primarily by mutations in the BRAF or RAS genes. The extracellular-signal-regulated kinases (ERK1 and ERK2) serve as central nodes within this pathway. The feasibility of targeting the RAS/MAPK pathway has been demonstrated by the clinical responses observed through the use of BRAF and MEK inhibitors in BRAF V600E/K metastatic melanoma; however, resistance frequently develops. Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors, where RAS/MAPK pathway reactivation has occurred, such as relapsed BRAF V600E/K melanoma. We describe our structure-based design approach leading to the discovery of AZD0364, a potent and selective inhibitor of ERK1 and ERK2. AZD0364 exhibits high cellular potency (IC<sub>50</sub> = 6 nM) as well as excellent physicochemical and absorption, distribution, metabolism, and excretion (ADME) properties and has demonstrated encouraging antitumor activity in preclinical models.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The MAPK (RAS/RAF/MEK/ERK) pathway has been intensively studied for many years and is known to play a key role in cell cycle progression, protein synthesis, differentiation, migration, survival, and senescence.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Receptor tyrosine kinases (RTKs), G-protein-coupled receptors (GPCRs), and cytokine receptors can activate the pathway, which subsequently causes the activation of KRAS, HRAS, and NRAS. When this pathway is activated, signals are transmitted downstream through the RAF family of kinases (BRAF, CRAF, and ARAF) and MEK1/2. Both ERK1 and ERK2 can be activated by MEK1 or MEK2 through phosphorylation of the T-E-Y motif in the kinase activation loop.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Due to its relative positioning on the MAPK pathway, both ERK1 and ERK2 control the output by activating their (numerous) nuclear and cytoplasmic substrates. There is a clear rationale for targeting this pathway by small molecule inhibitors, where a high frequency of mutations has been identified in diseases such as melanoma as well as thyroid and colorectal cancer.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In addition, members of the RAS family are mutated in colorectal, melanoma, and pancreatic tumors. Multiple drug approvals, such as vemurafenib and dabrafenib, have now been reported, which target the V600E mutation of BRAF.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> However, resistance to these treatments occur rapidly from MAPK pathway reactivation, and a combination approach of BRAF and MEK inhibitors (such as trametinib) is now commonly used in melanoma.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a></div><div class="NLM_p">As an additional potentially “druggable” target on the pathway, the direct inhibition of ERK1/2 may provide valuable therapeutic options for cancers driven by BRAF or RAS mutations. Alternatively, ERK1/2 inhibitors could provide an alternative treatment for patients who have progressed on RAF and or MEK inhibitor treatment due to pathway reactivation.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Such interest has resulted in a number of small molecule ERK1/2 inhibitors being reported in recent years (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), including <b>1</b> (SCH772984),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a><b>2</b> (SCH900353),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a><b>3</b> (ulixertinib/BVD-523),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a><b>4</b> (GDC-0994),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><b>5</b> (LY-3214996),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and <b>6</b> (CC-9003).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In addition, there are reports of ERK1/2 inhibitors being evaluated for clinical utility, where their chemical structures are yet to be disclosed, including examples from Novartis,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Kura Oncology,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Astex,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and Asana.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The identification of high-quality, potent, and selective inhibitors of ERK1/2 therefore continues to be an area of great interest for drug discovery efforts in oncology.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selection of published ERK1/2 inhibitors, <b>1</b> (SCH772984), <b>2</b> (SCH900353), <b>3</b> (ulixertinib/BVD-523), <b>4</b> (GDC-0994), <b>5</b> (LY-3214996), and <b>6</b> (CC-90003).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have previously reported the discovery of a novel, potent, and selective inhibitor of ERK1/2 (<b>7</b>), optimized from a promiscuous chemical start point informed by structure-based drug design.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> This inhibitor binds to the ATP pocket and is active via both inhibition of catalysis (IOC) and prevention of activation (POA) mechanisms and has demonstrated antitumor activity in preclinical models of cancer.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The IOC activity of ERK1/2 inhibitors can be measured by the impact on levels of phospho-RSK, and POA activity can be evaluated through changes in phospho-ERK. In this manuscript, we report on our efforts to further develop this series to a molecule with suitable properties for clinical candidate evaluation. Our primary design objectives were to increase the ERK1/2 potency while maintaining, or possibly improving, the kinase selectivity and ADME properties to enable a low predicted human dose.<named-content content-type="anchor" rid="tbl1" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Profile of Lead Compound (<b>7</b>)<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0010.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>7</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, <i>k</i><sub>M</sub> ATP IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="center"><0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, high ATP IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="center">0.0005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell MOA A375 pERK/pRSK IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="center">0.012/0.062</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility (μM)<a class="ref internalNav" href="#t1fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">>480</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity (<i>N</i> > 80% out of 128 kinase panel)<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">All IC<sub>50</sub> data are reported as μM and are the mean of at least three independent measurements.</p></div><div class="footnote" id="t1fn1"><sup><sup>b</sup></sup><p class="last">Distribution coefficient between 1-octanol and aqueous phosphate buffer at pH 7.4.</p></div><div class="footnote" id="t1fn2"><sup><sup>c</sup></sup><p class="last">Solubility of compounds in aqueous phosphate buffer at pH 7.4 after 24 h at 25 °C (μM).</p></div><div class="footnote" id="t1fn3"><sup><sup>d</sup></sup><p class="last">Kinase selectivity data measured at 1 μM compound concentration, two of these nine kinases were ERK1 and ERK2 with three being coupled assays with ERK (MEK1, BRAF, and CRAF).</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Scaffold Hopping</h3><div class="NLM_p">Having reported on the optimization of our early pyrololactam-based series and then the subsequent move to a pyrrolopyrazinone core, we decided to identify additional scaffolds which may enable us to improve target potency and provide potential for improved kinase selectivity. A selection of cores were evaluated using the quantum mechanical (QM) computational approach described in our previous manuscript to ensure that the appropriate binding mode conformation could be fulfilled with minimal energetic penalty. One addition was made to this protocol due to the observation that a methyl group on the 5-position of the pyrimidine consistently increased potency. Therefore, conformational calculations were also carried out with this substituent to understand if it was likely to be tolerated. The most interesting potential core from this analysis was the dihydroimidazopyrazinone core (<b>B</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), where the binding mode appeared to be more energetically favored over the 180° flipped conformation when compared to our previous pyrrolopyrazinone core (<b>A</b>). Using the higher level B3LYP/6-31G* basis set, it can be observed that the binding mode (at 0°) is favored by around 7–8 kcal/mol for the dihydroimidazopyrazinone (<b>B</b>) core, with little impact of the additional methyl group. This profile can be rationalized by a potential clash of lone pairs between the imidazole and pyrimidine groups in the higher energy conformation. In addition, the methyl group has a preference to be positioned adjacent to the imidazole, whereas it would be expected to be less complementary with the C–H in the alternative conformation. This compares to the pyrrolopyrazinone (<b>A</b>), where this difference was around 2 kcal/mol between the expected binding mode and the 180° flipped conformation.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. QM torsion profile of an alternative dihydroimidazopyrazinone ring system (<b>B</b>) compared to a pyrrolopyrazinone core (<b>A</b>) with and without a methyl group substituent. Gas phase energy reported in kcal/mol calculated in Jaguar (Maestro version 2016-1, Schrodinger) using a relaxed coordinate scan with PM3 and B3LYP/6-31G* basis sets. Binding mode consistent with 0° dihedral angle on these charts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to the energetic rationale above, we also speculated that the introduction of a hydrogen bond acceptor in this position on the core may enable an improved complementarity with the gatekeeper residue in ERK1/2 (Gln-105), which is rare across the kinome (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The binding mode of a selected example from our previous disclosure (<b>8</b>) shows how a key water molecule forms a bridge between the carbonyl group on the inhibitor (2.7 Å) and Gln-105 (3.5 Å). The distance between Gln-105 and the position of the introduced nitrogen on the core was expected to be around 4 Å using the 5NHP crystal structure as reference. Although the distance between this nitrogen on the core and Gln-105 is potentially too far for a direct interaction, it is possible that the inhibitor and or gatekeeper residue could move closer to each other if an appropriate interaction could be formed. Alternatively, and perhaps more likely, this change may modulate the existing water mediated interactions between ligand and the protein.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. ERK2 X-ray crystal structure of series exemplar (<b>8</b>) bound in ERK1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHP">5NHP</a>) highlighting the potential to target Gln-105.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In our previous scaffold hopping efforts, we initially synthesized a simplified version of novel cores for evaluation against our original pyrrololactam scaffold. However, in this case with greater confidence in our approach, we decided to initially synthesize more elaborated examples, using pyrrolopyrazinone <b>9</b> as a suitable reference molecule. Compound <b>10</b> proved to be an interesting lead molecule, as the biochemical and pRSK cell MOA activity was broadly comparable to <b>9</b>, but Log <i>D</i><sub>7.4</sub> was significantly reduced from 3.5 to 2.5. This modulation of Log <i>D</i><sub>7.4</sub> is consistent with the observed increase in aqueous solubility (112 versus 2 μM) and reduced human liver microsome (HLM) intrinsic clearance (CL<sub>nt</sub>) (13 versus 32 μL min<sup>–1</sup> mg<sup>–1</sup>). A particular attraction of this reduction in Log <i>D</i><sub>7.4</sub> was that it would enable the use of different SAR learnt on the original pyrololactam and pyrrolopyrazinone cores; in particular, SAR enabling increased potency, but which previously resulted in excessively high overall lipophilicity. Compound <b>10</b> also showed improved kinase selectivity to <b>9</b> (11 hits >80% compared to 22), suggesting our efforts to modulate the gatekeeper interaction may have proven beneficial. One further interesting difference between these two molecules was that <b>10</b> demonstrated a dual IOC/POA (i.e., pRSK ≈ pERK) profile as opposed to <b>9</b> where the data suggests an IOC only profile (i.e., pRSK > pERK).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Scaffold Elaboration</h3><div class="NLM_p">As we speculated that the SAR around the dihydroimidazopyrazinone core may be broadly consistent in terms of potency with our earlier cores, we utilized a Free–Wilson approach<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> to rapidly identify preferred substituents based on our previously synthesized compounds. Using this approach, substituents were computationally stripped from the respective cores using in-house software and exhaustively enumerated producing 9432 potential virtual target structures (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The biochemical (high ATP) and cellular activity (pRSK) were then estimated on the enumerated set by Free–Wilson theory and used to prioritize compounds along with prediction of Log<i>D</i><sub>7.4</sub> (1.5–3.5) and intrinsic permeability (CaCo2 A to B <i>P</i><sub>app</sub> > 5 × 10<sup>–6</sup> cm/s).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> These models were quantitative structure property relationship (QSPR)-based models using a range of 2D descriptors and trained on internal data. While prioritizing potential target molecules, we initially focused on examples with the preferred methyl in the 5-position of the pyrimidine and the specified pyrazolo solvent channel group. In addition, some groups were deprioritized based on wider data generated such as pharmacokinetic (PK), kinase selectivity, or hERG data.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representation of Free–Wilson analysis. (A) Substructures of compounds in the full data set, versus the Free–Wilson enumeration on the novel core and filtered output using preferred substituents. (B) Representation of Free–Wilson analysis by R1-R3 colored by predicted biochemical pIC<sub>50</sub> coefficient.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A selection of favored R1 and R3 groups that emerged from the Free–Wilson analysis (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) are shown ranked by the Free–Wilson coefficient from the high ATP biochemical activity data. Acceptable combinations of these were identified by the calculation of predicted properties within the physicochemical property space highlighted; therefore, combinations were not synthesized exhaustively. Although our preferred Log <i>D</i><sub>7.4</sub> range to target reasonable physicochemical properties and favorable permeability was between 2 and 3, these constraints were relaxed when filtering to account for model error. One of the most interesting early dihydroimidazopyrazinone core examples synthesized was <b>11</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), with a pRSK cellular activity of 0.031 μM. The specific SAR that was identified from the Free–Wilson approach was the 2,3-difluoro group (ranked third), exemplified by pyrrolopyrazinone <b>12</b>, which binds in the glycine-rich loop but when utilized on this core, the molecule suffered from poor aqueous solubility (7 μM), likely driven by a high Log <i>D</i><sub>7.4</sub> (3.2). However, consistent with the initial observation around the potential for reduced lipophilicity of this core, the Log <i>D</i><sub>7.4</sub> of <b>11</b> was 2.2 with an aqueous solubility of 277 μM. As had been observed with our first dihydroimidazopyrazinone <b>10</b>, improved kinase selectivity was seen with this novel core (6 vs 20 hits >80% inhibition). A second key piece of SAR, which the Free–Wilson approach highlighted, was a methoxymethyl substituent on the pyrrolopyrazinone core (ranked first), exemplified by <b>13,</b> where our previous aim had been to exploit the glycine-rich loop region using our knowledge of the binding mode. Consistent with our design hypothesis, we observed good pRSK cell activity of 0.06 μM, compared to 0.15 μM for the <i>S</i>-enantiomer. As for the 2,3-difluoro group discussed previously, we believed this SAR could only be fully utilized on the pyrrolopyrazinone core with intrinsically less potent (but less lipophilic) heterocyclic groups in the adjacent position. However, the dihydroimidazopyrazinone core matched pairs were predicted to be highly potent and in a reasonable Log <i>D</i><sub>7.4</sub> range; therefore, the methyl (<b>14</b>) and methoxymethyl (<b>15</b>) substituted examples were both synthesized in the <i>R</i>-enantiomeric form. <b>14</b> demonstrated a slightly increased potency in the cell MOA assay with an IC<sub>50</sub> of 0.0034 vs 0.0091 μM in pERK compared to the matched pair <b>11</b> lacking the additional methyl group but equivalent activity in pRSK (0.038 vs 0.031 μM). Whereas, compound <b>15</b> demonstrated a particularly interesting profile with impressive pRSK potency of 0.0057 μM and 0.0017 μM potency in pERK. In addition, the molecule had excellent physicochemical properties (aqueous solubility 468 μM), low HLM and hepatocyte CL<sub>int</sub>, good intrinsic permeability in CaCo2 (<i>P</i><sub>app</sub> A to B 26.7 × 10<sup>–6</sup> cm/s), and acceptable hERG (11 μM). Compound <b>15</b> was the 16th compound synthesized with the dihydroimidazopyrazinone core, and approximately 50 were synthesized in total. <b>15</b> subsequently became our clinical candidate AZD0364. This speed at which this molecule was identified on this novel core provides some validation as to the value of the highlighted Free–Wilson approach. An additional observation of note with compounds <b>13</b>–<b>15</b> is that the cellular activity data are consistent with a dual IOC and POA profile. Additional potent and selective compounds were synthesized, in addition to examples varying R2, but no improvement was observed over <b>15</b> in terms of the overall profile.<named-content content-type="anchor" rid="tbl2a" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Scaffold Hopping to Dihydroimidazopyrazinone Core<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0011.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>9</b></th><th class="colsep0 rowsep0" align="center"><b>10</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, <i>k</i><sub>M</sub> ATP IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="center"><0.0003</td><td class="colsep0 rowsep0" align="center"><0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, high ATP IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="center">0.00013</td><td class="colsep0 rowsep0" align="center">0.00034</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell MOA A375 pERK/pRSK IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="center">>14/0.01</td><td class="colsep0 rowsep0" align="center">0.0047/0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#t2fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">3.5</td><td class="colsep0 rowsep0" align="center">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility (μM)<a class="ref internalNav" href="#t2fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">112</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro clearance HLM (μL/min/mg protein)</td><td class="colsep0 rowsep0" align="center">32</td><td class="colsep0 rowsep0" align="center">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity (<i>N</i> > 80% out of 140 kinase panel)<a class="ref internalNav" href="#t2fn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">22</td><td class="colsep0 rowsep0" align="center">11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">All IC<sub>50</sub> data are reported as μM and are the mean of at least three independent measurements.</p></div><div class="footnote" id="t2fn1"><sup><sup>b</sup></sup><p class="last">Distribution coefficient between 1-octanol and aqueous phosphate buffer at pH 7.4.</p></div><div class="footnote" id="t2fn2"><sup><sup>c</sup></sup><p class="last">Solubility of compounds in aqueous phosphate buffer at pH 7.4 after 24 h at 25 °C (μM).</p></div><div class="footnote" id="t2fn3"><sup><sup>d</sup></sup><p class="last">Kinase selectivity data measured at 1 μM compound concentration. One of these kinases was ERK2 with three being coupled assays with ERK (MEK1, BRAF, and CRAF).</p></div></div></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Selection of favored substituents from Free–Wilson analysis enumerated on the dihydroimidazopyrazinone core. Subsituents ordered using the Free–Wilson coefficient based on biochemical activity as a ranking.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2a"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Dihydroimidazopyrazinone Core Examples Synthesized Guided by Free–Wilson Approach<a class="ref internalNav" href="#tbl2a-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0012.gif" alt="" id="GRAPHIC-d7e1145-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>11</b></th><th class="colsep0 rowsep0" align="center"><b>12</b></th><th class="colsep0 rowsep0" align="center"><b>13</b></th><th class="colsep0 rowsep0" align="center"><b>14</b></th><th class="colsep0 rowsep0" align="center"><b>15</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, <i>k</i><sub>M</sub> ATP IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="center">0.00083</td><td class="colsep0 rowsep0" align="center"><0.0003</td><td class="colsep0 rowsep0" align="center"><0.0003</td><td class="colsep0 rowsep0" align="center"><0.0003</td><td class="colsep0 rowsep0" align="center"><0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK2 biochemical, high ATP IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="center">0.0026</td><td class="colsep0 rowsep0" align="center">0.00035</td><td class="colsep0 rowsep0" align="center">0.0006</td><td class="colsep0 rowsep0" align="center">0.00032</td><td class="colsep0 rowsep0" align="center">0.00066</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell MOA A375 pERK/pRSK IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="center">0.0091/0.031</td><td class="colsep0 rowsep0" align="center">ND/0.02</td><td class="colsep0 rowsep0" align="center">0.03/0.06</td><td class="colsep0 rowsep0" align="center">0.0034/0.038</td><td class="colsep0 rowsep0" align="center">0.0017/0.0057</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Log <i>D</i><sub>7.4</sub><a class="ref internalNav" href="#tbl2afn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">2.2</td><td class="colsep0 rowsep0" align="center">3.2</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility (μM)<a class="ref internalNav" href="#tbl2afn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">277</td><td class="colsep0 rowsep0" align="center">7</td><td class="colsep0 rowsep0" align="center">725</td><td class="colsep0 rowsep0" align="center">99</td><td class="colsep0 rowsep0" align="center">468</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity (<i>N</i> > 80% out of 140 kinase panel)<a class="ref internalNav" href="#tbl2afn3" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">20</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">7</td><td class="colsep0 rowsep0" align="center">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro clearance HLM (μL/min/mg protein) (rat/human heps (μL/min/×10<sup>6</sup> cells))<a class="ref internalNav" href="#tbl2afn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">4.3 (7.1/ND)</td><td class="colsep0 rowsep0" align="center">20.7 (10.9/ND)</td><td class="colsep0 rowsep0" align="center">14.6 (12.7/<1)</td><td class="colsep0 rowsep0" align="center">8.3 (3.9/<1)</td><td class="colsep0 rowsep0" align="center">8.7 (10.2/<1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CaCo2 A to B <i>P</i><sub>app</sub> + inhibitors (10<sup>–6</sup> cm/s)</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">49</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">26.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="center">23</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">20</td><td class="colsep0 rowsep0" align="center">23</td><td class="colsep0 rowsep0" align="center">11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2a-fn1"><div class="footnote" id="tbl2a-fn1"><sup><sup>a</sup></sup><p class="last">All IC<sub>50</sub> data are reported as μM and are the mean of at least three independent measurements.</p></div><div class="footnote" id="tbl2afn1"><sup><sup>b</sup></sup><p class="last">Distribution coefficient between 1-octanol and aqueous phosphate buffer at pH 7.4.</p></div><div class="footnote" id="tbl2afn2"><sup><sup>c</sup></sup><p class="last">Solubility of compounds in aqueous phosphate buffer at pH 7.4 after 24 h at 25 °C (μM).</p></div><div class="footnote" id="tbl2afn3"><sup><sup>d</sup></sup><p class="last">Kinase selectivity data measured at 1 μM compound concentration. One of these kinases was ERK2 with three being coupled assays with ERK (MEK1, BRAF, and CRAF).</p></div><div class="footnote" id="tbl2afn4"><sup><sup>e</sup></sup><p class="last">Human microsome (μL min<sup>–1</sup> mg<sup>–1</sup>) and rat hepatocyte metabolism intrinsic clearance (μL min<sup>–1</sup> million cells<sup>–1</sup>). ND, not determined.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Chemistry</h3><div class="NLM_p">Synthesis of <b>15</b> was performed in a 14-step overall sequence as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Two key building blocks were required before converging for the remaining six steps. Synthesis of the first building block was five steps starting with an SEM protection of commercially available ethyl 1<i>H</i>-imidazole-2-carboxylate. This imidazole intermediate was then brominated and converted to the boronic acid before a Suzuki–Miyaura cross coupling was carried out with 2,4-dichloro-5-methylpyrimidine. A final SEM deprotection step then afforded <b>15e</b>. The second building block was a shorter three-step sequence starting with reduction of commercial (<i>S</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-3-methoxypropanoic acid, followed by cyclization and oxidation to afford the BOC-sulfamidate <b>15h</b>. Ring opening of this BOC-sulfamidate with the imidazole NH of <b>15e</b>, followed by double deprotection, afforded primary amine <b>15k</b> as a bis-hydrochloride salt. Treatment of the salt with methanolic ammonia promoted cyclization to the dihydroimidazopyrazinone core. Alkylation with 4-(bromomethyl)-1,2-difluorobenzene and a final Buchwald–Hartwig cross coupling with second generation XantPhos precatalyst afforded <b>15</b>. Full compound synthesis experimental details and characterization for <b>15</b> can be found in the <a class="ref internalNav" href="#sec4" aria-label="experimental section">experimental section</a>, and all compound synthesis details can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_001.pdf" class="ext-link">Supporting Information</a>, S1.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>15</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) SEM-Cl, K<sub>2</sub>CO<sub>3</sub>, acetone, 0 °C, 85%; (ii) NBS, DMF, DCM, 0 °C, 51%; (iii) second generation XPhos precatalyst, 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane), KOAc, 1,4-dioxane, 25 °C, quant; (iv) Pd(Ph<sub>3</sub>P)<sub>4,</sub> 2,4-dichloro-5-methylpyrimidine, Cs<sub>2</sub>CO<sub>3,</sub> 1,4-dioxane, water, 85 °C, 70%; (v) TFA, DCM, 25 °C, 93%; (vi) (a) isobutyl chloroformate, <i>N</i>-methylmorpholine, THF, 0 °C, (b) NaBH4, H<sub>2</sub>O, 52%; (vii) imidazole, thionyl chloride, NEt<sub>3</sub>, DCM, −78 °C, 56%; (viii) sodium metaperiodate, ruthenium(III) chloride, MeCN, water, 0 °C, 80%; (ix) K<sub>2</sub>CO<sub>3</sub>, 18-crown-6, 1,4-dioxane, 100 °C, 100%; (x) 1 M HCl, EtOH, 50 °C, 24%; (xi) 4 M HCl in 1,4-dioxane, 25 °C, 85%; (xii) 1 M NH<sub>3</sub> in MeOH, 25 °C, 97%; (xiii) 4-(bromomethyl)-1,2-difluorobenzene, NaH, DMF, 25 °C, 95%; (xiv) second generation XantPhos precatalyst, 1-methyl-1<i>H</i>-pyrazol-5-amine, Cs<sub>2</sub>CO<sub>3,</sub> 1,4-dioxane, 100 °C, 64%.</p></p></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Kinase Selectivity</h3><div class="NLM_p">The wider kinase selectivity of <b>15</b> was then evaluated with only 14 kinase assays out of 353 in the larger panel showing % inhibition >80% (including four separate CDK2 assays), with a compound concentration of 1 μM. However, the MEK1, MEK2, COT, BRAF, and CRAF assays listed are all coupled pathway assays using ERK protein as part of the assay cascade; therefore, an inhibitor of ERK1/2 will show activity in these assays. In the same assay panel, the single-protein binding assays for MEK1, MEK2, BRAF and CRAF showed only −2.5%, −2.2%, 5.8% and −3.5% binding, respectively; therefore, <b>15</b> is not considered to be active against these kinases. A single-protein binding assay for COT was not available. Follow-up testing in these assays showed that the ERK7 binding affinity for AZD0364 was 0.03 μM, ARK5 had an IC50 of 0.4 μM, and CDK5 had IC50s of 0.3 μM in both CDK5/p25 and CDK5/p35 activity assays with a binding affinity for inactive CDK5 of 1.9 μM. Further biochemical testing was performed with in-house assays for both MEK1 and CDK2. <b>15</b> was inactive against the in-house MEK1 assay at the concentration range tested (>10 μM) and had an IC<sub>50</sub> of 1 μM against CDK2-cyclin E.<named-content content-type="anchor" rid="tbl3" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Kinase Panel Selectivity of <b>15</b><a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">% kinase inhibition/binding (@ 1 μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>MAP2K1 (MEK1)</b></td><td class="colsep0 rowsep0" align="center"><b>104</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAPK3 (ERK1)</td><td class="colsep0 rowsep0" align="center">105</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>MAP3K8 (COT)</b></td><td class="colsep0 rowsep0" align="center"><b>103</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>BRAF</b></td><td class="colsep0 rowsep0" align="center"><b>102</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAPK1 (ERK2)</td><td class="colsep0 rowsep0" align="center">102</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>MAP2K2 (MEK2)</b></td><td class="colsep0 rowsep0" align="center"><b>101</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>RAF1 (cRAF) Y340D Y341D</b></td><td class="colsep0 rowsep0" align="center"><b>101</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAPK15 (ERK7)</td><td class="colsep0 rowsep0" align="center">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2/cyclin O</td><td class="colsep0 rowsep0" align="center">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2/cyclin A1 (binding)</td><td class="colsep0 rowsep0" align="center">91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2/cyclin E1</td><td class="colsep0 rowsep0" align="center">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2/cyclin A (activity)</td><td class="colsep0 rowsep0" align="center">87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK5/p25</td><td class="colsep0 rowsep0" align="center">81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUAK1 (ARK5)</td><td class="colsep0 rowsep0" align="center">80</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">Kinases in the ThermoFisher 353 wild-type kinase panel that showed greater than 80% inhibition/binding after 1 μM treatment with <b>15</b> are shown (data combines two experiments—one using a subpanel of 122 kinases and one using the full 353 wild-type panel). Kinase assays that include inactive ERK2 protein as part of a coupled cascade assay are highlighted in <b>bold</b>.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Binding Mode Elucidation</h3><div class="NLM_p"><named-content content-type="anchor" rid="fig5a" type="simple"></named-content>ERK2 X-ray crystallography confirmed the binding mode of <b>15</b> in the ATP pocket and was broadly consistent with that of our previously disclosed series in terms of the key interactions and scaffold position. The pyrimidine group forms a key interaction with Met-108 and the pyrazole group forms a hydrogen bond to Lys-114. The 2,3-difluoro group is directed into the glycine-rich loop of the kinase contacting residues such as Val-39. The additional methoxymethyl group also makes contacts with Val-39 and hydrophobic interactions with Ile-31, consistent with improved potency and selectivity. The commonly conserved water molecule<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> is present, and the additional nitrogen on the dihydroimidazopyrazinone core has the potential to be involved in the interactions between the bridged water molecule (3.5 Å) and gatekeeper Gln-105 (2.7 Å). This water molecule is also in the contact range of a second water molecule (2.6 Å), which is hydrogen bonded to Glu-71 (2.7 Å).</div><figure id="fig5a" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0006.jpeg" id="GRAPHIC-d7e1653-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding mode of <b>15</b> elucidated in ERK2 by X-ray crystallography (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SLG">6SLG</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig5a"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Further profiling of <b>15</b> was carried out to assess the wider properties of the compound for evaluation in vivo and potential clinical candidate nomination. Gratifyingly, the excellent cellular MOA activity of <b>15</b> translated well into antiproliferative effects in the A375 (GI<sub>50</sub> 0.06 μM) and Calu-6 (GI<sub>50</sub> 0.2 μM) cell lines. The A375 cell line contains a BRAF V600E mutation, and Calu-6 contains a KRAS Q61K mutation. The physicochemical properties of the initial amorphous material were very good (aqueous solubility 468 μM); however, identifying a suitable method of obtaining crystalline material proved more challenging and will be covered in a later section. The in vitro clearance appeared relatively low in rodent species (rat heps 8.7 μL/min/million cells), suggesting this was a suitable example for preclinical in vivo evaluation of pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in antitumor models.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Target Residence Time</h3><div class="NLM_p">An additional interesting property of <b>15</b> was revealed when evaluated using surface plasma resonance (SPR) (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">5</a></a>), where the molecule demonstrated equivalent affinity to phosphorylated and unphosphorylated ERK2 (p<i>K</i><sub>d</sub> 10.3 and 10, respectively) but with a relatively long residence time in both forms (<i>t</i><sub>1/2</sub> 277 and 194 min, respectively). Interestingly, when a broader set of ERK1/2 inhibitors were tested in the same way, we observed clear differences in their kinetic behavior. <b>15</b> has greater affinity against both phosphorylated and nonphosphorylated forms of ERK2 than our chemical start point for this work, <b>7</b>, in addition to increased cellular activity and longer residence time. Compound <b>1</b> (SCH772984) also demonstrated high ERK2 affinity against both forms and high cellular potency along with extended residence times against both forms with some similarities to <b>15</b>. These data suggest that such levels of potency (and inhibitor to target residence times) can be achieved without the need for the extended group present in SCH772984. However, <b>3</b> (BVD-523) appears to have differential binding kinetics with higher affinity and a longer residence time against the phosphorylated form of ERK2 than the nonphosphorylated form. Interestingly, this example appears to have an IOC only profile with reduced cellular activity against pERK. Compound <b>4</b> (GDC-0994) has reduced, but equivalent, affinity toward the phosphorylated and nonphosphorylated forms of ERK2 and significantly shorter residence times, which may be consistent with the weaker cellular activity of the compound. Overall, in this set of compounds, the association rate constants are broadly comparable; however, they appear to show differential behavior in their dissociation rate constants with <b>15</b> and <b>1</b> having particularly slow dissociation rate constants.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Surface Plasma Resonance (SPR) Data on a Set of ERK1/2 Inhibitors<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">pRSK A375 mean IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">pERK A375 mean IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">ERK2 binding mean (p<i>K</i><sub>d</sub>) (ph/non-ph)</th><th class="colsep0 rowsep0" align="center">ERK2 <i>k</i><sub>on</sub> mean (M<sup>–1</sup>·s<sup>–1</sup>) (ph/non-ph)</th><th class="colsep0 rowsep0" align="center">ERK2 <i>k</i><sub>off</sub> mean (1/s) (ph/non-ph)</th><th class="colsep0 rowsep0" align="center">ERK2 <i>t</i><sub>1/2</sub> mean (min) (ph/non-ph)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>1</b> (SCH772984)</td><td class="colsep0 rowsep0" align="center">0.012</td><td class="colsep0 rowsep0" align="center">0.0025</td><td class="colsep0 rowsep0" align="center">10/10.3</td><td class="colsep0 rowsep0" align="center">1.3E06/9.4E05</td><td class="colsep0 rowsep0" align="center">1.0 × 10<sup>–04</sup>/4.4 × 10<sup>–05</sup></td><td class="colsep0 rowsep0" align="center">127/291</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>3</b> (BVD-523)</td><td class="colsep0 rowsep0" align="center">0.15</td><td class="colsep0 rowsep0" align="center">3.1</td><td class="colsep0 rowsep0" align="center">9.5/8</td><td class="colsep0 rowsep0" align="center">1.3E06/7.5E05</td><td class="colsep0 rowsep0" align="center">4.1 × 10<sup>–04</sup>/7.4 × 10<sup>–03</sup></td><td class="colsep0 rowsep0" align="center">35/2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>4</b> (GDC-0994)</td><td class="colsep0 rowsep0" align="center">0.086</td><td class="colsep0 rowsep0" align="center">0.031</td><td class="colsep0 rowsep0" align="center">8.8/8.8</td><td class="colsep0 rowsep0" align="center">9.8E06/6.2E06</td><td class="colsep0 rowsep0" align="center">1.6 × 10<sup>–02</sup>/9.9 × 10<sup>–03</sup></td><td class="colsep0 rowsep0" align="center">0.8/1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>7</b></td><td class="colsep0 rowsep0" align="center">0.044</td><td class="colsep0 rowsep0" align="center">0.012</td><td class="colsep0 rowsep0" align="center">9.8/9.1</td><td class="colsep0 rowsep0" align="center">1.9E06/1.3E06</td><td class="colsep0 rowsep0" align="center">3.2 × 10<sup>–04</sup>/1.0 × 10<sup>–03</sup></td><td class="colsep0 rowsep0" align="center">37/11.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>15</b></td><td class="colsep0 rowsep0" align="center">0.0057</td><td class="colsep0 rowsep0" align="center">0.0017</td><td class="colsep0 rowsep0" align="center">10.3/10</td><td class="colsep0 rowsep0" align="center">8.9 × 10<sup>–05</sup>/6.5E05</td><td class="colsep0 rowsep0" align="center">4.5 × 10<sup>–05</sup>/6.0 × 10<sup>–05</sup></td><td class="colsep0 rowsep0" align="center">277/194</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup><sup>a</sup></sup><p class="last">All data reported are a mean of at least three independent measurements. Ph = phosphorylated, non-ph = non-phosphorylated.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Salt/Cocrystal Screening of Compound <b>15</b></h3><div class="NLM_p last">With a view of evaluating suitable formulations for <b>15</b> in a clinical setting, X-ray powder diffraction had highlighted that early batches of <b>15</b> were noncrystalline. However, initial attempts to crystallize from a range of solvents yielded amorphous or glassy materials. Such materials may be challenging to develop as they can be chemically unstable, difficult to isolate in desired purity and yield, and can be challenging to formulate.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> A salt screening approach was therefore initiated using a large collection of counterions containing a variety of functionalities (such as carboxylic acids, dicarboxylic acids, sulfonic acids, disulfonic acids, aromatic acids, alcohols, and so on) to increase the probability of successful crystalline salt formation. From this evaluation, crystalline hits were obtained for the following acidic counterions: adipic, citric, ethanesulfonic, fumaric, hydrochloric, and phosphoric acids. Initial scale-up of HCl and phosphoric acid salts yielded poorly crystalline materials that were not investigated further. Scale-up of adipic and ethanesulfonic acid salts yielded highly crystalline material with suitable melting points (185 and 204 °C, respectively). Given the weakly basic nature of <b>15</b> (p<i>K</i><sub>a</sub> ≈ 2.6), the ethanesulfonic acid adduct was considered likely to exist as a salt (proton transfer from acid to base), whereas the adipic acid adduct was considered likely to exist as a cocrystal (no proton transfer from acid to base). NMR analysis confirmed this was indeed the case, with the ethanesulfonate salt containing a protonated basic nitrogen in <b>15</b> and an unprotonated basic nitrogen in the adipic acid cocrystal. Given the low p<i>K</i><sub>a</sub> of <b>15</b>, an ethanesulfonate salt was considered likely to be physically unstable in aqueous media, and this was the case which readily disproportionates back to the amorphous free base upon exposure to water. The adipic acid cocrystal however is physically stable in aqueous suspension up to pH 6.8, had favorable aqueous solubility across a relevant pH range, and has appropriate physiochemical properties to ensure low risk delivery at scale and minimal formulation risk. Therefore, the adipic acid cocrystal had an aqueous solubility of 142 μM and was selected to support the further development of <b>15</b>.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vivo Testing of Compound <b>15</b></h3><div class="NLM_p">The first in vivo antitumor model to be used to evaluate this inhibitor was a Calu-6 (KRAS Q61H) model, as we had reported on with our previously disclosed inhibitor <b>7</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">7</a></a>). As a monotherapy treatment, <b>15</b> demonstrated 93% tumor growth inhibition (TGI) at a dose of 15 mg/kg QD and tumor regression (49%) at 50 mg/kg QD. A PK/PD relationship was established, as the reduction in levels of pRSK observed were consistent with the PK (and binding kinetics) of the inhibitor. In this study, almost total knockdown of pRSK was observed at both 0.5 and 6 h time points after the final dose of the compound, with the free concentration of <b>15</b> showing a reduction at 6 h. In addition to the monotherapy study, <b>15</b> was evaluated in combination with the MEK1/2 inhibitor selumetinib in an antitumor study in an A549 (KRAS G12C mutant) cell line, which appeared to be less sensitive to monotherapy treatment with an ERK1/2 inhibitor (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">8</a></a>). The combination of <b>15</b> and selumetinib demonstrated tumor regressions (28% tumor regression) when both compounds were dosed at 25 mg/kg, with the monotherapy arm for each showing only modest inhibition of tumor growth.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Monotherapy antitumor activity of <b>15</b> in a Calu 6 (KRAS Q61H, panel A) mouse model and end of study PD/PK analysis (panel B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Monotherapy and combination antitumor activity of <b>15</b> and selumetinib in an A549 (KRAS G12C) mouse model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on these data, the preclinical species PK and the in vitro human data were utilized to predict the human PK.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> A range of human Cl<sub>int</sub> predictions was generated from human microsomes and hepatocytes (including different formats of hepatocytes to include plated and suspension); this gave rise to a range of predictions of clearance from 0.5 to 6 mL/min/kg. The human plasma protein binding (PPB) differences tested over a concentration range were also reflected in the range of predictions. From these data, a predicted oral human dose of between 20 and 110 mg was calculated based on the requirement for free cover for 12 h over the Calu-6 GI<sub>50</sub>, using BID dosing (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">6</a></a>). This range of predicted doses is consistent with one of our previously set out design aims to identify a high-quality clinical candidate with a low predicted human dose.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Broader Data Overview of Compound <b>15</b><a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center"><b>15</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell MoA A375 pRSK/pERK IC<sub>50</sub> μM</td><td class="colsep0 rowsep0" colspan="2" align="center">0.0017/0.0057</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">proliferation A375/Calu 6 GI<sub>50</sub> μM</td><td class="colsep0 rowsep0" colspan="2" align="center">0.06/0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding (% free) (mouse, rat, dog, human)</td><td class="colsep0 rowsep0" colspan="2" align="center">12, 21, 44, 6–27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vivo pharmacokinetics</td><td class="colsep0 rowsep0" align="center">rat</td><td class="colsep0 rowsep0" align="center">dog</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="center">38</td><td class="colsep0 rowsep0" align="center">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="center">1.5</td><td class="colsep0 rowsep0" align="center">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t5fn1" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">2.3</td><td class="colsep0 rowsep0" align="center">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human dose prediction (PO)</td><td class="colsep0 rowsep0" colspan="2" align="center">20–110 mg BID</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup><sup>a</sup></sup><p class="last">All IC<sub>50</sub> data are reported as μM and are the mean of at least three independent measurements (A375 BRAF V600E, Calu-6 KRAS Q61K).</p></div><div class="footnote" id="t5fn1"><sup><sup>b</sup></sup><p class="last">Oral administration.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18266" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18266" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have reported our drug discovery efforts on the identification of <b>15</b> (AZD0364), a potent and selective ERK1/2 inhibitor that prevents activation of ERK1/2 and inhibits activation of downstream targets. The ADME properties of <b>15</b> are favorable and enabled a low predicted oral dose in humans of between 20 and 110 mg BID. This inhibitor has excellent kinase selectivity and has also been shown to have high affinity to both phosphorylated and nonphosphorylated forms of ERK. <b>15</b> is also efficacious in disease relevant antitumor mouse xenograft models of cancer as a monotherapy and in combination with the MEK1/2 inhibitor selumetinib. Further disclosures will be reported in due course with broader preclinical efficacy data in additional cell lines and disease models. Clinical trials evaluating AZD0364 are planned to commence later this year.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22132" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22132" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthesis and Characterization of Compound <b>15</b></h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Chemistry Statement</h4><div class="NLM_p last">Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 300, 400, or 500 MHz instrument at room temperature unless otherwise stated. All <sup>1</sup>H NMR spectra were measured in parts per million (ppm) relative to the signals for residual dimethyl sulfoxide (DMSO) in deuterated DMSO (2.50 ppm), or the signals for tetramethylsilane (TMS) added into the deuterated chloroform (0 ppm). Data for <sup>1</sup>H NMR were reported as chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, h = heptet, m = multiplet, br = broad), coupling constants, and integration. LC–MS analyses were performed on a Waters 2795 Separations Module, using a Gemini NX-C18 column, with a Waters Micromass detector. All final compounds were found to be of 95% purity or greater by LC–MS.</div></div><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Ethyl 1-((2-(Trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole-2-carboxylate (<b>15a</b>)</h4><div class="NLM_p last">SEM-Cl (286 g, 1712.55 mmol) was added dropwise to ethyl 1<i>H</i>-imidazole-2-carboxylate (200 g, 1427.12 mmol) and K<sub>2</sub>CO<sub>3</sub> (592 g, 4281.37 mmol) in acetone (3 L) at 0 °C. The resulting mixture was stirred at ambient temperature for 16 h. The resulting precipitate was removed by filtration and washed with EtOAc (1 L). The combined organic layers were then dried over Na<sub>2</sub>SO<sub>4</sub>, and the volatiles were removed under reduced pressure. The resulting crude material was purified by flash silica chromatography, with an elution gradient of 0 to 30% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford ethyl 1-((2(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole-2-carboxylate (<b>15a</b>) (328 g, 85%) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ −0.04 (s, 9H), 0.85–0.94 (m, 2H), 1.42 (t, <i>J</i> = 7.1 Hz, 3H), 3.48–3.59 (m, 2H), 4.40 (q, <i>J</i> = 7.1 Hz, 2H), 5.78 (s, 2H), 7.18 (d, <i>J</i> = 1.0 Hz, 1H), 7.25 (d, <i>J</i> = 1.1 Hz, 1H). ES+ [M + H]+ <i>m</i>/<i>z</i> 271.</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Ethyl 4-Bromo-l-((2-(trimethylsilyl)ethoxy)methyl)-l<i>H</i>-imidazole-2-carboxylate (<b>15b</b>)</h4><div class="NLM_p last">NBS (158 g, 887.56 mmol) was added portionwise to ethyl 1-((2(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole-2-carboxylate (<b>15a</b>) (160 g, 591.71 mmol) in DMF (1200 mL) and DCM (1300 mL) at 0 °C. The resulting reaction was stirred at 25 °C for 48 h. The volatiles were removed under reduced pressue, and EtOAc (7 L) was added. The organic phase was then washed sequentially with saturated NaHCO<sub>3</sub> (1 L), water (1 L), and saturated brine (750 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to afford the crude product, which was purified by flash silica chromatography, with an elution gradient of 0 to 4% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford ethyl 4-bromo-1-((2(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole-2-carboxylate (<b>15b</b>) (106 g, 51.3%) as a pale yellow oil, which solidified on standing. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ −0.06 (s, 9H), 0.78–0.87 (m, 2H), 1.30 (t, <i>J</i> = 7.1 Hz, 3H), 3.49–3.56 (m, 2H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 5.66 (s, 2H), 7.84 (s, 1H). ES+ [M + H]+ <i>m</i>/<i>z</i> 349/351.</div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (2-(Ethoxycarbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-4-yl)boronic acid (<b>15c</b>)</h4><div class="NLM_p last">Second generation XPhos precatalyst (0.788 g, 1.00 mmol) was added to ethyl 4-bromo-1-((2(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole-2-carboxylate (<b>15b</b>) (7 g, 20.04 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (7.63 g, 30.06 mmol), and KOAc (3.93 g, 40.08 mmol) in 1,4-dioxane (100 mL) at 25 °C under nitrogen. The resulting mixture was then stirred at 85 °C for 3 h. The reaction mixture was filtered, and the filtrate containing (2-(ethoxycarbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-4-yl)boronic acid (<b>15c</b>) was used in the next step directly without further purification. ES+ [M + H]+ <i>m</i>/<i>z</i> 315.</div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Ethyl 4-(2-Chloro-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole-2-carboxylate (<b>15d</b>)</h4><div class="NLM_p last">Pd(Ph<sub>3</sub>P)<sub>4</sub> (1.158 g, 1.00 mmol) was added to (2-(ethoxycarbonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-4-yl)boronic acid (<b>15c</b>) (6.3 g, 20.05 mmol), 2,4-dichloro-5-methylpyrimidine (3.27 g, 20.05 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (13.07 g, 40.10 mmol) in 1,4-dioxane (120 mL) and water (20 mL) at 25 °C under nitrogen, and the resulting mixture was stirred at 85 °C for 2 h. The reaction mixture was poured into water (200 mL) and extracted with DCM (2 × 250 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude product was purified by flash silica chromatography, with an elution gradient of 0 to 10% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford ethyl 4-(2-chloro-5-methylpyrimidin-4-yl)-1-((2(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole-2-carboxylate (<b>15d</b>) (5.60 g, 70.4%) as a pale yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ −0.07 (s, 9H), 0.78–0.9 (m, 2H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H), 2.61 (s, 3H), 3.52–3.62 (m, 2H), 4.36 (q, <i>J</i> = 7.1 Hz, 2H), 5.78 (s, 2H), 8.45 (s, 1H), 8.6–8.62 (m, 1H). ES+ [M + H]+ <i>m</i>/<i>z</i> 397.</div></div><div id="sec4_1_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Ethyl 4-(2-Chloro-5-methylpyrimidin-4-yl)-l<i>H</i>-imidazole-2-carboxylate (<b>15e</b>)</h4><div class="NLM_p last">Trifluoroacetic acid (20 mL, 259.60 mmol) was added to ethyl 4-(2-chloro-5-methylpyrimidin-4-yl)- 1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole-2-carboxylate (<b>15d</b>) (5.6 g, 14.1 1 mmol) in DCM (20 mL) at 25 °C, and the resulting mixture was stirred at 25 °C for 12 h. The volatiles were then removed under reduced pressure, and the reaction mixture was basified with saturated NaHCO<sub>3</sub>. The resulting precipitate formed was collected by filtration, washed with water (100 mL), and dried under vacuum to afford ethyl 4-(2-chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-imidazole-2-carboxylate (<b>15e</b>) (3.50 g, 93%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.34 (t, <i>J</i> = 7.1 Hz, 3H), 2.61 (s, 3H), 4.37 (q, <i>J</i> = 7.1 Hz, 2H), 8.12 (s, 1H), 8.61 (s, 1H), 13.96 (s, 1H). ES+ [M + H]+ <i>m</i>/<i>z</i> 267.</div></div><div id="sec4_1_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>R</i>)-<i>tert</i>-Butyl (1-Hydroxy-3-methoxypropan-2-yl)carbamate (<b>15f</b>)</h4><div class="NLM_p last">Isobutyl chloroformate (5.39 mL, 41.05 mmol) was added dropwise to (<i>S</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-3-methoxypropanoic acid (9.00 g, 41.05 mmol) and <i>N</i>-methylmorpholine (4.51 mL, 41.05 mmol) in THF (54 mL) cooled to 0 °C over a period of 20 min under nitrogen. The resulting suspension was stirred at 0 °C for 30 min. Sodium borohydride (4.50 g, 119.05 mmol) was added to the reaction followed by water (10.80 mL) at 0 °C. The reaction was then left to stir at 0 °C for 30 min before been diluted with EtOAc (200 mL), and the reaction was left to stir overnight. The white precipitate was removed by filtration, and the solution was concentrated. The solution was diluted with water (200 mL) and neutralized with aqueous HCl (2M). The organic layer was separated and dried over magnesium sulfate. Evaporation of the solvent gave a crude product. The crude product was purified by flash silica chromatography, with an elution gradient of 0 to 50% EtOAc in heptane. Pure fractions were evaporated to dryness to afford (R)-<i>tert</i>-butyl (1-hydroxy-3-methoxypropan-2-yl)carbamate (<b>15f</b>) (4.40 g, 52.2%) as a colorless oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.44 (s, 9H), 3.35 (s, 3H), 3.48–3.59 (m, 2H), 3.63–3.71 (m, 1H), 3.73–3.84 (m, 2H), 5.17 (s, 1H). No LC–MS, as no chromophore.</div></div><div id="sec4_1_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (4<i>S</i>)-<i>tert</i>-Butyl 4-(Methoxymethyl)-1,2,3-oxathiazolidine-3-carboxylate 2-oxide (<b>15g</b>)</h4><div class="NLM_p last">Imidazole (1.63 g, 23.92 mmol) was added in one portion to thionyl chloride (1.75 mL, 23.92 mmol) and triethylamine (3.33 mL, 23.92 mmol) in DCM (100 mL) cooled to −78 °C under nitrogen. The resulting solution was stirred at −78 °C for 20 min. (<i>R</i>)-<i>tert</i>-Butyl (1-hydroxy-3-methoxypropan-2-yl)carbamate (<b>15f</b>) (4.91 g, 23.92 mmol) dissolved in DCM (26.7 mL) was added dropwise over 10 min. The resulting solution was stirred at −78 °C for 3 h, and then, the reaction was allowed to warm to room temperature. The reaction mixture was quenched with water (100 mL) and extracted with DCM (2 × 100 mL). The organics were combined and washed with brine (100 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and evaporated to afford a crude product. The crude product was purified by flash silica chromatography, eluting with 10% Et<sub>2</sub>O in DCM. Pure fractions were evaporated to dryness to afford (4S)-<i>tert</i>-butyl 4-(methoxymethyl)-1,2,3-oxathiazolidine-3-carboxylate 2-oxide (<b>15g</b>) (3.34 g, 55.6%) as a colorless oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.55–1.58 (m, 9H), 3.31 (t, <i>J</i> = 9.1 Hz, 0.5H), 3.41 (s, 3H), 3.52–3.63 (m, 1H), 3.90 (dd, <i>J</i> = 3.8, 9.1 Hz, 0.5 H), 4.17–4.4 (m, 1H), 4.64–4.92 (m, 1H), 4.94–5.07 (m, 1H). ES+ [M + H]+ <i>m</i>/<i>z</i> 252. HRMS (ES+) for C<sub>9</sub>H<sub>17</sub>NO<sub>5</sub>S (MH+) calculated 252.0906, found 252.0898.</div></div><div id="sec4_1_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (S)-<i>tert</i>-Butyl 4-(Methoxymethyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (<b>15h</b>)</h4><div class="NLM_p last">To a solution of (4S)-<i>tert</i>-butyl 4-(methoxymethyl)-l,2,3-oxathiazolidine-3-carboxylate 2 oxide (<b>15g</b>) (3.34 g, 13.29 mmol) in acetonitrile (30 mL) at 0 °C under nitrogen was added sequentially sodium metaperiodate (3.13 g, 14.62 mmol), ruthenium(III) chloride (0.276 g, 1.33 mmol), and water (30.0 mL), and then, the solution was stirred at 0 °C for 3 h. The reaction mixture was diluted with water (100 mL) and filtered to remove insoluble inorganic salts. The resulting solution was extracted with ether (2 × 100 mL), washed with brine (2 × 100 mL), and dried over MgSO<sub>4</sub> to give (S)-<i>tert</i>-butyl 4-(methoxymethyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (<b>15h</b>) (2.86 g, 80%) as an oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.56 (s, 9H), 3.41 (s, 3H), 3.59 (t, <i>J</i> = 9.2 Hz, 1H), 3.66 (ddd, <i>J</i> = 0.8, 4.1, 9.4 Hz, 1H), 4.38 (dddd, <i>J</i> = 2.3, 4.1, 5.5, 7.8 Hz, 1H), 4.52–4.67 (m, 2H). ES+ [M + H]+ <i>m</i>/<i>z</i> 268.</div></div><div id="sec4_1_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>R</i>)-(<i>tert</i>-Butoxycarbonyl)(1-(4-(2-chloro-5-methylpyrimidin-4-yl)-2-(ethoxycarbonyl)-1<i>H</i>-imidazol-1-yl)-3-methoxypropan-2-yl)sulfamic acid (<b>15i</b>)</h4><div class="NLM_p last">(S)-<i>tert</i>-Butyl 4-(methoxymethyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (<b>15c</b>) (3.26 g, 12.19 mmol) was added portionwise to ethyl 4-(2-chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-imidazole-2-carboxylate (<b>15h</b>) (2.5 g, 9.37 mmol), K<sub>2</sub>CO<sub>3</sub> (3.89 g, 28.12 mmol), and 18-crown-6 (0.496 g, 1.87 mmol) in 1,4-dioxane (30 mL) at 100 °C under nitrogen, and the resulting mixture was stirred at 100 °C for 12 h. The reaction mixture was then filtered and washed with DCM, and the solvent was removed under reduced pressure to afford the desired product (<i>R</i>)-(<i>tert</i>-butoxycarbonyl)(l-(4-(2-chloro-5-methylpyrimidin-4-yl)-2-(ethoxycarbonyl)-1<i>H</i>-imidazol-l-yl)-3-methoxypropan-2-yl)sulfamic acid (<b>15i</b>) (5.00 g, 100%) as a yellow oil. ES+ [M + H]+ <i>m</i>/<i>z</i> 534.</div></div><div id="sec4_1_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>R</i>)-Ethyl 1-(2-((<i>tert</i>-Butoxycarbonyl)amino)-3-methoxypropyl)-4-(2-chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-imidazole-2-carboxylate (<b>15j</b>)</h4><div class="NLM_p last">1 M HCl (20 mL, 20.00 mmol) was added to (<i>R</i>)-(<i>tert</i>-butoxycarbonyl)(l-(4-(2-chloro-5-methylpyrimidin-4-yl)-2-(ethoxycarbonyl)-1<i>H</i>-imidazol-1-yl)-3-methoxypropan-2-yl)sulfamic acid (<b>15i</b>) (5.0 g, 9.36 mmol) in EtOH (20 mL) at 25 °C under air, and the resulting mixture was stirred at 50 °C for 20 min. The reaction mixture was quenched with saturated NaHCO<sub>3</sub> (50 mL) and extracted with DCM (3 × 100 mL), and the organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to afford yellow residue. The crude product was purified by flash silica chromatography, with an elution gradient of 0 to 30% EtOAc in petroleum ether. Pure fractions were evaporated to dryness to afford (<i>R</i>)-ethyl 1-(2-((<i>tert</i>-butoxycarbonyl)amino)-3-methoxypropyl)-4-(2-chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-imidazole-2-carboxylate (<b>15j</b>) (1.0 g, 23.5%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.30 (s, 9H), 1.45 (t, <i>J</i> = 7.2 Hz, 3H), 2.69 (s, 3H), 3.37 (s, 3H), 3.47 (dd, <i>J</i> = 9.5, 4.1 Hz, 1H), 3.52 (dd, <i>J</i> = 9.5, 2.9 Hz, 1H), 4.16–4.26 (m, 1H), 4.39–4.55 (m, 3H), 4.70 (dd, <i>J</i> = 13.6, 4.6 Hz, 1H), 5.09 (d, <i>J</i> = 8.7 Hz, 1H), 7.96 (s, 1H), 8.39 (s, 1H). ES+ [M + H]+ <i>m</i>/<i>z</i> 454.</div></div><div id="sec4_1_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>R</i>)-Ethyl l-(2-Amino-3-methoxypropyl)-4-(2-chloro-5-methylpyrimidin-4-yl)-l<i>H</i>-imidazole-2 carboxylate dihydrochloride (<b>15k</b>)</h4><div class="NLM_p last">A solution of (<i>R</i>)-ethyl l-(2-((<i>tert</i>-butoxycarbonyl)amino)-3-methoxypropyl)-4-(2-chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-imidazole-2-carboxylate (<b>15j</b>) (1.0 g, 2.20 mmol) in 4 M HCl in 1,4-dioxane (20 mL) was stirred at 25 °C overnight. The precipitate was collected by filtration, washed with EtOAc (20 mL), and dried under vacuum to afford (<i>R</i>)-ethyl l-(2-amino-3-methoxypropyl)-4-(2-chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-imidazole-2 carboxylate dihydrochloride (<b>15k</b>) (0.80 g, 85%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.35 (t, <i>J</i> = 7.1 Hz, 3H), 2.63 (s, 3H), 3.52 (dd, <i>J</i> = 10.4, 5.0 Hz, 1H), 3.56 (s, 3H), 3.61 (dd, <i>J</i> = 10.5, 4.0 Hz, 1H), 3.8–3.89 (m, 1H), 4.38 (q, <i>J</i> = 7.1 Hz, 2H), 4.64–4.76 (m, 2H), 8.35 (s, 2H), 8.40 (s, 1H), 8.63–8.65 (m, 1H). ES+ [M + H]+ <i>m</i>/<i>z</i> 354.</div></div><div id="sec4_1_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>R</i>)-2-(2-Chloro-5-methylpyrimidin-4-yl)-6-(methoxymethyl)-6,7-dihydroimidazo[l,2-<i>a</i>]pyrazin-8(5<i>H</i>)-one (<b>15l</b>)</h4><div class="NLM_p last">A solution of (<i>R</i>)-ethyl 1-(2-amino-3-methoxypropyl)-4-(2-chloro-5-methylpyrimidin-4-yl)-1<i>H</i>-imidazole-2-carboxylate dihydrochloride (<b>15k</b>) (400 mg, 0.94 mmol) in 1 M NH<sub>3</sub> in MeOH (15 mL, 105.00 mmol) was stirred at 25 °C overnight. The solvent was then removed under reduced pressure, and the crude product was purified by flash silica chromatography, with an elution gradient of 0 to 5% MeOH in DCM. Pure fractions were evaporated to dryness to afford (<i>R</i>)-2-(2-chloro-5-methylpyrimidin-4-yl)-6-(methoxymethyl)-6,7-dihydroimidazo[l,2-<i>a</i>]pyrazin-8(5<i>H</i>)-one (<b>15l</b>) (280 mg, 97%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.76 (s, 3H), 3.40 (s, 3H), 3.52 (d, <i>J</i> = 6.5 Hz, 2H), 4.12–4.2 (m, 1H), 4.25 (dd, <i>J</i> = 12.7, 7.5 Hz, 1H), 4.35 (dd, <i>J</i> = 12.7, 4.7 Hz, 1H), 6.54 (s, 1H), 7.98 (s, 1H), 8.43 (s, 1H). ES+ [M + H]+ <i>m</i>/<i>z</i> 308.</div></div><div id="sec4_1_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>R</i>)-2-(2-Chloro-5-methylpyrimidin-4-yl)-7-(3,4-difluorobenzyl)-6-(methoxymethyl)-6,7-dihydroimidazo[1,2-<i>a</i>]pyrazin-8(5<i>H</i>)-one (<b>15m</b>)</h4><div class="NLM_p last">4-(Bromomethyl)-1,2-difluorobenzene (6.05 g, 29.25 mmol) was added to a stirred solution of (<i>R</i>)-2-(2-chloro-5-methylpyrimidin-4-yl)-6-(methoxymethyl)-6,7-dihydroimidazo[l,2-<i>a</i>]pyrazin-8(5<i>H</i>)-one (<b>15l</b>) (6.0 g, 19.50 mmol) and NaH (2.0 g, 50.0 mmol, 60% in mineral oil) in DMF (80 mL) at 25 °C under nitrogen. The resulting mixture was stirred at 25 °C for 2 h. The reaction mixture was quenched with saturated NaHCO<sub>3</sub> (400 mL) and extracted with EtOAc (3 × 250 mL), and the organic layers were washed with brine, dried over Na<sub>2</sub>S0<sub>4</sub>, filtered, and evaporated to afford crude material. The crude product was purified by flash silica chromatography, with an elution gradient of 0 to 5% MeOH in DCM. Pure fractions were evaporated to dryness to afford (<i>R</i>)-2-(2-chloro-5-methylpyrimidin-4-yl)-7-(3,4-difluorobenzyl)-6-(methoxymethyl)-6,7-dihydroimidazo[l,2-<i>a</i>]pyrazin-8(5<i>H</i>)-one (<b>15m</b>) (8.00 g, 95%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.76 (s, 3H), 3.22–3.31 (m, 4H), 3.37 (dd, <i>J</i> = 9.4, 4.9 Hz, 1H), 3.76–3.86 (m, 1H), 4.15–4.26 (m, 2H), 4.42 (d, <i>J</i> = 13.0 Hz, 1H), 5.33 (d, <i>J</i> = 15.0 Hz, 1H), 7.06–7.26 (m, 3H), 7.94 (s, 1H), 8.42 (s, 1H). ES+ [M + H]+ <i>m</i>/<i>z</i> 434.</div></div><div id="sec4_1_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>R</i>)-7-(3,4-Difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-<i>a</i>]pyrazin-8(5<i>H</i>)-one (<b>15</b>)</h4><div class="NLM_p last">Second generation XantPhos precatalyst (0.784 g, 0.86 mmol) was added to <i>(</i>R)-2-(2-chloro-5-methylpyrimidin-4-yl)-7-(3,4-difluorobenzyl)-6-(methoxymethyl)-6,7-dihydroimidazo[l,2-<i>a</i>]pyrazin-8(5<i>H</i>)-one (<b>15m</b>) (7.5 g, 17.29 mmol), 1-methyl-1<i>H</i>-pyrazol-5-amine (4.20 g, 43.22 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (11.27 g, 34.58 mmol) in 1,4-dioxane (200 mL) at 25 °C under nitrogen. The resulting mixture was stirred at 100 °C for 8 h before the solvent was removed under reduced pressure. The crude product was purified by flash silica chromatography, with an elution gradient of 0 to 6% MeOH in DCM. Product containing fractions were evaporated to dryness to afford a residue, which was purified further by C18-flash chromatography, with an elution gradient of 5 to 50% MeCN in water (0.1% NH<sub>4</sub>HCO<sub>3</sub>). Pure fractions were evaporated to dryness to afford (<i>R</i>)-7-(3,4-difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[l,2-<i>a</i>]pyrazin-8(5<i>H</i>)-one (<b>15</b>) (5.50 g, 64.3%) as a solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.51 (s, 3H), 3.17 (s, 3H), 3.30 (dd, <i>J</i> = 7.3, 10.1 Hz, 1H), 3.39 (dd, <i>J</i> = 5.0, 10.1 Hz, 1H), 3.69 (s, 3H), 4.03 (dtd, <i>J</i> = 1.5, 4.9, 6.8 Hz, 1H), 4.38 (d, <i>J</i> = 15.4 Hz, 1H), 4.44 (dd, <i>J</i> = 4.9, 13.6 Hz, 1H), 4.51 (dd, <i>J</i> = 1.6, 13.8 Hz, 1H), 5.08 (d, <i>J</i> = 15.4 Hz, 1H), 6.30 (d, <i>J</i> = 1.9 Hz, 1H), 7.22–7.28 (m, 1H), 7.31–7.35 (d, <i>J</i> = 1.9 Hz, 1H), 7.41 (dt, <i>J</i> = 8.4, 10.8 Hz, 1H), 7.47 (ddd, <i>J</i> = 2.2, 7.8, 11.7 Hz, 1H), 7.91–7.95 (s, 1H), 8.29–8.34 (s, 1H), 9.19–9.23 (s, 1H). ES+ [M + H]+ <i>m</i>/<i>z</i> 495. The absolute configuration of <b>15</b> was confirmed by vibrational circular dichroism spectroscopy; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Salt Screening Methodology of Compound <b>15</b></h3><div class="NLM_p">Salt screening was carried out in a high-throughput manner using glass 96-well plates. Equimolar solutions (0.025M) of <b>15</b> and each acidic counterion were prepared in methanol. From these solutions, 100 μL of <b>15</b> and 100 μL of each counterion were added to each well of a glass 96-well plate (equimolar stoichiometry). The wells were sealed with foil and pin-holed to allow slow evaporation of the solvent. The plates were placed at 25 °C and gently shaken for 1–2 days until evaporation of the solvent was complete. Each well was subsequently analyzed by polarized light microscopy (PLM) to detect the presence of crystalline, birefringent material (as opposed to nonbirefringent amorphous material/liquid). To give any potential salt an increased opportunity to crystallize, four further rounds of solvent addition and evaporation were applied. Thus, 200 μL of ethyl acetate, acetonitrile, acetone, and propan-2-ol/water (50/50) were next added to the wells, allowed to evaporate, and analyzed by PLM. See <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">7</a></a> for acidic counterions used in salt screening.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Acidic Counterions Evaluated in Salt Screening</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">acetic</td><td class="colsep0 rowsep0" align="center">HCl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">adipic</td><td class="colsep0 rowsep0" align="center"><span class="smallcaps smallerCapital">l</span>-tartaric</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">benzoic</td><td class="colsep0 rowsep0" align="center">maleic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">benzenesulfonic</td><td class="colsep0 rowsep0" align="center">malic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">camphor-10-sulfonic</td><td class="colsep0 rowsep0" align="center">malonic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">cinnamic</td><td class="colsep0 rowsep0" align="center">mesitylene sulfonic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">citric</td><td class="colsep0 rowsep0" align="center">methanesulfonic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">lactic</td><td class="colsep0 rowsep0" align="center">naphthalene sulfonic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">ethanedisulfonic</td><td class="colsep0 rowsep0" align="center">phosphoric</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">ethanesulfonic</td><td class="colsep0 rowsep0" align="center">saccharin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">fumaric</td><td class="colsep0 rowsep0" align="center">sulfuric</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">toluenesulfonic</td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div></div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Xenograft Mouse Studies</h3><div class="NLM_p last">Athymic Nude-Foxn1 nu mice (Envigo) were housed under specific pathogen-free conditions in individually ventilated cages (Techniplast) at Alderley Park, United Kingdom. Mice had access to water and food ad libitum. Experiments were conducted in 8 to 12 week old female mice in full accordance with the UK Home Office Animal (Scientific Procedures) Act 1986. Calu-6 nonsmall cell–lung cancer cells were grown in RPMI 1640, and A549 nonsmall cell–lung cancer cells were grown in DMEM both supplemented with 10% fetal calf serum and 1% <span class="smallcaps smallerCapital">l</span>-glutamine (all cell culture supplies sourced from Sigma-Aldrich) under standard cell culture conditions. Cells were harvested, and mice were injected subcutaneously with 1 × 10<sup>6</sup> cells/mouse of Calu-6 cells and 5 × 10<sup>6</sup> cells/mouse of A549 cells both in 1:1 v/v mice of Matrigel (Becton Dickinson). Tumor growth was monitored by calliper measurement, and volume was calculated using the following equation: (3.142 × max (length:width) × min (length:width) × min (length:width))/6000. Mice were enrolled into study when tumors reached an average size of 0.2 cm<sup>3</sup>; all studies were appropriately statistically powered.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Efficacy and Pharmacodynamic (PD) Evaluation</h3><div class="NLM_p last">To evaluate the efficacy of <b>15</b>, mice were dosed orally once daily with the compound formulated in 10% DMSO and 90% of a 40% Kleptose solution as a single agent or in combination with selumetinib, which was dosed twice daily at 25 mg/kg formulated in 0.5% Methocel (hydroxypropyl methocellulose)/0.1% Polysorbate 80. Mice were dosed for up to 21 days, and tumor growth was monitored twice weekly for the duration. The geomean (average of log10 volumes) of each group was calculated and plotted using GraphPad Prism 8 for Windows (Graph Pad Software Inc.). PD evaluation in the Calu-6 model was carried out from samples taken at the end of the efficacy study. Animals were euthanised at either 0.5 or 6 h post the last dose, terminal blood samples were taken for mass spectrometry quantification of compound levels, and tumors were excised and snap frozen for Western blot analysis. Western blot was carried out as described previously<sup>30</sup> with antibodies again phospho-p90RSK (Abcam).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Biochemical and Cellular Assays</h3><div class="NLM_p last">A full description of compound handling and experimental methods for all of the biochemical and cellular assays used in this work can be found in our previous publication.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> IC<sub>50</sub> data reported as <0.0003 μM refers to values below the tight binding limit of the ERK2 biochemical assays.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> CDK2:Cyclin E Electromobility Shift Assay</h3><div class="NLM_p last">The inhibitory activity of test compounds against CDK2 was determined with a Caliper off-chip incubation mobility shift assay, using a microfluidic chip to measure the conversion of a fluorescently labeled peptide to a phosphorylated product. The protein complex of recombinant full-length human CDK2 containing a C-terminal His6-tag and recombinant full-length human cyclin E containing an N-terminal GST-tag (expressed by baculovirus in Sf21 insect cells), was obtained from Upstate. A custom peptide substrate with a fluorescent tag, sequence specific for CDK2, was obtained from Cambridge Research Biochemicals (Cleveland, UK). Enzymes, peptide substrates, and ATP were incubated in the presence of compound diluted in DMSO (1% v/v DMSO assay final), in white Greiner 384-well low-volume plates, in a total reaction volume of 12 μL. The kinase reaction [90 μM (<i>K</i><sub>m</sub>) ATP, 1 nM CDK2 enzyme, 1.5 μM substrate] in phosphorylation buffer [50 mM HEPES (pH 7.5), 5 mM MgCl<sub>2</sub>, 1 mM DTT, 0.05% CHAPSO] was allowed to progress for 60 min at room temperature, before being quenched by the addition of a stop buffer [comprising 100 mM HEPES (pH 7.5), 5% DMSO, 88 mM EDTA, 0.22% Caliper Coating Reagent #3, 0.033% Brij-35 solution]. Stopped assay plates were then read using the Caliper LabChip LC3000.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Surface Plasmon Resonance (SPR) Binding Assays</h3><div class="NLM_p last">Unphosphorylated biotinylated-ERK2 protein and MEK-activated (diphosphorylated) biotinylated-ERK2 protein were both expressed and purified in-house. A streptavidin Biacore chip (#BR100531, GE Healthcare) was docked into a Biacore T200 instrument. Assay buffer consisting of 20 mM Tris (pH 7.7), 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 0.5 mM TCEP (tris(2-carboxyethyl)phosphine), 0.005% (v/v) Tween-20 (polyoxyethylene(20)sorbitan monolaurate), and 1% DMSO (dimethyl sulfoxide) was equilibrated at 25 °C (room temperature) on the T200 instrument and used to dilute compounds. Flow cell 1 was used as a reference.  Biotinylated avi-tagged ERK2 protein (2 μg/mL) was prepared in assay buffer, and approximately, 500 RU of biotinylated protein was immobilized onto flow cell 2 (unphosphorylated ERK2) or flow cells 3 and 4 (diphosphorylated ERK2) of the streptavidin biacore chip using the “aim for” method in the T200 Control Software (GE Healthcare). Unbound sites were blocked with 50 μM amino-PEG biotin (#21346, ThermoFisher). Compounds were prepared in assay buffer in a 384-well plate (#781201, Greiner). Binding was determined using the “Single Cycle Kinetics” method in the Biacore T200 Evaluation software, including solvent correction and a 50% DMSO wash between samples. The injection time was 260 s, and the dissociation time was 3000 s. Blanks were run before and after compound injections, and data was double-referenced. Data was analyzed, and rate constants/affinities were calculated using the Biacore T200 Evaluation software (GE Healthcare).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> ERK2 Protein Crystal Structures</h3><div class="NLM_p">Protein crystals were generated using the hanging drop technique by mixing equal volumes of protein solution (approximately 10 mg/mL human ERK2 in 20 mM HEPES, pH 7.8, 200 mM NaCl, 0.5 mM TCEP) and crystallization buffer (30% PegMME2K, 100 mM HEPES, pH 7.6, 200 mM ammonium sulfate). Data collections were carried out at the Diamond Light Source synchrotron beamline i04 at cryogenic temperatures, using ethylene glycol as cryoprotectant. The CCP4 and autoBUSTER software packages were used to solve and refine the structures, and the program Coot was used for manual building of the models. Data collection and refinement are listed below. Binding mode figures including electron density maps can be found in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_001.pdf" class="ext-link">Supporting Information</a>, Figure S2.<named-content content-type="anchor" rid="tbl6a" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl6a"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. ERK2 Protein Crystal Structure Data Collection and Refinement Statistics (PDB Code 6SLG)<a class="ref internalNav" href="#tbl6a-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PDB code</th><th class="colsep0 rowsep0" align="center">6SLG</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="center"><i>P</i>2<sub>1</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>a</i> [Å]</td><td class="colsep0 rowsep0" align="center">48.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>b</i> [Å]</td><td class="colsep0 rowsep0" align="center">70.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>c</i> [Å]</td><td class="colsep0 rowsep0" align="center">60.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">β [°]</td><td class="colsep0 rowsep0" align="center">109.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution [Å]</td><td class="colsep0 rowsep0" align="center">1.34 (1.41–1.34)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unique reflections</td><td class="colsep0 rowsep0" align="center">70 428</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">multiplicity</td><td class="colsep0 rowsep0" align="center">4.4 (2.0)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness</td><td class="colsep0 rowsep0" align="center">88.0 (37.0)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>meas</sub></td><td class="colsep0 rowsep0" align="center">0.031 (0.64)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mean (<i>I</i>)/SD</td><td class="colsep0 rowsep0" align="center">24.9 (1.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">reflections</td><td class="colsep0 rowsep0" align="center">306 381 (7101)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>/<i>R</i><sub>free</sub></td><td class="colsep0 rowsep0" align="center">0.206/0.228</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CC (1/2)</td><td class="colsep0 rowsep0" align="center">0.99 (0.75)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">deviation from ideal geometry</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bond lengths</td><td class="colsep0 rowsep0" align="center">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bond angles</td><td class="colsep0 rowsep0" align="center">1.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ramachandran plot (%)</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">preferred region</td><td class="colsep0 rowsep0" align="center">96.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">generously allowed region</td><td class="colsep0 rowsep0" align="center">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">disallowed region</td><td class="colsep0 rowsep0" align="center">0.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6a-fn1"><div class="footnote" id="tbl6a-fn1"><sup><sup>a</sup></sup><p class="last">Data in parentheses refer to the highest resolution shell.</p></div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01295" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08242" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08242" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01295?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01295</a>. <ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional data analyses, experimental information, compound molecular formula strings, and compound characterization (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">ERK2 biochemical, kM ATP IC50 (μM); ERK2 biochemical, high ATP IC50 (μM); cell MOA A375 pERK IC50 (μM); cell MOA A375 pRSK IC50 (μM) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_001.pdf">jm9b01295_si_001.pdf (508.06 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_002.csv">jm9b01295_si_002.csv (1.29 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates and structure factors have been deposited in the Protein Data Bank under the accession code 6SLG. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01295" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40832" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40832" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard A. Ward</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2310-9477" title="Orcid link">http://orcid.org/0000-0002-2310-9477</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e5978c868d849781cb84cb92849781a584969197849f808b808684cb868a88"><span class="__cf_email__" data-cfemail="8efce7ede6effceaa0efa0f9effceaceeffdfafceff4ebe0ebedefa0ede1e3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark J. Anderton</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Bethel</span> - <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Breed</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Calum Cook</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emma J. Davies</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Dobson</span> - <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiqiang Dong</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary Fairley</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Farrington</span> - <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lyman Feron</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vikki Flemington</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francis D. Gibbons</span> - <span class="hlFld-Affiliation affiliation">DMPK, Oncology
R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Graham</span> - <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan Greenwood</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lyndsey Hanson</span> - <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Hopcroft</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachel Howells</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julian Hudson</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">DMPK, Oncology
R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals
R&D, AstraZeneca, Gothenburg 431 50, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael James</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">DMPK, Oncology
R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals
R&D, AstraZeneca, Gothenburg 431 50, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clifford D. Jones</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">DMPK, Oncology
R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals
R&D, AstraZeneca, Gothenburg 431 50, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher R. Jones</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">DMPK, Oncology
R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals
R&D, AstraZeneca, Gothenburg 431 50, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongchao Li</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Lamont</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Lewis</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals
R&D, AstraZeneca, Gothenburg 431 50, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicola Lindsay</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James McCabe</span> - <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas McGuire</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Rawlins</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Roberts</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linda Sandin</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">DMPK, Oncology
R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals
R&D, AstraZeneca, Gothenburg 431 50, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iain Simpson</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Bioscience,
Oncology R&D, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">DMPK, Oncology
R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals
R&D, AstraZeneca, Gothenburg 431 50, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Swallow</span> - <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Tang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary Tomkinson</span> - <span class="hlFld-Affiliation affiliation">Chemical
Development, Pharmaceutical Technology & Development, AstraZeneca, Macclesfield Campus, Macclesfield SK10
2NA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Tonge</span> - <span class="hlFld-Affiliation affiliation">Oncology
and Discovery Sciences R&D, AstraZeneca, Darwin Building and Hodgkin Building, c/o Darwin
Building, 310 Cambridge Science Park, Milton Rd, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenhua Wang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Baochang Zhai</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All the work in this manuscript was funded by AstraZeneca.<br /></br><p class="inlineNote">Former employee of AstraZeneca. (J.H., M.J., C.D.J., C.R.J., L.S., I.S.)</p></div></li></ul></div><div class="ack" id="ACK-d7e3374-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank all colleagues at AstraZeneca who were involved in the work reported in this manuscript. This includes all project team members and functions including compound purification, compound handling, and technical support across the organization. All the work in this manuscript was funded by AstraZeneca.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">IOC</td><td class="NLM_def"><p class="first last">inhibition of catalysis</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">MOA</td><td class="NLM_def"><p class="first last">mechanism of action</p></td></tr><tr><td class="NLM_term">POA</td><td class="NLM_def"><p class="first last">prevention of activation</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41130" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41130" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 26 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolch, W.</span></span> <span> </span><span class="NLM_article-title">MAP Kinase Signalling Pathways In Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3279</span>– <span class="NLM_lpage">3290</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&issue=22&author=A.+S.+Dhillonauthor=S.+Haganauthor=O.+Rathauthor=W.+Kolch&title=MAP+Kinase+Signalling+Pathways+In+Cancer&doi=10.1038%2Fsj.onc.1210421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0lirLfoNKotSgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DRath%26aufirst%3DO.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520Kinase%2520Signalling%2520Pathways%2520In%2520Cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26issue%3D22%26spage%3D3279%26epage%3D3290%26doi%3D10.1038%2Fsj.onc.1210421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of Cancer: The Next Generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&issue=5&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+Cancer%3A+The+Next+Generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lirLfoNKotSgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520Cancer%253A%2520The%2520Next%2520Generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26issue%3D5%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seger, R.</span></span> <span> </span><span class="NLM_article-title">The Extracellular Signal-Regulated Kinase: Multiple Substrates Regulate Diverse Cellular Functions</span>. <i>Growth Factors</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1080/02699050500284218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1080%2F02699050500284218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=16393692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlGht7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=21-44&issue=1&author=S.+Yoonauthor=R.+Seger&title=The+Extracellular+Signal-Regulated+Kinase%3A+Multiple+Substrates+Regulate+Diverse+Cellular+Functions&doi=10.1080%2F02699050500284218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions</span></div><div class="casAuthors">Yoon, Seunghee; Seger, Rony</div><div class="citationInfo"><span class="NLM_cas:title">Growth Factors</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-44</span>CODEN:
                <span class="NLM_cas:coden">GRFAEC</span>;
        ISSN:<span class="NLM_cas:issn">0897-7194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The extracellular signal-regulated kinase (ERK) cascade is a central pathway that transmits signals from many extracellular agents to regulate cellular processes such as proliferation, differentiation, and cell cycle progression.  The signaling via the ERK cascade is mediated by sequential phosphorylation and activation of protein kinases in the different tiers of the cascade.  Although the main core phosphorylation chain of the cascade includes Raf kinases, MEK1/2, ERK1/2 (ERKs) and RSKs, other alternatively spliced forms and distinct components exist in the different tiers, and participate in ERK signaling under specific conditions.  These components enhance the complexity of the ERK cascade and thereby, enable the wide variety of functions that are regulated by it.  Another factor that is important for the dissemination of ERKs' signals is the multiplicity of the cascade's substrates, which include transcription factors, protein kinases and phosphatases, cytoskeletal elements, regulators of apoptosis, and a variety of other signaling-related mols.  About 160 substrates have already been discovered for ERKs, and the list of these substrates, as well as the function and mechanism of activation of representative substrates, are described in the current review.  Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation.  However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis, and apoptosis.  Understanding of these processes may provide a full picture of the distinct, and even opposing cellular processes that are regulated by the ERK cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdE2tenNpAU7Vg90H21EOLACvtfcHk0ljW82iRLbw9DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlGht7jP&md5=746d0818f7fc07229673dfdd6b4165b3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F02699050500284218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F02699050500284218%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DSeger%26aufirst%3DR.%26atitle%3DThe%2520Extracellular%2520Signal-Regulated%2520Kinase%253A%2520Multiple%2520Substrates%2520Regulate%2520Diverse%2520Cellular%2520Functions%26jtitle%3DGrowth%2520Factors%26date%3D2006%26volume%3D24%26issue%3D1%26spage%3D21%26epage%3D44%26doi%3D10.1080%2F02699050500284218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyse, S. M.</span></span> <span> </span><span class="NLM_article-title">Differential Regulation of MAP Kinase Signalling By Dual-Specificity Protein Phosphatases</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3203</span>– <span class="NLM_lpage">3213</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1038%2Fsj.onc.1210412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=17496916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3203-3213&issue=22&author=D.+M.+Owensauthor=S.+M.+Keyse&title=Differential+Regulation+of+MAP+Kinase+Signalling+By+Dual-Specificity+Protein+Phosphatases&doi=10.1038%2Fsj.onc.1210412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases</span></div><div class="casAuthors">Owens, D. M.; Keyse, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3203-3213</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The regulated dephosphorylation of mitogen-activated protein kinases (MAPKs) plays a key role in detg. the magnitude and duration of kinase activation and hence the physiol. outcome of signaling.  In mammalian cells, an important component of this control is mediated by the differential expression and activities of a family of 10 dual-specificity (Thr/Tyr) MAPK phosphatases (MKPs).  These enzymes share a common structure in which MAPK substrate recognition is detd. by sequences within an amino-terminal non-catalytic domain whereas MAPK binding often leads to a conformational change within the C-terminal catalytic domain resulting in increased enzyme activity.  MKPs can either recognize and inactivate a single class of MAP kinase, as in the specific inactivation of extracellular signal regulated kinase (ERK) by the cytoplasmic phosphatase DUSP6/MKP-3 or can regulate more than one MAPK pathway as illustrated by the ability of DUSP1/MKP-1 to dephosphorylate ERK, c-Jun amino-terminal kinase and p38 in the cell nucleus.  These properties, coupled with transcriptional regulation of MKP expression in response to stimuli that activate MAPK signaling, suggest a complex neg. regulatory network in which individual MAPK activities can be subject to neg. feedback control, but also raise the possibility that signaling through multiple MAPK pathways may be integrated at the level of regulation by MKPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCRQreSvWHwbVg90H21EOLACvtfcHk0ljW82iRLbw9DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktL0%253D&md5=02c50290ecf041cb33318272ca5c8024</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210412%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DD.%2BM.%26aulast%3DKeyse%26aufirst%3DS.%2BM.%26atitle%3DDifferential%2520Regulation%2520of%2520MAP%2520Kinase%2520Signalling%2520By%2520Dual-Specificity%2520Protein%2520Phosphatases%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26issue%3D22%26spage%3D3203%26epage%3D3213%26doi%3D10.1038%2Fsj.onc.1210412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vakiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">KRAS and BRAF: Drug Targets and Predictive Biomarkers</span>. <i>J. Pathol</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>223</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1002/path.2796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1002%2Fpath.2796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2011&pages=220-230&issue=2&author=E.+Vakianiauthor=D.+B.+Solit&title=KRAS+and+BRAF%3A+Drug+Targets+and+Predictive+Biomarkers&doi=10.1002%2Fpath.2796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fpath.2796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2796%26sid%3Dliteratum%253Aachs%26aulast%3DVakiani%26aufirst%3DE.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DKRAS%2520and%2520BRAF%253A%2520Drug%2520Targets%2520and%2520Predictive%2520Biomarkers%26jtitle%3DJ.%2520Pathol%26date%3D2011%26volume%3D223%26issue%3D2%26spage%3D220%26epage%3D230%26doi%3D10.1002%2Fpath.2796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebolt-Leopold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">BRAF Mutation Predicts Sensitivity to MEK Inhibition</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>439</i></span> (<span class="NLM_issue">7074</span>),  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1038/nature04304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1038%2Fnature04304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=16273091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=358-362&issue=7074&author=D.+B.+Solitauthor=L.+A.+Garrawayauthor=C.+A.+Pratilasauthor=A.+Sawaiauthor=G.+Getzauthor=A.+Bassoauthor=Q.+Yeauthor=J.+M.+Loboauthor=Y.+Sheauthor=I.+Osmanauthor=T.+R.+Golubauthor=J.+Sebolt-Leopoldauthor=W.+R.+Sellersauthor=N.+Rosen&title=BRAF+Mutation+Predicts+Sensitivity+to+MEK+Inhibition&doi=10.1038%2Fnature04304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF mutation predicts sensitivity to MEK inhibition</span></div><div class="casAuthors">Solit, David B.; Garraway, Levi A.; Pratilas, Christine A.; Sawai, Ayana; Getz, Gad; Basso, Andrea; Ye, Qing; Lobo, Jose M.; She, Yuhong; Osman, Iman; Golub, Todd R.; Sebolt-Leopold, Judith; Sellers, William R.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7074</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumors, often through gain-of-function mutations of RAS and RAF family members.  Using small-mol. inhibitors of MEK and an integrated genetic and pharmacol. anal., we find that mutation of BRAF is assocd. with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harboring a RAS mutation.  This MEK dependency was obsd. in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest.  Pharmacol. MEK inhibition completely abrogated tumor growth in BRAF mutant xenografts, whereas RAS mutant tumors were only partially inhibited.  These data suggest an exquisite dependency on MEK activity in BRAF mutant tumors, and offer a rational therapeutic strategy for this genetically defined tumor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpBpONOvd0vbVg90H21EOLACvtfcHk0ljW82iRLbw9DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D&md5=37c8976aa5bb371ef5580aab2a91f89e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature04304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04304%26sid%3Dliteratum%253Aachs%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSawai%26aufirst%3DA.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DLobo%26aufirst%3DJ.%2BM.%26aulast%3DShe%26aufirst%3DY.%26aulast%3DOsman%26aufirst%3DI.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DBRAF%2520Mutation%2520Predicts%2520Sensitivity%2520to%2520MEK%2520Inhibition%26jtitle%3DNature%26date%3D2006%26volume%3D439%26issue%3D7074%26spage%3D358%26epage%3D362%26doi%3D10.1038%2Fnature04304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dwyer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Mutated, Activated BRAF in Metastatic Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1002011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&issue=9&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+Mutated%2C+Activated+BRAF+in+Metastatic+Melanoma&doi=10.1056%2FNEJMoa1002011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lgXhQzPBwgcuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520Mutated%252C%2520Activated%2520BRAF%2520in%2520Metastatic%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D9%26spage%3D809%26epage%3D819%26doi%3D10.1056%2FNEJMoa1002011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span> <span> </span><span class="NLM_article-title">Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1210093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1056%2FNEJMoa1210093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=23020132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1694-1703&issue=18&author=K.+T.+Flahertyauthor=J.+R.+Infanteauthor=A.+Daudauthor=R.+Gonzalezauthor=R.+F.+Keffordauthor=J.+Sosmanauthor=O.+Hamidauthor=L.+Schuchterauthor=J.+Cebonauthor=N.+Ibrahimauthor=R.+Kudchadkarauthor=H.+A.+Burrisauthor=G.+Falchookauthor=A.+Algaziauthor=K.+Lewisauthor=G.+V.+Longauthor=I.+Puzanovauthor=P.+Lebowitzauthor=A.+Singhauthor=S.+Littleauthor=P.+Sunauthor=A.+Allredauthor=D.+Ouelletauthor=K.+B.+Kimauthor=K.+Patelauthor=J.+Weber&title=Combined+BRAF+and+MEK+Inhibition+in+Melanoma+with+BRAF+V600+Mutations&doi=10.1056%2FNEJMoa1210093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span></div><div class="casAuthors">Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Resistance to therapy with BRAF kinase inhibitors is assocd. with reactivation of the mitogen-activated protein kinase (MAPK) pathway.  To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.  METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy.  The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.  Secondary end points were overall survival and pharmacokinetic activity.  RESULTS Dose-limiting toxic effects were infrequently obsd. in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2).  Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%).  Median progression-free survival in the combination 150/2 group was 9.4 mo, as compared with 5.8 mo in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001).  The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).  CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses.  The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced.  Progression-free survival was significantly improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk7I8zrGTVbVg90H21EOLACvtfcHk0lgXhQzPBwgcuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ&md5=199ae281d44c3b41309b934d88674cd3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1210093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1210093%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLittle%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DAllred%26aufirst%3DA.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520Inhibition%2520in%2520Melanoma%2520with%2520BRAF%2520V600%2520Mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D18%26spage%3D1694%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1210093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang-Gillam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchbinder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacouture, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Crescenzo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groover, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varterasian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span> <span> </span><span class="NLM_article-title">First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-1119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1158%2F2159-8290.CD-17-1119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=29247021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFCrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=184-195&issue=2&author=R.+J.+Sullivanauthor=J.+R.+Infanteauthor=F.+Jankuauthor=D.+J.+L.+Wongauthor=J.+A.+Sosmanauthor=V.+Keedyauthor=M.+R.+Patelauthor=G.+I.+Shapiroauthor=J.+W.+Mierauthor=A.+W.+Tolcherauthor=A.+Wang-Gillamauthor=M.+Sznolauthor=K.+Flahertyauthor=E.+Buchbinderauthor=R.+D.+Carvajalauthor=A.+M.+Vargheseauthor=M.+E.+Lacoutureauthor=A.+Ribasauthor=S.+P.+Patelauthor=G.+A.+De+Crescenzoauthor=C.+M.+Emeryauthor=A.+L.+Grooverauthor=S.+Sahaauthor=M.+Varterasianauthor=D.+J.+Welschauthor=D.+M.+Hymanauthor=B.+T.+Li&title=First-in-Class+ERK1%2F2+Inhibitor+Ulixertinib+%28BVD-523%29+in+Patients+with+MAPK+Mutant+Advanced+Solid+Tumors%3A+Results+of+a+Phase+I+Dose-Escalation+and+Expansion+Study&doi=10.1158%2F2159-8290.CD-17-1119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study</span></div><div class="casAuthors">Sullivan, Ryan J.; Infante, Jeffrey R.; Janku, Filip; Wong, Deborah Jean Lee; Sosman, Jeffrey A.; Keedy, Vicki; Patel, Manish R.; Shapiro, Geoffrey I.; Mier, James W.; Tolcher, Anthony W.; Wang-Gillam, Andrea; Sznol, Mario; Flaherty, Keith; Buchbinder, Elizabeth; Carvajal, Richard D.; Varghese, Anna M.; Lacouture, Mario E.; Ribas, Antoni; Patel, Sapna P.; De Crescenzo, Gary A.; Emery, Caroline M.; Groover, Anna L.; Saha, Saurabh; Varterasian, Mary; Welsch, Dean J.; Hyman, David M.; Li, Bob T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-195</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclin. activity in BRAF- and RAS-mutant cell lines.  In this multicenter phase I trial (NCT01781429), 135 patients were enrolled to an accelerated 3 + 3 dose-escalation cohort and six distinct dose-expansion cohorts.  Dose escalation included 27 patients, dosed from 10 to 900 mg twice daily and established the recommended phase II dose (RP2D) of 600 mg twice daily.  Ulixertinib exposure was dose proportional to the RP2D, which provided near-complete inhibition of ERK activity in whole blood.  In the 108-patient expansion cohort, 32% of patients required dose redn.  The most common treatment-related adverse events were diarrhea (48%), fatigue (42%), nausea (41%), and dermatitis acneiform (31%).  Partial responses were seen in 3 of 18 (17%) patients dosed at or above max. tolerated dose and in 11 of 81 (14%) evaluable patients in dose expansion.  Responses occurred in patients with NRAS-, BRAF V600-, and non-V600 BRAF-mutant solid tumors.  Here, we describe the first-in-human dose-escalation study of an ERK1/2 inhibitor for the treatment of patients with advanced solid tumors.  Ulixertinib has an acceptable safety profile with favorable pharmacokinetics and has shown early evidence of clin. activity in NRAS- and BRAF V600- and non-V600-mutant solid-tumor malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYm_KSTskkaLVg90H21EOLACvtfcHk0lhOMSTQF_Yp_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFCrt7w%253D&md5=9ddff8422bdf7e7d605cb069741058fc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-1119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-1119%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DWong%26aufirst%3DD.%2BJ.%2BL.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKeedy%26aufirst%3DV.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DMier%26aufirst%3DJ.%2BW.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DWang-Gillam%26aufirst%3DA.%26aulast%3DSznol%26aufirst%3DM.%26aulast%3DFlaherty%26aufirst%3DK.%26aulast%3DBuchbinder%26aufirst%3DE.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DVarghese%26aufirst%3DA.%2BM.%26aulast%3DLacouture%26aufirst%3DM.%2BE.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DS.%2BP.%26aulast%3DDe%2BCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DEmery%26aufirst%3DC.%2BM.%26aulast%3DGroover%26aufirst%3DA.%2BL.%26aulast%3DSaha%26aufirst%3DS.%26aulast%3DVarterasian%26aufirst%3DM.%26aulast%3DWelsch%26aufirst%3DD.%2BJ.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DLi%26aufirst%3DB.%2BT.%26atitle%3DFirst-in-Class%2520ERK1%252F2%2520Inhibitor%2520Ulixertinib%2520%2528BVD-523%2529%2520in%2520Patients%2520with%2520MAPK%2520Mutant%2520Advanced%2520Solid%2520Tumors%253A%2520Results%2520of%2520a%2520Phase%2520I%2520Dose-Escalation%2520and%2520Expansion%2520Study%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D2%26spage%3D184%26epage%3D195%26doi%3D10.1158%2F2159-8290.CD-17-1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restaino, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayananth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNunzio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angagaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipps, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daublain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliphaivanh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&issue=7&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+DiNunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagawauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+A.+Samatar&title=Discovery+of+a+Novel+ERK+Inhibitor+with+Activity+in+Models+of+Acquired+Resistance+to+BRAF+and+MEK+Inhibitors&doi=10.1158%2F2159-8290.CD-13-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0lhOMSTQF_Yp_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDiNunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520ERK%2520Inhibitor%2520with%2520Activity%2520in%2520Models%2520of%2520Acquired%2520Resistance%2520to%2520BRAF%2520and%2520MEK%2520Inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D7%26spage%3D742%26epage%3D750%26doi%3D10.1158%2F2159-8290.CD-13-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moschos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawbi, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, T. S.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miselis, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayananth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipps, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Development of MK-8353, an Orally Administered ERK1/2 Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">e92352</span>, <span class="refDoi"> DOI: 10.1172/jci.insight.92352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1172%2Fjci.insight.92352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=29467321" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=e92352&issue=4&author=S.+J.+Moschosauthor=R.+J.+Sullivanauthor=W.+J.+Hwuauthor=R.+K.+Ramanathanauthor=A.+A.+Adjeiauthor=P.+C.+Fongauthor=R.+Shapira-Frommerauthor=H.+A.+Tawbiauthor=J.+Rubinoauthor=T.+S.+Rushauthor=D.+Zhangauthor=N.+R.+Miselisauthor=A.+A.+Samatarauthor=P.+Chunauthor=E.+H.+Rubinauthor=J.+Schillerauthor=B.+J.+Longauthor=P.+Dayananthauthor=D.+Carrauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=Y.+Dengauthor=A.+Cooperauthor=G.+W.+Shippsauthor=B.+H.+Morenoauthor=L.+Robertauthor=A.+Ribasauthor=K.+T.+Flaherty&title=Development+of+MK-8353%2C+an+Orally+Administered+ERK1%2F2+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1172%2Fjci.insight.92352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.92352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.92352%26sid%3Dliteratum%253Aachs%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DTawbi%26aufirst%3DH.%2BA.%26aulast%3DRubino%26aufirst%3DJ.%26aulast%3DRush%26aufirst%3DT.%2BS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMiselis%26aufirst%3DN.%2BR.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DChun%26aufirst%3DP.%26aulast%3DRubin%26aufirst%3DE.%2BH.%26aulast%3DSchiller%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DB.%2BJ.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DShipps%26aufirst%3DG.%2BW.%26aulast%3DMoreno%26aufirst%3DB.%2BH.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DDevelopment%2520of%2520MK-8353%252C%2520an%2520Orally%2520Administered%2520ERK1%252F2%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJCI%2520Insight%26date%3D2018%26volume%3D3%26issue%3D4%26spage%3De92352%26doi%3D10.1172%2Fjci.insight.92352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linghu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudino, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of GDC-0994: A Selective and Efficacious Small Molecule Inhibitor of ERK1/2</span>. <i>Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 1</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1307</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1021/bk-2018-1307.ch001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bk-2018-1307.ch001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1307&publication_year=2018&pages=1-28&author=X.+Linghuauthor=N.+Wongauthor=J.+F.+Blakeauthor=J.+J.+Gaudinoauthor=J.+G.+Moffat&title=Discovery+and+Development+of+GDC-0994%3A+A+Selective+and+Efficacious+Small+Molecule+Inhibitor+of+ERK1%2F2&doi=10.1021%2Fbk-2018-1307.ch001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fbk-2018-1307.ch001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbk-2018-1307.ch001%26sid%3Dliteratum%253Aachs%26aulast%3DLinghu%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DN.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520GDC-0994%253A%2520A%2520Selective%2520and%2520Efficacious%2520Small%2520Molecule%2520Inhibitor%2520of%2520ERK1%252F2%26jtitle%3DComplete%2520Accounts%2520of%2520Integrated%2520Drug%2520Discovery%2520and%2520Development%253A%2520Recent%2520Examples%2520from%2520the%2520Pharmaceutical%2520Industry%2520Volume%25201%26date%3D2018%26volume%3D1307%26spage%3D1%26epage%3D28%26doi%3D10.1021%2Fbk-2018-1307.ch001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillen, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flack, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dropsey, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiu, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery of LY3214996, a Selective and Novel ERK1/2 Inhibitor with Potent Antitumor Activities in Cancer Models with MAPK pathway</span>. <i>Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4973</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-4973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1158%2F1538-7445.AM2017-4973" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4973&issue=13&author=S.+V.+Bhagwatauthor=W.+T.+McMillenauthor=S.+Caiauthor=B.+Zhaoauthor=M.+Whitesellauthor=L.+Kindlerauthor=R.+S.+Flackauthor=W.+Wuauthor=K.+Hussauthor=B.+Andersonauthor=X.-J.+Yuanauthor=S.+Jakenauthor=D.+McCannauthor=B.+Mathesauthor=A.+J.+Dropseyauthor=J.+Manroauthor=J.+Walgrenauthor=E.+Yuenauthor=X.+Gongauthor=M.+J.+Rodriguezauthor=J.+Huangauthor=R.+V.+Tiuauthor=S.+Josephauthor=S.-B.+Peng&title=Discovery+of+LY3214996%2C+a+Selective+and+Novel+ERK1%2F2+Inhibitor+with+Potent+Antitumor+Activities+in+Cancer+Models+with+MAPK+pathway&doi=10.1158%2F1538-7445.AM2017-4973"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-4973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-4973%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwat%26aufirst%3DS.%2BV.%26aulast%3DMcMillen%26aufirst%3DW.%2BT.%26aulast%3DCai%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DWhitesell%26aufirst%3DM.%26aulast%3DKindler%26aufirst%3DL.%26aulast%3DFlack%26aufirst%3DR.%2BS.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DX.-J.%26aulast%3DJaken%26aufirst%3DS.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DMathes%26aufirst%3DB.%26aulast%3DDropsey%26aufirst%3DA.%2BJ.%26aulast%3DManro%26aufirst%3DJ.%26aulast%3DWalgren%26aufirst%3DJ.%26aulast%3DYuen%26aufirst%3DE.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DRodriguez%26aufirst%3DM.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DTiu%26aufirst%3DR.%2BV.%26aulast%3DJoseph%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DS.-B.%26atitle%3DDiscovery%2520of%2520LY3214996%252C%2520a%2520Selective%2520and%2520Novel%2520ERK1%252F2%2520Inhibitor%2520with%2520Potent%2520Antitumor%2520Activities%2520in%2520Cancer%2520Models%2520with%2520MAPK%2520pathway%26jtitle%3DProceedings%253A%2520AACR%2520Annual%2520Meeting%25202017%253B%2520April%25201-5%252C%25202017%253B%2520Washington%252C%2520DC%26date%3D2017%26volume%3D77%26issue%3D13%26spage%3D4973%26doi%3D10.1158%2F1538-7445.AM2017-4973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronchik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavrommatis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filvaroff, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">642</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-17-0554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1158%2F1541-7786.MCR-17-0554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=30275173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=642-654&issue=2&author=I.+Aronchikauthor=Y.+Daiauthor=M.+Malekauthor=K.+Mavrommatisauthor=G.+L.+Brayauthor=E.+H.+Filvaroffauthor=M.+Labenskiauthor=C.+Barnesauthor=T.+Jonesauthor=L.+Qiaoauthor=L.+Beebeauthor=W.+Elisauthor=T.+Shi&title=Efficacy+of+a+Covalent+ERK1%2F2+Inhibitor%2C+CC-90003%2C+in+KRAS-Mutant+Cancer+Models+Reveals+Novel+Mechanisms+of+Response+and+Resistance&doi=10.1158%2F1541-7786.MCR-17-0554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a covalent ERK1/2 inhibitor, CC-90003, in KRAS-mutant cancer models reveals novel mechanisms of response and resistance</span></div><div class="casAuthors">Aronchik, Ida; Dai, Yumin; Labenski, Matt; Barnes, Carmen; Jones, Terri; Qiao, Lixin; Beebe, Lisa; Malek, Mehnaz; Elis, Winfried; Shi, Tao; Mavrommatis, Konstantinos; Bray, Gordon L.; Filvaroff, Ellen H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">642-654</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">As a crit. signaling node, ERK1/2 are attractive drug targets, particularly in tumors driven by activation of the MAPK pathway.  Utility of targeting the MAPK pathway has been demonstrated by clin. responses to inhibitors of MEK1/2 or RAF kinases in some mutant BRAF-activated malignancies.  Unlike tumors with mutations in BRAF, those with mutations in KRAS (>30% of all cancers and >90% of certain cancer types) are generally not responsive to inhibitors of MEK1/2 or RAF.  Here, a covalent ERK1/2 inhibitor, CC-90003, was characterized and shown to be active in preclin. models of KRAS-mutant tumors.  A unique occupancy assay was used to understand the mechanism of resistance in a KRAS-mutant patient-derived xenograft (PDX) model of colorectal cancer.  Finally, combination of CC-90003 with docetaxel achieved full tumor regression and prevented tumor regrowth after cessation of treatment in a PDX model of lung cancer.  This effect corresponded to changes in a stemness gene network, revealing a potential effect on tumor stem cell reprograming.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFCCEbE4dt8bVg90H21EOLACvtfcHk0lgAS3I54z2kOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCltrg%253D&md5=66f18cb85cdcb558e20cd213d791f4ac</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-17-0554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-17-0554%26sid%3Dliteratum%253Aachs%26aulast%3DAronchik%26aufirst%3DI.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DMalek%26aufirst%3DM.%26aulast%3DMavrommatis%26aufirst%3DK.%26aulast%3DBray%26aufirst%3DG.%2BL.%26aulast%3DFilvaroff%26aufirst%3DE.%2BH.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DBarnes%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DQiao%26aufirst%3DL.%26aulast%3DBeebe%26aufirst%3DL.%26aulast%3DElis%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DT.%26atitle%3DEfficacy%2520of%2520a%2520Covalent%2520ERK1%252F2%2520Inhibitor%252C%2520CC-90003%252C%2520in%2520KRAS-Mutant%2520Cancer%2520Models%2520Reveals%2520Novel%2520Mechanisms%2520of%2520Response%2520and%2520Resistance%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26issue%3D2%26spage%3D642%26epage%3D654%26doi%3D10.1158%2F1541-7786.MCR-17-0554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span> </span><span class="NLM_article-title">A Phase I Clinical
Study
With Investigational Compound LTT462 in Adult Patients With Specific
Advanced Cancers</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT02711345" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02711345</a> (accessed June 1, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+Phase+I+Clinical%0AStudy%0AWith+Investigational+Compound+LTT462+in+Adult+Patients+With+Specific%0AAdvanced+Cancers.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02711345+%28accessed+June+1%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DA%2520Phase%2520I%2520Clinical%250AStudy%250AWith%2520Investigational%2520Compound%2520LTT462%2520in%2520Adult%2520Patients%2520With%2520Specific%250AAdvanced%2520Cancers" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span> </span><span class="NLM_article-title">First-in-Human Study
of KO-947 in Non-Hematological Malignancies</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03051035" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03051035</a> (accessed June 1, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+First-in-Human+Study%0Aof+KO-947+in+Non-Hematological+Malignancies.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03051035+%28accessed+June+1%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFirst-in-Human%2520Study%250Aof%2520KO-947%2520in%2520Non-Hematological%2520Malignancies" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braithwaite, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths-Jones, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muench, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathuri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilsher, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onions, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4978</span>– <span class="NLM_lpage">4992</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00421</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00421" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps12lsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4978-4992&issue=11&author=T.+D.+Heightmanauthor=V.+Berdiniauthor=H.+Braithwaiteauthor=I.+M.+Buckauthor=M.+Cassidyauthor=J.+Castroauthor=A.+Courtinauthor=J.+E.+H.+Dayauthor=C.+Eastauthor=L.+Fazalauthor=B.+Grahamauthor=C.+M.+Griffiths-Jonesauthor=J.+F.+Lyonsauthor=V.+Martinsauthor=S.+Muenchauthor=J.+M.+Munckauthor=D.+Nortonauthor=M.+O%E2%80%99Reillyauthor=N.+Palmerauthor=P.+Pathuriauthor=M.+Readerauthor=D.+C.+Reesauthor=S.+J.+Richauthor=C.+Richardsonauthor=H.+Sainiauthor=N.+T.+Thompsonauthor=N.+G.+Wallisauthor=H.+Waltonauthor=N.+E.+Wilsherauthor=A.+J.+A.+Woolfordauthor=C.+W.+Murrayauthor=M.+Cookeauthor=D.+Cousinauthor=S.+Onionsauthor=J.+Shannonauthor=J.+Watts&title=Fragment-Based+Discovery+of+a+Potent%2C+Orally+Bioavailable+Inhibitor+That+Modulates+the+Phosphorylation+and+Catalytic+Activity+of+ERK1%2F2&doi=10.1021%2Facs.jmedchem.8b00421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2</span></div><div class="casAuthors">Heightman, Tom D.; Berdini, Valerio; Braithwaite, Hannah; Buck, Ildiko M.; Cassidy, Megan; Castro, Juan; Courtin, Aurelie; Day, James E. H.; East, Charlotte; Fazal, Lynsey; Graham, Brent; Griffiths-Jones, Charlotte M.; Lyons, John F.; Martins, Vanessa; Muench, Sandra; Munck, Joanne M.; Norton, David; O'Reilly, Marc; Palmer, Nick; Pathuri, Puja; Reader, Michael; Rees, David C.; Rich, Sharna J.; Richardson, Caroline; Saini, Harpreet; Thompson, Neil T.; Wallis, Nicola G.; Walton, Hugh; Wilsher, Nicola E.; Woolford, Alison J.-A.; Cooke, Michael; Cousin, David; Onions, Stuart; Shannon, Jonathan; Watts, John; Murray, Christopher W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4978-4992</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant activation of the MAPK pathway drives cell proliferation in multiple cancers.  Inhibitors of BRAF and MEK kinases are approved for the treatment of BRAF mutant melanoma, but resistance frequently emerges, often mediated by increased signaling through ERK1/2.  Here, we describe the fragment-based generation of ERK1/2 inhibitors that block catalytic phosphorylation of downstream substrates such as RSK but also modulate phosphorylation of ERK1/2 by MEK without directly inhibiting MEK.  X-ray crystallog. and biophys. fragment screening followed by structure-guided optimization and growth from the hinge into a pocket proximal to the C-α helix afforded highly potent ERK1/2 inhibitors with excellent kinome selectivity.  In BRAF mutant cells, the lead compd. suppresses pRSK and pERK levels and inhibits proliferation at low nanomolar concns.  The lead exhibits tumor regression upon oral dosing in BRAF mutant xenograft models, providing a promising basis for further optimization toward clin. pERK1/2 modulating ERK1/2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqstOOt0nyKg7Vg90H21EOLACvtfcHk0lgAS3I54z2kOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps12lsLY%253D&md5=c2bd7c16be85e5f6af5525ce60272aa1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00421%26sid%3Dliteratum%253Aachs%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBraithwaite%26aufirst%3DH.%26aulast%3DBuck%26aufirst%3DI.%2BM.%26aulast%3DCassidy%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DCourtin%26aufirst%3DA.%26aulast%3DDay%26aufirst%3DJ.%2BE.%2BH.%26aulast%3DEast%26aufirst%3DC.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DGriffiths-Jones%26aufirst%3DC.%2BM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMuench%26aufirst%3DS.%26aulast%3DMunck%26aufirst%3DJ.%2BM.%26aulast%3DNorton%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DN.%26aulast%3DPathuri%26aufirst%3DP.%26aulast%3DReader%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%2BJ.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DSaini%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26aulast%3DWalton%26aufirst%3DH.%26aulast%3DWilsher%26aufirst%3DN.%2BE.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%2BA.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCooke%26aufirst%3DM.%26aulast%3DCousin%26aufirst%3DD.%26aulast%3DOnions%26aufirst%3DS.%26aulast%3DShannon%26aufirst%3DJ.%26aulast%3DWatts%26aufirst%3DJ.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Potent%252C%2520Orally%2520Bioavailable%2520Inhibitor%2520That%2520Modulates%2520the%2520Phosphorylation%2520and%2520Catalytic%2520Activity%2520of%2520ERK1%252F2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D11%26spage%3D4978%26epage%3D4992%26doi%3D10.1021%2Facs.jmedchem.8b00421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span> </span><span class="NLM_article-title">A Study
of ASN007 in
Patients With Advanced Solid Tumors</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03415126" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03415126</a> (accessed June 1, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+Study%0Aof+ASN007+in%0APatients+With+Advanced+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03415126+%28accessed+June+1%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DA%2520Study%250Aof%2520ASN007%2520in%250APatients%2520With%2520Advanced%2520Solid%2520Tumors" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemington, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopcroft, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Gallay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, B.</span></span> <span> </span><span class="NLM_article-title">Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3438</span>– <span class="NLM_lpage">3450</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00267</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00267" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3438-3450&issue=8&author=R.+A.+Wardauthor=P.+Bethelauthor=C.+Cookauthor=E.+Daviesauthor=J.+E.+Debreczeniauthor=G.+Fairleyauthor=L.+Feronauthor=V.+Flemingtonauthor=M.+A.+Grahamauthor=R.+Greenwoodauthor=N.+Griffinauthor=L.+Hansonauthor=P.+Hopcroftauthor=T.+D.+Howardauthor=J.+Hudsonauthor=M.+Jamesauthor=C.+D.+Jonesauthor=C.+R.+Jonesauthor=S.+Lamontauthor=R.+Lewisauthor=N.+Lindsayauthor=K.+Robertsauthor=I.+Simpsonauthor=S.+St-Gallayauthor=S.+Swallowauthor=J.+Tangauthor=M.+Tongeauthor=Z.+Wangauthor=B.+Zhai&title=Structure-Guided+Discovery+of+Potent+and+Selective+Inhibitors+of+ERK1%2F2+from+a+Modestly+Active+and+Promiscuous+Chemical+Start+Point&doi=10.1021%2Facs.jmedchem.7b00267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point</span></div><div class="casAuthors">Ward, Richard A.; Bethel, Paul; Cook, Calum; Davies, Emma; Debreczeni, Judit E.; Fairley, Gary; Feron, Lyman; Flemington, Vikki; Graham, Mark A.; Greenwood, Ryan; Griffin, Nicola; Hanson, Lyndsey; Hopcroft, Philip; Howard, Tina D.; Hudson, Julian; James, Michael; Jones, Clifford D.; Jones, Christopher R.; Lamont, Scott; Lewis, Richard; Lindsay, Nicola; Roberts, Karen; Simpson, Iain; St-Gallay, Steve; Swallow, Steve; Tang, Jia; Tonge, Michael; Wang, Zhenhua; Zhai, Baochang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3438-3450</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are a no. of small-mol. inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clin. development for oncol. across a range of disease indications.  The inhibition of ERK1/2 is of significant current interest, as cell lines with acquired resistance to BRAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition in preclin. models.  This article reports on authors' recent work to identify novel, potent, and selective reversible ERK1/2 inhibitors from a low-mol.-wt., modestly active, and highly promiscuous chem. start point, compd. I.  To guide and inform the evolution of this series, inhibitor binding mode information from X-ray crystal structures was crit. in the rapid exploration of this template to compd. II, which was active when tested in in vivo antitumor efficacy expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokuJLRaK0sLLVg90H21EOLACvtfcHk0libu-XQ2faUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7c%253D&md5=2ab5cd30f6a9c887a9a21010b492cb34</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00267%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DBethel%26aufirst%3DP.%26aulast%3DCook%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DE.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DFairley%26aufirst%3DG.%26aulast%3DFeron%26aufirst%3DL.%26aulast%3DFlemington%26aufirst%3DV.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DGriffin%26aufirst%3DN.%26aulast%3DHanson%26aufirst%3DL.%26aulast%3DHopcroft%26aufirst%3DP.%26aulast%3DHoward%26aufirst%3DT.%2BD.%26aulast%3DHudson%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BR.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DR.%26aulast%3DLindsay%26aufirst%3DN.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DSimpson%26aufirst%3DI.%26aulast%3DSt-Gallay%26aufirst%3DS.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhai%26aufirst%3DB.%26atitle%3DStructure-Guided%2520Discovery%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520ERK1%252F2%2520from%2520a%2520Modestly%2520Active%2520and%2520Promiscuous%2520Chemical%2520Start%2520Point%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D8%26spage%3D3438%26epage%3D3450%26doi%3D10.1021%2Facs.jmedchem.7b00267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">VanScyoc, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holdgate, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, W. H. J.</span></span> <span> </span><span class="NLM_article-title">Enzyme Kinetics and Binding Studies on Inhibitors of MEK Protein Kinase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5017</span>– <span class="NLM_lpage">5027</span>, <span class="refDoi"> DOI: 10.1021/bi701811x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi701811x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksVSgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=5017-5027&issue=17&author=W.+S.+VanScyocauthor=G.+A.+Holdgateauthor=J.+E.+Sullivanauthor=W.+H.+J.+Ward&title=Enzyme+Kinetics+and+Binding+Studies+on+Inhibitors+of+MEK+Protein+Kinase&doi=10.1021%2Fbi701811x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Enzyme Kinetics and Binding Studies on Inhibitors of MEK Protein Kinase</span></div><div class="casAuthors">VanScyoc, Wendy S.; Holdgate, Geoffrey A.; Sullivan, Jane E.; Ward, Walter H. J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5017-5027</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the protein kinase, MEK1, is a potential approach for the treatment of cancer.  Inhibitors may act by prevention of activation (PoA), which involves interfering with phosphorylation of nonactivated MEK1 by the upstream kinase, B-RAF.  Modulation also may occur by inhibition of catalysis (IoC) during phosphorylation of the downstream substrate, ERK2, by activated MEK1.  Here, five MEK inhibitors are characterized in terms of binding affinity, PoA, and IoC.  The compds. are a butadiene (U-0126), an N-alkoxy amide (CI-1040), two CI-1040 analogs (an anthranilic acid and an N-alkyl amide), and a cyanoquinoline.  Some compds. give different mechanisms of inhibition (ATP-competitive, noncompetitive, or uncompetitive) in PoA compared to IoC or show a change in potency between the assays.  The inhibitors also exhibit different shifts in potency when either PoA or IoC is compared with binding to nonactivated MEK.  The inhibitor potency ranking, therefore, is dependent upon the assay format.  When the ATP concn. equals Km, IoC IC50 increases in the order CI-1040 ≈ cyanoquinoline ≤ anthranilic acid ≈ U-0126 < alkyl amide.  Conversely, the Kd from nonactivated MEK1 for four of the compds. varies between more than 6-fold lower and over 18-fold higher than this IC50, with U-0126 having the lowest Kd and CI-1040 having the highest.  In PoA when the ATP concn. equals Km, U-0126 has the lowest IC50, becoming more potent than CI-1040, the cyanoquinoline, and the anthranilic acid.  These observations have implications for understanding structure-activity relationships of MEK inhibitors and illustrate how assays can be designed to favor different compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmkJnmjsHeO7Vg90H21EOLACvtfcHk0libu-XQ2faUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksVSgsLo%253D&md5=88fa65b9c8e43e674b79208720e8d8fd</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fbi701811x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi701811x%26sid%3Dliteratum%253Aachs%26aulast%3DVanScyoc%26aufirst%3DW.%2BS.%26aulast%3DHoldgate%26aufirst%3DG.%2BA.%26aulast%3DSullivan%26aufirst%3DJ.%2BE.%26aulast%3DWard%26aufirst%3DW.%2BH.%2BJ.%26atitle%3DEnzyme%2520Kinetics%2520and%2520Binding%2520Studies%2520on%2520Inhibitors%2520of%2520MEK%2520Protein%2520Kinase%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26issue%3D17%26spage%3D5017%26epage%3D5027%26doi%3D10.1021%2Fbi701811x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafleur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caflisch, A.</span></span> <span> </span><span class="NLM_article-title">Kinase Selectivity Potential for Inhibitors Targeting the ATP Binding Site: A Network Analysis</span>. <i>Bioinformatics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1093/bioinformatics/btp650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1093%2Fbioinformatics%2Fbtp650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=19942586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2010&pages=198-204&issue=2&author=D.+Huangauthor=T.+Zhouauthor=K.+Lafleurauthor=C.+Nevadoauthor=A.+Caflisch&title=Kinase+Selectivity+Potential+for+Inhibitors+Targeting+the+ATP+Binding+Site%3A+A+Network+Analysis&doi=10.1093%2Fbioinformatics%2Fbtp650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis</span></div><div class="casAuthors">Huang, Danzhi; Zhou, Ting; Lafleur, Karine; Nevado, Cristina; Caflisch, Amedeo</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-204</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4803</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Small-mol. inhibitors targeting the ATP binding pocket of the catalytic domain of protein kinases have potential to become drugs devoid of (major) side effects, particularly if they bind selectively.  Here, the sequences of the 518 human kinases are first mapped onto the structural alignment of 116 kinases of known three-dimensional structure.  The multiple structure alignment is then used to encode the known strategies for developing selective inhibitors into a fingerprint.  Finally, a network anal. is used to partition the kinases into clusters according to similarity of their fingerprints, i.e., physico-chem. characteristics of the residues responsible for selective binding.  For each kinase the network anal. reveals the likelihood to find selective inhibitors targeting the ATP binding site.  Systematic guidelines are proposed to develop selective inhibitors.  Importantly, the network anal. suggests that the tyrosine kinase EphB4 has high selectivity potential, which is consistent with the selectivity profile of two novel EphB4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQVQsrpqB_ILVg90H21EOLACvtfcHk0libu-XQ2faUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlGkug%253D%253D&md5=b6c63ccd4654219a56752f9cfc1356a3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtp650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtp650%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DLafleur%26aufirst%3DK.%26aulast%3DNevado%26aufirst%3DC.%26aulast%3DCaflisch%26aufirst%3DA.%26atitle%3DKinase%2520Selectivity%2520Potential%2520for%2520Inhibitors%2520Targeting%2520the%2520ATP%2520Binding%2520Site%253A%2520A%2520Network%2520Analysis%26jtitle%3DBioinformatics%26date%3D2010%26volume%3D26%26issue%3D2%26spage%3D198%26epage%3D204%26doi%3D10.1093%2Fbioinformatics%2Fbtp650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Free, S. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. W.</span></span> <span> </span><span class="NLM_article-title">A Mathematical Contribution to Structure-Activity Studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1964</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1021/jm00334a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00334a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADyaF2cXkt1OltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1964&pages=395-399&issue=4&author=S.+M.+Freeauthor=J.+W.+Wilson&title=A+Mathematical+Contribution+to+Structure-Activity+Studies&doi=10.1021%2Fjm00334a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A mathematical contribution to structure-activity studies</span></div><div class="casAuthors">Free, Spencer M., Jr.; Wilson, James W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">395-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A math. technique is suggested as a means of describing structure-activity relation of a series of chem. analogs.  The data requirements included specific side chain arrangements and performance characteristics of all analogs tested.  Two examples illustrate the use of the additive math. model where the performance characteristics are measures of biol. activity.  The results rank the structural changes per position by estg. the amt. of biol. response attributed to each change.  The estimates are both pos. and neg.  Several uses for the math. soln. are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRyTj3xI-aH7Vg90H21EOLACvtfcHk0lg4Q1P2JbUxWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXkt1OltbY%253D&md5=88fabb64d7a5635506a11418a2744bd6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm00334a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00334a001%26sid%3Dliteratum%253Aachs%26aulast%3DFree%26aufirst%3DS.%2BM.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26atitle%3DA%2520Mathematical%2520Contribution%2520to%2520Structure-Activity%2520Studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1964%26volume%3D7%26issue%3D4%26spage%3D395%26epage%3D399%26doi%3D10.1021%2Fjm00334a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muresan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeberlein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Chemical Predictive Modelling to Improve Compound Quality</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1038/nrd4128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1038%2Fnrd4128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=24287782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGrtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=948-962&issue=12&author=J.+G.+Cummingauthor=A.+M.+Davisauthor=S.+Muresanauthor=M.+Haeberleinauthor=H.+Chen&title=Chemical+Predictive+Modelling+to+Improve+Compound+Quality&doi=10.1038%2Fnrd4128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical predictive modelling to improve compound quality</span></div><div class="casAuthors">Cumming, John G.; Davis, Andrew M.; Muresan, Sorel; Haeberlein, Markus; Chen, Hongming</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">948-962</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The 'quality' of small-mol. drug candidates, encompassing aspects including their potency, selectivity and ADMET (absorption, distribution, metab., excretion and toxicity) characteristics, is a key factor influencing the chances of success in clin. trials.  Importantly, such characteristics are under the control of chemists during the identification and optimization of lead compds.  Here, we discuss the application of computational methods, particularly quant. structure-activity relationships (QSARs), in guiding the selection of higher-quality drug candidates, as well as cultural factors that may have affected their use and impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4XwzW0wcxYbVg90H21EOLACvtfcHk0lg4Q1P2JbUxWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGrtLjF&md5=e0a4265bb306ae5544d00f3c9e3e4050</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd4128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4128%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26aulast%3DMuresan%26aufirst%3DS.%26aulast%3DHaeberlein%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DChemical%2520Predictive%2520Modelling%2520to%2520Improve%2520Compound%2520Quality%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26issue%3D12%26spage%3D948%26epage%3D962%26doi%3D10.1038%2Fnrd4128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grohganz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löbmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priemel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarp Jensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rades, T.</span></span> <span> </span><span class="NLM_article-title">Amorphous Drugs and Dosage Forms</span>. <i>J. Drug Delivery Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1016/S1773-2247(13)50057-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1016%2FS1773-2247%2813%2950057-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCqsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=403-408&issue=4&author=H.+Grohganzauthor=K.+L%C3%B6bmannauthor=P.+Priemelauthor=K.+Tarp+Jensenauthor=K.+Graeserauthor=C.+Strachanauthor=T.+Rades&title=Amorphous+Drugs+and+Dosage+Forms&doi=10.1016%2FS1773-2247%2813%2950057-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Amorphous drugs and dosage forms</span></div><div class="casAuthors">Grohganz, H.; Lobmann, K.; Priemel, P.; Jensen, K. Tarp; Graeser, K.; Strachan, C.; Rades, T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Delivery Science and Technology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">403-408</span>CODEN:
                <span class="NLM_cas:coden">JDDSAL</span>;
        ISSN:<span class="NLM_cas:issn">1773-2247</span>.
    
            (<span class="NLM_cas:orgname">Editions de Sante</span>)
        </div><div class="casAbstract">A review.  The transformation to an amorphous form is one of the most promising approaches to address the low soly. of drug compds., the latter being an increasing challenge in the development of new drug candidates.  However, amorphous forms are high energy solids and tend to recrystallize.  New formulation principles are needed to ensure the stability of amorphous drug forms.  The formation of solid dispersions is still the most investigated approach, but addnl. approaches are desirable to overcome the shortcomings of solid dispersions.  Spatial sepn. by either coating or the use of micro-containers has shown potential to prevent or delay recrystn.  Another recent approach is the formation of co-amorphous mixts. between either two drugs or one drug and one low mol. wt. excipient.  Mol. interactions between the two mols. provide an energy barrier that has to be overcome before single mols. are available for the formation of crystal nuclei, thus stabilizing the amorphous form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvjnM1tqLHyrVg90H21EOLACvtfcHk0ljMF7-3swpS_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCqsrbN&md5=e51f9cbeed9dcd64f196d80fa10cf673</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1773-2247%2813%2950057-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1773-2247%252813%252950057-8%26sid%3Dliteratum%253Aachs%26aulast%3DGrohganz%26aufirst%3DH.%26aulast%3DL%25C3%25B6bmann%26aufirst%3DK.%26aulast%3DPriemel%26aufirst%3DP.%26aulast%3DTarp%2BJensen%26aufirst%3DK.%26aulast%3DGraeser%26aufirst%3DK.%26aulast%3DStrachan%26aufirst%3DC.%26aulast%3DRades%26aufirst%3DT.%26atitle%3DAmorphous%2520Drugs%2520and%2520Dosage%2520Forms%26jtitle%3DJ.%2520Drug%2520Delivery%2520Sci.%2520Technol.%26date%3D2013%26volume%3D23%26issue%3D4%26spage%3D403%26epage%3D408%26doi%3D10.1016%2FS1773-2247%2813%2950057-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Human Pharmacokinetics, Therapeutic Dose and Exposure Predictions Using Marketed Oral Drugs</span>. <i>Current Drug Metabolism</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.2174/138920007780866799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.2174%2F138920007780866799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=17584017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsl2jtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=463-479&issue=5&author=D.+F.+McGinnityauthor=J.+Collingtonauthor=R.+P.+Austinauthor=R.+J.+Riley&title=Evaluation+of+Human+Pharmacokinetics%2C+Therapeutic+Dose+and+Exposure+Predictions+Using+Marketed+Oral+Drugs&doi=10.2174%2F138920007780866799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs</span></div><div class="casAuthors">McGinnity, D. F.; Collington, J.; Austin, R. P.; Riley, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-479</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In this article approaches to predict human pharmacokinetics (PK) are discussed and the capability of the exemplified methodologies to est. individual PK parameters and therapeutic dose for a set of marketed oral drugs has been assessed.  For a set of 63 drugs where the min. efficacious concn. (MEC) and human PK were known, the clin. dose was shown to be well predicted or in some cases over-estd. using a simple one-compartment oral PK model.  For a subset of these drugs, in vitro potency against the primary human targets was gathered, and compared to the obsd. MEC.  When cor. for plasma protein binding, the MEC of the majority of compds. was ≤ 3 fold over the resp. in vitro target potency value.  A series of in vitro and in vivo expts. were conducted to predict the human PK parameters.  Metabolic clearance was generally predicted well from human hepatocytes.  Interestingly, for this compd. set, allometry or glomerular filtration rate (GFR) ratio methods appeared to be applicable for renal CL even where CLrenal > GFR.  For ∼90% of compds. studied, the predicted CL using in vitro-in vivo (IVIV) extrapolation together with a CLrenal est., where appropriate, was within 2-fold of that obsd. clin.  Encouragingly vol. of distribution at steady state (Vss) estd. in preclin. species (rat and dog) when cor. for plasma protein binding, predicted human Vss successfully on the majority of occasions - 73% of compds. within 2-fold.  In this lab., absorption estd. from oral rat PK studies was lower than the obsd. human absorption for most drugs, even when soly. and permeability appeared not to be limiting.  Preliminary data indicate absorption in the dog may be more representative of human for compds. absorbed via the transcellular pathway.  Using predicted PK and MEC values estd. from in vitro potency assays there was a good correlation between predicted and obsd. dose.  This anal. suggests that for oral therapies, human PK parameters and clin. dose can be estd. from a consideration of data obtained from in vitro screens using human derived material and in vivo animal studies.  The benefits and limitations of this holistic approach to PK and dose prediction within the drug discovery process are exemplified and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdbfKDFLO_UrVg90H21EOLACvtfcHk0ljMF7-3swpS_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsl2jtL4%253D&md5=765bdc4b870b660e813e36ae3719ddb5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F138920007780866799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007780866799%26sid%3Dliteratum%253Aachs%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DCollington%26aufirst%3DJ.%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DEvaluation%2520of%2520Human%2520Pharmacokinetics%252C%2520Therapeutic%2520Dose%2520and%2520Exposure%2520Predictions%2520Using%2520Marketed%2520Oral%2520Drugs%26jtitle%3DCurrent%2520Drug%2520Metabolism%26date%3D2007%26volume%3D8%26issue%3D5%26spage%3D463%26epage%3D479%26doi%3D10.2174%2F138920007780866799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challinor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckersley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemington, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopcroft, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renshaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K.</span></span> <span> </span><span class="NLM_article-title">Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4790</span>– <span class="NLM_lpage">4801</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4790-4801&issue=11&author=R.+A.+Wardauthor=N.+Colcloughauthor=M.+Challinorauthor=J.+E.+Debreczeniauthor=K.+Eckersleyauthor=G.+Fairleyauthor=L.+Feronauthor=V.+Flemingtonauthor=M.+A.+Grahamauthor=R.+Greenwoodauthor=P.+Hopcroftauthor=T.+D.+Howardauthor=M.+Jamesauthor=C.+D.+Jonesauthor=C.+R.+Jonesauthor=J.+Renshawauthor=K.+Robertsauthor=L.+Snowauthor=M.+Tongeauthor=K.+Yeung&title=Structure-Guided+Design+of+Highly+Selective+and+Potent+Covalent+Inhibitors+of+ERK1%2F2&doi=10.1021%2Facs.jmedchem.5b00466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2</span></div><div class="casAuthors">Ward, Richard A.; Colclough, Nicola; Challinor, Mairi; Debreczeni, Judit E.; Eckersley, Kay; Fairley, Gary; Feron, Lyman; Flemington, Vikki; Graham, Mark A.; Greenwood, Ryan; Hopcroft, Philip; Howard, Tina D.; James, Michael; Jones, Clifford D.; Jones, Christopher R.; Renshaw, Jonathan; Roberts, Karen; Snow, Lindsay; Tonge, Michael; Yeung, Kay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4790-4801</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The RAS/RAF/MEK/ERK signaling pathway has been targeted with a no. of small mol. inhibitors in oncol. clin. development across multiple disease indications.  Importantly, cell lines with acquired resistance to B-RAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition by small mol. inhibitors.  There are a no. of selective, noncovalent ERK1/2 inhibitors reported along with the promiscuous hypothemycin (and related analogs) that act via a covalent mechanism of action.  This article reports the identification of multiple series of highly selective covalent ERK1/2 inhibitors informed by structure-based drug design (SBDD).  As a starting point for these covalent inhibitors, reported ERK1/2 inhibitors and a chem. series identified via high-throughput screening were exploited.  These approaches resulted in the identification of selective covalent tool compds. for potential in vitro and in vivo studies to assess the risks and or benefits of targeting this pathway through such a mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLDLwUCW_ANrVg90H21EOLACvtfcHk0ljMF7-3swpS_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D&md5=40b47d8671c966434434f056ac88b3a7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00466%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEckersley%26aufirst%3DK.%26aulast%3DFairley%26aufirst%3DG.%26aulast%3DFeron%26aufirst%3DL.%26aulast%3DFlemington%26aufirst%3DV.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHopcroft%26aufirst%3DP.%26aulast%3DHoward%26aufirst%3DT.%2BD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BR.%26aulast%3DRenshaw%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DSnow%26aufirst%3DL.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DYeung%26aufirst%3DK.%26atitle%3DStructure-Guided%2520Design%2520of%2520Highly%2520Selective%2520and%2520Potent%2520Covalent%2520Inhibitors%2520of%2520ERK1%252F2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D11%26spage%3D4790%26epage%3D4801%26doi%3D10.1021%2Facs.jmedchem.5b00466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua D. G.  Leach</span>, <span class="hlFld-ContribAuthor ">Nikola  Vlahov</span>, <span class="hlFld-ContribAuthor ">Petros  Tsantoulis</span>, <span class="hlFld-ContribAuthor ">Rachel A.  Ridgway</span>, <span class="hlFld-ContribAuthor ">Dustin J.  Flanagan</span>, <span class="hlFld-ContribAuthor ">Kathryn  Gilroy</span>, <span class="hlFld-ContribAuthor ">Nathalie  Sphyris</span>, <span class="hlFld-ContribAuthor ">Ester G.  Vázquez</span>, <span class="hlFld-ContribAuthor ">David F.  Vincent</span>, <span class="hlFld-ContribAuthor ">William J.  Faller</span>, <span class="hlFld-ContribAuthor ">Michael C.  Hodder</span>, <span class="hlFld-ContribAuthor ">Alexander  Raven</span>, <span class="hlFld-ContribAuthor ">Sigrid  Fey</span>, <span class="hlFld-ContribAuthor ">Arafath K.  Najumudeen</span>, <span class="hlFld-ContribAuthor ">Douglas  Strathdee</span>, <span class="hlFld-ContribAuthor ">Colin  Nixon</span>, <span class="hlFld-ContribAuthor ">Mark  Hughes</span>, <span class="hlFld-ContribAuthor ">William  Clark</span>, <span class="hlFld-ContribAuthor ">Robin  Shaw</span>, , <span class="hlFld-ContribAuthor ">Tim  Maughan</span>, <span class="hlFld-ContribAuthor ">Manuel  Salto-Tellez</span>, <span class="hlFld-ContribAuthor ">Philip  Quirke</span>, <span class="hlFld-ContribAuthor ">Viktor  Koelzer</span>, <span class="hlFld-ContribAuthor ">Philip  Dunne</span>, <span class="hlFld-ContribAuthor ">Andrew  Beggs</span>, <span class="hlFld-ContribAuthor ">Peter  Campbell</span>, <span class="hlFld-ContribAuthor ">Francesca  Buffa</span>, <span class="hlFld-ContribAuthor ">Chris  Holmes</span>, <span class="hlFld-ContribAuthor ">Rick  Kaplan</span>, <span class="hlFld-ContribAuthor ">Louise  Brown</span>, <span class="hlFld-ContribAuthor ">Mark  Lawler</span>, <span class="hlFld-ContribAuthor ">Joshua  Hordern</span>, <span class="hlFld-ContribAuthor ">Ian  Tomlinson</span>, <span class="hlFld-ContribAuthor ">Simon  Leedham</span>, <span class="hlFld-ContribAuthor ">Dion  Morton</span>, <span class="hlFld-ContribAuthor ">Sander R.  van Hooff</span>, <span class="hlFld-ContribAuthor ">David J.  Huels</span>, <span class="hlFld-ContribAuthor ">Jan Paul  Medema</span>, <span class="hlFld-ContribAuthor ">Simon T.  Barry</span>, <span class="hlFld-ContribAuthor ">Margaret C.  Frame</span>, <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>, <span class="hlFld-ContribAuthor ">Simon J.  Leedham</span>, <span class="hlFld-ContribAuthor ">Gareth J.  Inman</span>, <span class="hlFld-ContribAuthor ">Rene  Jackstadt</span>, <span class="hlFld-ContribAuthor ">Barry J.  Thompson</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Campbell</span>, <span class="hlFld-ContribAuthor ">Sabine  Tejpar</span>, <span class="hlFld-ContribAuthor ">Owen J.  Sansom</span>. </span><span class="cited-content_cbyCitation_article-title">Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-021-23717-5" title="DOI URL">https://doi.org/10.1038/s41467-021-23717-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-021-23717-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-021-23717-5%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DOncogenic%252BBRAF%25252C%252Bunrestrained%252Bby%252BTGF%2525CE%2525B2-receptor%252Bsignalling%25252C%252Bdrives%252Bright-sided%252Bcolonic%252Btumorigenesis%26aulast%3DLeach%26aufirst%3DJoshua%2BD.%2BG.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kun  Chen</span>, <span class="hlFld-ContribAuthor ">Yalei  Zhang</span>, <span class="hlFld-ContribAuthor ">Ling  Qian</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging strategies to target RAS signaling in human cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2021,</strong> <em>14 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-021-01127-w" title="DOI URL">https://doi.org/10.1186/s13045-021-01127-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-021-01127-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-021-01127-w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DEmerging%252Bstrategies%252Bto%252Btarget%252BRAS%252Bsignaling%252Bin%252Bhuman%252Bcancer%252Btherapy%26aulast%3DChen%26aufirst%3DKun%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingtian  Min</span>, <span class="hlFld-ContribAuthor ">Yu  Wu</span>, <span class="hlFld-ContribAuthor ">Gang  Cao</span>, <span class="hlFld-ContribAuthor ">Daguo  Mi</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">A network pharmacology strategy to investigate the anti-osteoarthritis mechanism of main lignans components of Schisandrae Fructus. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2021,</strong> <em>98 </em>, 107873. <a href="https://doi.org/10.1016/j.intimp.2021.107873" title="DOI URL">https://doi.org/10.1016/j.intimp.2021.107873</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2021.107873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2021.107873%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DA%252Bnetwork%252Bpharmacology%252Bstrategy%252Bto%252Binvestigate%252Bthe%252Banti-osteoarthritis%252Bmechanism%252Bof%252Bmain%252Blignans%252Bcomponents%252Bof%252BSchisandrae%252BFructus%26aulast%3DMin%26aufirst%3DLingtian%26date%3D2021%26volume%3D98%26spage%3D107873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rahim  Ullah</span>, <span class="hlFld-ContribAuthor ">Qing  Yin</span>, <span class="hlFld-ContribAuthor ">Aidan H.  Snell</span>, <span class="hlFld-ContribAuthor ">Lixin  Wan</span>. </span><span class="cited-content_cbyCitation_article-title">RAF-MEK-ERK pathway in cancer evolution and treatment. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>84 </em><a href="https://doi.org/10.1016/j.semcancer.2021.05.010" title="DOI URL">https://doi.org/10.1016/j.semcancer.2021.05.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2021.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2021.05.010%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DRAF-MEK-ERK%252Bpathway%252Bin%252Bcancer%252Bevolution%252Band%252Btreatment%26aulast%3DUllah%26aufirst%3DRahim%26date%3D2021%26volume%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seungbeom  Lee</span>, <span class="hlFld-ContribAuthor ">Jisu  Kim</span>, <span class="hlFld-ContribAuthor ">Jeyun  Jo</span>, <span class="hlFld-ContribAuthor ">Jae Won  Chang</span>, <span class="hlFld-ContribAuthor ">Jaehoon  Sim</span>, <span class="hlFld-ContribAuthor ">Hwayoung  Yun</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in development of hetero-bivalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113318. <a href="https://doi.org/10.1016/j.ejmech.2021.113318" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113318</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113318%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bdevelopment%252Bof%252Bhetero-bivalent%252Bkinase%252Binhibitors%26aulast%3DLee%26aufirst%3DSeungbeom%26date%3D2021%26volume%3D216%26spage%3D113318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vikki  Flemington</span>, <span class="hlFld-ContribAuthor ">Emma J.  Davies</span>, <span class="hlFld-ContribAuthor ">David  Robinson</span>, <span class="hlFld-ContribAuthor ">Linda C.  Sandin</span>, <span class="hlFld-ContribAuthor ">Oona  Delpuech</span>, <span class="hlFld-ContribAuthor ">Pei  Zhang</span>, <span class="hlFld-ContribAuthor ">Lyndsey  Hanson</span>, <span class="hlFld-ContribAuthor ">Paul  Farrington</span>, <span class="hlFld-ContribAuthor ">Sigourney  Bell</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Falenta</span>, <span class="hlFld-ContribAuthor ">Francis D.  Gibbons</span>, <span class="hlFld-ContribAuthor ">Nicola  Lindsay</span>, <span class="hlFld-ContribAuthor ">Aaron  Smith</span>, <span class="hlFld-ContribAuthor ">Joanne  Wilson</span>, <span class="hlFld-ContribAuthor ">Karen  Roberts</span>, <span class="hlFld-ContribAuthor ">Michael  Tonge</span>, <span class="hlFld-ContribAuthor ">Philip  Hopcroft</span>, <span class="hlFld-ContribAuthor ">Sophie E.  Willis</span>, <span class="hlFld-ContribAuthor ">Martine P.  Roudier</span>, <span class="hlFld-ContribAuthor ">Claire  Rooney</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Coker</span>, <span class="hlFld-ContribAuthor ">Patricia  Jaaks</span>, <span class="hlFld-ContribAuthor ">Mathew J.  Garnett</span>, <span class="hlFld-ContribAuthor ">Stephen E.  Fawell</span>, <span class="hlFld-ContribAuthor ">Clifford D.  Jones</span>, <span class="hlFld-ContribAuthor ">Richard A.  Ward</span>, <span class="hlFld-ContribAuthor ">Iain  Simpson</span>, <span class="hlFld-ContribAuthor ">Sabina C.  Cosulich</span>, <span class="hlFld-ContribAuthor ">J. Elizabeth  Pease</span>, <span class="hlFld-ContribAuthor ">Paul D.  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in
              KRAS
              -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2021,</strong> <em>20 </em>
                                    (2)
                                     , 238-249. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0002" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0002%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DAZD0364%252BIs%252Ba%252BPotent%252Band%252BSelective%252BERK1%25252F2%252BInhibitor%252BThat%252BEnhances%252BAntitumor%252BActivity%252Bin%252BKRAS%252B-Mutant%252BTumor%252BModels%252Bwhen%252BCombined%252Bwith%252Bthe%252BMEK%252BInhibitor%25252C%252BSelumetinib%26aulast%3DFlemington%26aufirst%3DVikki%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D2%26spage%3D238%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing  An</span>, <span class="hlFld-ContribAuthor ">Zipeng  Zhou</span>, <span class="hlFld-ContribAuthor ">Yi  Xie</span>, <span class="hlFld-ContribAuthor ">Yu  Sun</span>, <span class="hlFld-ContribAuthor ">Haixiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yang  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Knockdown of long non-coding RNA NEAT1 relieves the inflammatory response of spinal cord injury through targeting miR-211-5p/MAPK1 axis. </span><span class="cited-content_cbyCitation_journal-name">Bioengineered</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 2702-2712. <a href="https://doi.org/10.1080/21655979.2021.1930925" title="DOI URL">https://doi.org/10.1080/21655979.2021.1930925</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/21655979.2021.1930925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F21655979.2021.1930925%26sid%3Dliteratum%253Aachs%26jtitle%3DBioengineered%26atitle%3DKnockdown%252Bof%252Blong%252Bnon-coding%252BRNA%252BNEAT1%252Brelieves%252Bthe%252Binflammatory%252Bresponse%252Bof%252Bspinal%252Bcord%252Binjury%252Bthrough%252Btargeting%252BmiR-211-5p%25252FMAPK1%252Baxis%26aulast%3DAn%26aufirst%3DQing%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1%26spage%3D2702%26epage%3D2712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marco  Mazzorana</span>, <span class="hlFld-ContribAuthor ">Elizabeth J.  Shotton</span>, <span class="hlFld-ContribAuthor ">David R.  Hall</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive approach to X-ray crystallography for drug discovery at a synchrotron facility — The example of Diamond Light Source. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today: Technologies</span><span> <strong>2020,</strong> <em>27 </em><a href="https://doi.org/10.1016/j.ddtec.2020.10.003" title="DOI URL">https://doi.org/10.1016/j.ddtec.2020.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ddtec.2020.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ddtec.2020.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technologies%26atitle%3DA%252Bcomprehensive%252Bapproach%252Bto%252BX-ray%252Bcrystallography%252Bfor%252Bdrug%252Bdiscovery%252Bat%252Ba%252Bsynchrotron%252Bfacility%252B%2525E2%252580%252594%252BThe%252Bexample%252Bof%252BDiamond%252BLight%252BSource%26aulast%3DMazzorana%26aufirst%3DMarco%26date%3D2020%26volume%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew A.  Ingersoll</span>, <span class="hlFld-ContribAuthor ">Emma A.  Malloy</span>, <span class="hlFld-ContribAuthor ">Lauryn E.  Caster</span>, <span class="hlFld-ContribAuthor ">Eva M.  Holland</span>, <span class="hlFld-ContribAuthor ">Zhenhang  Xu</span>, <span class="hlFld-ContribAuthor ">Marisa  Zallocchi</span>, <span class="hlFld-ContribAuthor ">Duane  Currier</span>, <span class="hlFld-ContribAuthor ">Huizhan  Liu</span>, <span class="hlFld-ContribAuthor ">David Z.Z.  He</span>, <span class="hlFld-ContribAuthor ">Jaeki  Min</span>, <span class="hlFld-ContribAuthor ">Taosheng  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Zuo</span>, <span class="hlFld-ContribAuthor ">Tal  Teitz</span>. </span><span class="cited-content_cbyCitation_article-title">BRAF inhibition protects against hearing loss in mice. </span><span class="cited-content_cbyCitation_journal-name">Science Advances</span><span> <strong>2020,</strong> <em>6 </em>
                                    (49)
                                     , eabd0561. <a href="https://doi.org/10.1126/sciadv.abd0561" title="DOI URL">https://doi.org/10.1126/sciadv.abd0561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciadv.abd0561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciadv.abd0561%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Advances%26atitle%3DBRAF%252Binhibition%252Bprotects%252Bagainst%252Bhearing%252Bloss%252Bin%252Bmice%26aulast%3DIngersoll%26aufirst%3DMatthew%2BA.%26date%3D2020%26date%3D2020%26volume%3D6%26issue%3D49%26spage%3Deabd0561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selection of published ERK1/2 inhibitors, <b>1</b> (SCH772984), <b>2</b> (SCH900353), <b>3</b> (ulixertinib/BVD-523), <b>4</b> (GDC-0994), <b>5</b> (LY-3214996), and <b>6</b> (CC-90003).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. QM torsion profile of an alternative dihydroimidazopyrazinone ring system (<b>B</b>) compared to a pyrrolopyrazinone core (<b>A</b>) with and without a methyl group substituent. Gas phase energy reported in kcal/mol calculated in Jaguar (Maestro version 2016-1, Schrodinger) using a relaxed coordinate scan with PM3 and B3LYP/6-31G* basis sets. Binding mode consistent with 0° dihedral angle on these charts.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. ERK2 X-ray crystal structure of series exemplar (<b>8</b>) bound in ERK1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHP">5NHP</a>) highlighting the potential to target Gln-105.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representation of Free–Wilson analysis. (A) Substructures of compounds in the full data set, versus the Free–Wilson enumeration on the novel core and filtered output using preferred substituents. (B) Representation of Free–Wilson analysis by R1-R3 colored by predicted biochemical pIC<sub>50</sub> coefficient.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Selection of favored substituents from Free–Wilson analysis enumerated on the dihydroimidazopyrazinone core. Subsituents ordered using the Free–Wilson coefficient based on biochemical activity as a ranking.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>15</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) SEM-Cl, K<sub>2</sub>CO<sub>3</sub>, acetone, 0 °C, 85%; (ii) NBS, DMF, DCM, 0 °C, 51%; (iii) second generation XPhos precatalyst, 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane), KOAc, 1,4-dioxane, 25 °C, quant; (iv) Pd(Ph<sub>3</sub>P)<sub>4,</sub> 2,4-dichloro-5-methylpyrimidine, Cs<sub>2</sub>CO<sub>3,</sub> 1,4-dioxane, water, 85 °C, 70%; (v) TFA, DCM, 25 °C, 93%; (vi) (a) isobutyl chloroformate, <i>N</i>-methylmorpholine, THF, 0 °C, (b) NaBH4, H<sub>2</sub>O, 52%; (vii) imidazole, thionyl chloride, NEt<sub>3</sub>, DCM, −78 °C, 56%; (viii) sodium metaperiodate, ruthenium(III) chloride, MeCN, water, 0 °C, 80%; (ix) K<sub>2</sub>CO<sub>3</sub>, 18-crown-6, 1,4-dioxane, 100 °C, 100%; (x) 1 M HCl, EtOH, 50 °C, 24%; (xi) 4 M HCl in 1,4-dioxane, 25 °C, 85%; (xii) 1 M NH<sub>3</sub> in MeOH, 25 °C, 97%; (xiii) 4-(bromomethyl)-1,2-difluorobenzene, NaH, DMF, 25 °C, 95%; (xiv) second generation XantPhos precatalyst, 1-methyl-1<i>H</i>-pyrazol-5-amine, Cs<sub>2</sub>CO<sub>3,</sub> 1,4-dioxane, 100 °C, 64%.</p></p></figure><figure data-id="fig5a" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0006.jpeg" id="rightTab-GRAPHIC-d7e1653-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding mode of <b>15</b> elucidated in ERK2 by X-ray crystallography (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SLG">6SLG</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig5a"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Monotherapy antitumor activity of <b>15</b> in a Calu 6 (KRAS Q61H, panel A) mouse model and end of study PD/PK analysis (panel B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/medium/jm9b01295_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Monotherapy and combination antitumor activity of <b>15</b> and selumetinib in an A549 (KRAS G12C) mouse model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01295/20191219/images/large/jm9b01295_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01295&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07011" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07011" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 26 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolch, W.</span></span> <span> </span><span class="NLM_article-title">MAP Kinase Signalling Pathways In Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3279</span>– <span class="NLM_lpage">3290</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&issue=22&author=A.+S.+Dhillonauthor=S.+Haganauthor=O.+Rathauthor=W.+Kolch&title=MAP+Kinase+Signalling+Pathways+In+Cancer&doi=10.1038%2Fsj.onc.1210421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0ljivakwUhs_XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DRath%26aufirst%3DO.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520Kinase%2520Signalling%2520Pathways%2520In%2520Cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26issue%3D22%26spage%3D3279%26epage%3D3290%26doi%3D10.1038%2Fsj.onc.1210421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of Cancer: The Next Generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&issue=5&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+Cancer%3A+The+Next+Generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lgEeQVfTZeGLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520Cancer%253A%2520The%2520Next%2520Generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26issue%3D5%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seger, R.</span></span> <span> </span><span class="NLM_article-title">The Extracellular Signal-Regulated Kinase: Multiple Substrates Regulate Diverse Cellular Functions</span>. <i>Growth Factors</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1080/02699050500284218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1080%2F02699050500284218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=16393692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlGht7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=21-44&issue=1&author=S.+Yoonauthor=R.+Seger&title=The+Extracellular+Signal-Regulated+Kinase%3A+Multiple+Substrates+Regulate+Diverse+Cellular+Functions&doi=10.1080%2F02699050500284218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions</span></div><div class="casAuthors">Yoon, Seunghee; Seger, Rony</div><div class="citationInfo"><span class="NLM_cas:title">Growth Factors</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-44</span>CODEN:
                <span class="NLM_cas:coden">GRFAEC</span>;
        ISSN:<span class="NLM_cas:issn">0897-7194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The extracellular signal-regulated kinase (ERK) cascade is a central pathway that transmits signals from many extracellular agents to regulate cellular processes such as proliferation, differentiation, and cell cycle progression.  The signaling via the ERK cascade is mediated by sequential phosphorylation and activation of protein kinases in the different tiers of the cascade.  Although the main core phosphorylation chain of the cascade includes Raf kinases, MEK1/2, ERK1/2 (ERKs) and RSKs, other alternatively spliced forms and distinct components exist in the different tiers, and participate in ERK signaling under specific conditions.  These components enhance the complexity of the ERK cascade and thereby, enable the wide variety of functions that are regulated by it.  Another factor that is important for the dissemination of ERKs' signals is the multiplicity of the cascade's substrates, which include transcription factors, protein kinases and phosphatases, cytoskeletal elements, regulators of apoptosis, and a variety of other signaling-related mols.  About 160 substrates have already been discovered for ERKs, and the list of these substrates, as well as the function and mechanism of activation of representative substrates, are described in the current review.  Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation.  However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis, and apoptosis.  Understanding of these processes may provide a full picture of the distinct, and even opposing cellular processes that are regulated by the ERK cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdE2tenNpAU7Vg90H21EOLACvtfcHk0lgEeQVfTZeGLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlGht7jP&md5=746d0818f7fc07229673dfdd6b4165b3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1080%2F02699050500284218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F02699050500284218%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DSeger%26aufirst%3DR.%26atitle%3DThe%2520Extracellular%2520Signal-Regulated%2520Kinase%253A%2520Multiple%2520Substrates%2520Regulate%2520Diverse%2520Cellular%2520Functions%26jtitle%3DGrowth%2520Factors%26date%3D2006%26volume%3D24%26issue%3D1%26spage%3D21%26epage%3D44%26doi%3D10.1080%2F02699050500284218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyse, S. M.</span></span> <span> </span><span class="NLM_article-title">Differential Regulation of MAP Kinase Signalling By Dual-Specificity Protein Phosphatases</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">3203</span>– <span class="NLM_lpage">3213</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1038%2Fsj.onc.1210412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=17496916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3203-3213&issue=22&author=D.+M.+Owensauthor=S.+M.+Keyse&title=Differential+Regulation+of+MAP+Kinase+Signalling+By+Dual-Specificity+Protein+Phosphatases&doi=10.1038%2Fsj.onc.1210412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases</span></div><div class="casAuthors">Owens, D. M.; Keyse, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3203-3213</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The regulated dephosphorylation of mitogen-activated protein kinases (MAPKs) plays a key role in detg. the magnitude and duration of kinase activation and hence the physiol. outcome of signaling.  In mammalian cells, an important component of this control is mediated by the differential expression and activities of a family of 10 dual-specificity (Thr/Tyr) MAPK phosphatases (MKPs).  These enzymes share a common structure in which MAPK substrate recognition is detd. by sequences within an amino-terminal non-catalytic domain whereas MAPK binding often leads to a conformational change within the C-terminal catalytic domain resulting in increased enzyme activity.  MKPs can either recognize and inactivate a single class of MAP kinase, as in the specific inactivation of extracellular signal regulated kinase (ERK) by the cytoplasmic phosphatase DUSP6/MKP-3 or can regulate more than one MAPK pathway as illustrated by the ability of DUSP1/MKP-1 to dephosphorylate ERK, c-Jun amino-terminal kinase and p38 in the cell nucleus.  These properties, coupled with transcriptional regulation of MKP expression in response to stimuli that activate MAPK signaling, suggest a complex neg. regulatory network in which individual MAPK activities can be subject to neg. feedback control, but also raise the possibility that signaling through multiple MAPK pathways may be integrated at the level of regulation by MKPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCRQreSvWHwbVg90H21EOLACvtfcHk0lgEeQVfTZeGLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktL0%253D&md5=02c50290ecf041cb33318272ca5c8024</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210412%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DD.%2BM.%26aulast%3DKeyse%26aufirst%3DS.%2BM.%26atitle%3DDifferential%2520Regulation%2520of%2520MAP%2520Kinase%2520Signalling%2520By%2520Dual-Specificity%2520Protein%2520Phosphatases%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26issue%3D22%26spage%3D3203%26epage%3D3213%26doi%3D10.1038%2Fsj.onc.1210412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vakiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">KRAS and BRAF: Drug Targets and Predictive Biomarkers</span>. <i>J. Pathol</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>223</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1002/path.2796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1002%2Fpath.2796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2011&pages=220-230&issue=2&author=E.+Vakianiauthor=D.+B.+Solit&title=KRAS+and+BRAF%3A+Drug+Targets+and+Predictive+Biomarkers&doi=10.1002%2Fpath.2796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fpath.2796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2796%26sid%3Dliteratum%253Aachs%26aulast%3DVakiani%26aufirst%3DE.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DKRAS%2520and%2520BRAF%253A%2520Drug%2520Targets%2520and%2520Predictive%2520Biomarkers%26jtitle%3DJ.%2520Pathol%26date%3D2011%26volume%3D223%26issue%3D2%26spage%3D220%26epage%3D230%26doi%3D10.1002%2Fpath.2796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebolt-Leopold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">BRAF Mutation Predicts Sensitivity to MEK Inhibition</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>439</i></span> (<span class="NLM_issue">7074</span>),  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1038/nature04304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1038%2Fnature04304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=16273091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=439&publication_year=2006&pages=358-362&issue=7074&author=D.+B.+Solitauthor=L.+A.+Garrawayauthor=C.+A.+Pratilasauthor=A.+Sawaiauthor=G.+Getzauthor=A.+Bassoauthor=Q.+Yeauthor=J.+M.+Loboauthor=Y.+Sheauthor=I.+Osmanauthor=T.+R.+Golubauthor=J.+Sebolt-Leopoldauthor=W.+R.+Sellersauthor=N.+Rosen&title=BRAF+Mutation+Predicts+Sensitivity+to+MEK+Inhibition&doi=10.1038%2Fnature04304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF mutation predicts sensitivity to MEK inhibition</span></div><div class="casAuthors">Solit, David B.; Garraway, Levi A.; Pratilas, Christine A.; Sawai, Ayana; Getz, Gad; Basso, Andrea; Ye, Qing; Lobo, Jose M.; She, Yuhong; Osman, Iman; Golub, Todd R.; Sebolt-Leopold, Judith; Sellers, William R.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">439</span>
        (<span class="NLM_cas:issue">7074</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumors, often through gain-of-function mutations of RAS and RAF family members.  Using small-mol. inhibitors of MEK and an integrated genetic and pharmacol. anal., we find that mutation of BRAF is assocd. with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harboring a RAS mutation.  This MEK dependency was obsd. in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest.  Pharmacol. MEK inhibition completely abrogated tumor growth in BRAF mutant xenografts, whereas RAS mutant tumors were only partially inhibited.  These data suggest an exquisite dependency on MEK activity in BRAF mutant tumors, and offer a rational therapeutic strategy for this genetically defined tumor subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpBpONOvd0vbVg90H21EOLACvtfcHk0li90TlCn5v_Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2mtw%253D%253D&md5=37c8976aa5bb371ef5580aab2a91f89e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature04304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04304%26sid%3Dliteratum%253Aachs%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DSawai%26aufirst%3DA.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DBasso%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DLobo%26aufirst%3DJ.%2BM.%26aulast%3DShe%26aufirst%3DY.%26aulast%3DOsman%26aufirst%3DI.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DBRAF%2520Mutation%2520Predicts%2520Sensitivity%2520to%2520MEK%2520Inhibition%26jtitle%3DNature%26date%3D2006%26volume%3D439%26issue%3D7074%26spage%3D358%26epage%3D362%26doi%3D10.1038%2Fnature04304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dwyer, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Mutated, Activated BRAF in Metastatic Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1002011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&issue=9&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+Mutated%2C+Activated+BRAF+in+Metastatic+Melanoma&doi=10.1056%2FNEJMoa1002011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0li90TlCn5v_Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520Mutated%252C%2520Activated%2520BRAF%2520in%2520Metastatic%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D9%26spage%3D809%26epage%3D819%26doi%3D10.1056%2FNEJMoa1002011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span> <span> </span><span class="NLM_article-title">Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1210093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1056%2FNEJMoa1210093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=23020132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1694-1703&issue=18&author=K.+T.+Flahertyauthor=J.+R.+Infanteauthor=A.+Daudauthor=R.+Gonzalezauthor=R.+F.+Keffordauthor=J.+Sosmanauthor=O.+Hamidauthor=L.+Schuchterauthor=J.+Cebonauthor=N.+Ibrahimauthor=R.+Kudchadkarauthor=H.+A.+Burrisauthor=G.+Falchookauthor=A.+Algaziauthor=K.+Lewisauthor=G.+V.+Longauthor=I.+Puzanovauthor=P.+Lebowitzauthor=A.+Singhauthor=S.+Littleauthor=P.+Sunauthor=A.+Allredauthor=D.+Ouelletauthor=K.+B.+Kimauthor=K.+Patelauthor=J.+Weber&title=Combined+BRAF+and+MEK+Inhibition+in+Melanoma+with+BRAF+V600+Mutations&doi=10.1056%2FNEJMoa1210093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span></div><div class="casAuthors">Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Resistance to therapy with BRAF kinase inhibitors is assocd. with reactivation of the mitogen-activated protein kinase (MAPK) pathway.  To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.  METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy.  The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.  Secondary end points were overall survival and pharmacokinetic activity.  RESULTS Dose-limiting toxic effects were infrequently obsd. in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2).  Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%).  Median progression-free survival in the combination 150/2 group was 9.4 mo, as compared with 5.8 mo in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001).  The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).  CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses.  The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced.  Progression-free survival was significantly improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk7I8zrGTVbVg90H21EOLACvtfcHk0ljRNBAXDoJeWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ&md5=199ae281d44c3b41309b934d88674cd3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1210093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1210093%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLittle%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DAllred%26aufirst%3DA.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520Inhibition%2520in%2520Melanoma%2520with%2520BRAF%2520V600%2520Mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D18%26spage%3D1694%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1210093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang-Gillam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchbinder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacouture, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Crescenzo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groover, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varterasian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsch, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span> <span> </span><span class="NLM_article-title">First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-1119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1158%2F2159-8290.CD-17-1119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=29247021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFCrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=184-195&issue=2&author=R.+J.+Sullivanauthor=J.+R.+Infanteauthor=F.+Jankuauthor=D.+J.+L.+Wongauthor=J.+A.+Sosmanauthor=V.+Keedyauthor=M.+R.+Patelauthor=G.+I.+Shapiroauthor=J.+W.+Mierauthor=A.+W.+Tolcherauthor=A.+Wang-Gillamauthor=M.+Sznolauthor=K.+Flahertyauthor=E.+Buchbinderauthor=R.+D.+Carvajalauthor=A.+M.+Vargheseauthor=M.+E.+Lacoutureauthor=A.+Ribasauthor=S.+P.+Patelauthor=G.+A.+De+Crescenzoauthor=C.+M.+Emeryauthor=A.+L.+Grooverauthor=S.+Sahaauthor=M.+Varterasianauthor=D.+J.+Welschauthor=D.+M.+Hymanauthor=B.+T.+Li&title=First-in-Class+ERK1%2F2+Inhibitor+Ulixertinib+%28BVD-523%29+in+Patients+with+MAPK+Mutant+Advanced+Solid+Tumors%3A+Results+of+a+Phase+I+Dose-Escalation+and+Expansion+Study&doi=10.1158%2F2159-8290.CD-17-1119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study</span></div><div class="casAuthors">Sullivan, Ryan J.; Infante, Jeffrey R.; Janku, Filip; Wong, Deborah Jean Lee; Sosman, Jeffrey A.; Keedy, Vicki; Patel, Manish R.; Shapiro, Geoffrey I.; Mier, James W.; Tolcher, Anthony W.; Wang-Gillam, Andrea; Sznol, Mario; Flaherty, Keith; Buchbinder, Elizabeth; Carvajal, Richard D.; Varghese, Anna M.; Lacouture, Mario E.; Ribas, Antoni; Patel, Sapna P.; De Crescenzo, Gary A.; Emery, Caroline M.; Groover, Anna L.; Saha, Saurabh; Varterasian, Mary; Welsch, Dean J.; Hyman, David M.; Li, Bob T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-195</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclin. activity in BRAF- and RAS-mutant cell lines.  In this multicenter phase I trial (NCT01781429), 135 patients were enrolled to an accelerated 3 + 3 dose-escalation cohort and six distinct dose-expansion cohorts.  Dose escalation included 27 patients, dosed from 10 to 900 mg twice daily and established the recommended phase II dose (RP2D) of 600 mg twice daily.  Ulixertinib exposure was dose proportional to the RP2D, which provided near-complete inhibition of ERK activity in whole blood.  In the 108-patient expansion cohort, 32% of patients required dose redn.  The most common treatment-related adverse events were diarrhea (48%), fatigue (42%), nausea (41%), and dermatitis acneiform (31%).  Partial responses were seen in 3 of 18 (17%) patients dosed at or above max. tolerated dose and in 11 of 81 (14%) evaluable patients in dose expansion.  Responses occurred in patients with NRAS-, BRAF V600-, and non-V600 BRAF-mutant solid tumors.  Here, we describe the first-in-human dose-escalation study of an ERK1/2 inhibitor for the treatment of patients with advanced solid tumors.  Ulixertinib has an acceptable safety profile with favorable pharmacokinetics and has shown early evidence of clin. activity in NRAS- and BRAF V600- and non-V600-mutant solid-tumor malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYm_KSTskkaLVg90H21EOLACvtfcHk0ljRNBAXDoJeWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFCrt7w%253D&md5=9ddff8422bdf7e7d605cb069741058fc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-1119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-1119%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DWong%26aufirst%3DD.%2BJ.%2BL.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKeedy%26aufirst%3DV.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DMier%26aufirst%3DJ.%2BW.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DWang-Gillam%26aufirst%3DA.%26aulast%3DSznol%26aufirst%3DM.%26aulast%3DFlaherty%26aufirst%3DK.%26aulast%3DBuchbinder%26aufirst%3DE.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DVarghese%26aufirst%3DA.%2BM.%26aulast%3DLacouture%26aufirst%3DM.%2BE.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DS.%2BP.%26aulast%3DDe%2BCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DEmery%26aufirst%3DC.%2BM.%26aulast%3DGroover%26aufirst%3DA.%2BL.%26aulast%3DSaha%26aufirst%3DS.%26aulast%3DVarterasian%26aufirst%3DM.%26aulast%3DWelsch%26aufirst%3DD.%2BJ.%26aulast%3DHyman%26aufirst%3DD.%2BM.%26aulast%3DLi%26aufirst%3DB.%2BT.%26atitle%3DFirst-in-Class%2520ERK1%252F2%2520Inhibitor%2520Ulixertinib%2520%2528BVD-523%2529%2520in%2520Patients%2520with%2520MAPK%2520Mutant%2520Advanced%2520Solid%2520Tumors%253A%2520Results%2520of%2520a%2520Phase%2520I%2520Dose-Escalation%2520and%2520Expansion%2520Study%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D2%26spage%3D184%26epage%3D195%26doi%3D10.1158%2F2159-8290.CD-17-1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restaino, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayananth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNunzio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angagaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipps, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daublain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliphaivanh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&issue=7&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+DiNunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagawauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+A.+Samatar&title=Discovery+of+a+Novel+ERK+Inhibitor+with+Activity+in+Models+of+Acquired+Resistance+to+BRAF+and+MEK+Inhibitors&doi=10.1158%2F2159-8290.CD-13-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0lgcxu5pNPctrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDiNunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520ERK%2520Inhibitor%2520with%2520Activity%2520in%2520Models%2520of%2520Acquired%2520Resistance%2520to%2520BRAF%2520and%2520MEK%2520Inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D7%26spage%3D742%26epage%3D750%26doi%3D10.1158%2F2159-8290.CD-13-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moschos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawbi, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, T. S.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miselis, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayananth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipps, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Development of MK-8353, an Orally Administered ERK1/2 Inhibitor, in Patients with Advanced Solid Tumors</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">e92352</span>, <span class="refDoi"> DOI: 10.1172/jci.insight.92352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1172%2Fjci.insight.92352" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=29467321" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=e92352&issue=4&author=S.+J.+Moschosauthor=R.+J.+Sullivanauthor=W.+J.+Hwuauthor=R.+K.+Ramanathanauthor=A.+A.+Adjeiauthor=P.+C.+Fongauthor=R.+Shapira-Frommerauthor=H.+A.+Tawbiauthor=J.+Rubinoauthor=T.+S.+Rushauthor=D.+Zhangauthor=N.+R.+Miselisauthor=A.+A.+Samatarauthor=P.+Chunauthor=E.+H.+Rubinauthor=J.+Schillerauthor=B.+J.+Longauthor=P.+Dayananthauthor=D.+Carrauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=Y.+Dengauthor=A.+Cooperauthor=G.+W.+Shippsauthor=B.+H.+Morenoauthor=L.+Robertauthor=A.+Ribasauthor=K.+T.+Flaherty&title=Development+of+MK-8353%2C+an+Orally+Administered+ERK1%2F2+Inhibitor%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1172%2Fjci.insight.92352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.92352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.92352%26sid%3Dliteratum%253Aachs%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DTawbi%26aufirst%3DH.%2BA.%26aulast%3DRubino%26aufirst%3DJ.%26aulast%3DRush%26aufirst%3DT.%2BS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMiselis%26aufirst%3DN.%2BR.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DChun%26aufirst%3DP.%26aulast%3DRubin%26aufirst%3DE.%2BH.%26aulast%3DSchiller%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DB.%2BJ.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DShipps%26aufirst%3DG.%2BW.%26aulast%3DMoreno%26aufirst%3DB.%2BH.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DDevelopment%2520of%2520MK-8353%252C%2520an%2520Orally%2520Administered%2520ERK1%252F2%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJCI%2520Insight%26date%3D2018%26volume%3D3%26issue%3D4%26spage%3De92352%26doi%3D10.1172%2Fjci.insight.92352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linghu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudino, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of GDC-0994: A Selective and Efficacious Small Molecule Inhibitor of ERK1/2</span>. <i>Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 1</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1307</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1021/bk-2018-1307.ch001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bk-2018-1307.ch001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1307&publication_year=2018&pages=1-28&author=X.+Linghuauthor=N.+Wongauthor=J.+F.+Blakeauthor=J.+J.+Gaudinoauthor=J.+G.+Moffat&title=Discovery+and+Development+of+GDC-0994%3A+A+Selective+and+Efficacious+Small+Molecule+Inhibitor+of+ERK1%2F2&doi=10.1021%2Fbk-2018-1307.ch001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fbk-2018-1307.ch001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbk-2018-1307.ch001%26sid%3Dliteratum%253Aachs%26aulast%3DLinghu%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DN.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DGaudino%26aufirst%3DJ.%2BJ.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520GDC-0994%253A%2520A%2520Selective%2520and%2520Efficacious%2520Small%2520Molecule%2520Inhibitor%2520of%2520ERK1%252F2%26jtitle%3DComplete%2520Accounts%2520of%2520Integrated%2520Drug%2520Discovery%2520and%2520Development%253A%2520Recent%2520Examples%2520from%2520the%2520Pharmaceutical%2520Industry%2520Volume%25201%26date%3D2018%26volume%3D1307%26spage%3D1%26epage%3D28%26doi%3D10.1021%2Fbk-2018-1307.ch001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillen, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flack, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dropsey, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiu, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery of LY3214996, a Selective and Novel ERK1/2 Inhibitor with Potent Antitumor Activities in Cancer Models with MAPK pathway</span>. <i>Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4973</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-4973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1158%2F1538-7445.AM2017-4973" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4973&issue=13&author=S.+V.+Bhagwatauthor=W.+T.+McMillenauthor=S.+Caiauthor=B.+Zhaoauthor=M.+Whitesellauthor=L.+Kindlerauthor=R.+S.+Flackauthor=W.+Wuauthor=K.+Hussauthor=B.+Andersonauthor=X.-J.+Yuanauthor=S.+Jakenauthor=D.+McCannauthor=B.+Mathesauthor=A.+J.+Dropseyauthor=J.+Manroauthor=J.+Walgrenauthor=E.+Yuenauthor=X.+Gongauthor=M.+J.+Rodriguezauthor=J.+Huangauthor=R.+V.+Tiuauthor=S.+Josephauthor=S.-B.+Peng&title=Discovery+of+LY3214996%2C+a+Selective+and+Novel+ERK1%2F2+Inhibitor+with+Potent+Antitumor+Activities+in+Cancer+Models+with+MAPK+pathway&doi=10.1158%2F1538-7445.AM2017-4973"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-4973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-4973%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwat%26aufirst%3DS.%2BV.%26aulast%3DMcMillen%26aufirst%3DW.%2BT.%26aulast%3DCai%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DWhitesell%26aufirst%3DM.%26aulast%3DKindler%26aufirst%3DL.%26aulast%3DFlack%26aufirst%3DR.%2BS.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DX.-J.%26aulast%3DJaken%26aufirst%3DS.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DMathes%26aufirst%3DB.%26aulast%3DDropsey%26aufirst%3DA.%2BJ.%26aulast%3DManro%26aufirst%3DJ.%26aulast%3DWalgren%26aufirst%3DJ.%26aulast%3DYuen%26aufirst%3DE.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DRodriguez%26aufirst%3DM.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DTiu%26aufirst%3DR.%2BV.%26aulast%3DJoseph%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DS.-B.%26atitle%3DDiscovery%2520of%2520LY3214996%252C%2520a%2520Selective%2520and%2520Novel%2520ERK1%252F2%2520Inhibitor%2520with%2520Potent%2520Antitumor%2520Activities%2520in%2520Cancer%2520Models%2520with%2520MAPK%2520pathway%26jtitle%3DProceedings%253A%2520AACR%2520Annual%2520Meeting%25202017%253B%2520April%25201-5%252C%25202017%253B%2520Washington%252C%2520DC%26date%3D2017%26volume%3D77%26issue%3D13%26spage%3D4973%26doi%3D10.1158%2F1538-7445.AM2017-4973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronchik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavrommatis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filvaroff, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beebe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">642</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-17-0554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1158%2F1541-7786.MCR-17-0554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=30275173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=642-654&issue=2&author=I.+Aronchikauthor=Y.+Daiauthor=M.+Malekauthor=K.+Mavrommatisauthor=G.+L.+Brayauthor=E.+H.+Filvaroffauthor=M.+Labenskiauthor=C.+Barnesauthor=T.+Jonesauthor=L.+Qiaoauthor=L.+Beebeauthor=W.+Elisauthor=T.+Shi&title=Efficacy+of+a+Covalent+ERK1%2F2+Inhibitor%2C+CC-90003%2C+in+KRAS-Mutant+Cancer+Models+Reveals+Novel+Mechanisms+of+Response+and+Resistance&doi=10.1158%2F1541-7786.MCR-17-0554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a covalent ERK1/2 inhibitor, CC-90003, in KRAS-mutant cancer models reveals novel mechanisms of response and resistance</span></div><div class="casAuthors">Aronchik, Ida; Dai, Yumin; Labenski, Matt; Barnes, Carmen; Jones, Terri; Qiao, Lixin; Beebe, Lisa; Malek, Mehnaz; Elis, Winfried; Shi, Tao; Mavrommatis, Konstantinos; Bray, Gordon L.; Filvaroff, Ellen H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">642-654</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">As a crit. signaling node, ERK1/2 are attractive drug targets, particularly in tumors driven by activation of the MAPK pathway.  Utility of targeting the MAPK pathway has been demonstrated by clin. responses to inhibitors of MEK1/2 or RAF kinases in some mutant BRAF-activated malignancies.  Unlike tumors with mutations in BRAF, those with mutations in KRAS (>30% of all cancers and >90% of certain cancer types) are generally not responsive to inhibitors of MEK1/2 or RAF.  Here, a covalent ERK1/2 inhibitor, CC-90003, was characterized and shown to be active in preclin. models of KRAS-mutant tumors.  A unique occupancy assay was used to understand the mechanism of resistance in a KRAS-mutant patient-derived xenograft (PDX) model of colorectal cancer.  Finally, combination of CC-90003 with docetaxel achieved full tumor regression and prevented tumor regrowth after cessation of treatment in a PDX model of lung cancer.  This effect corresponded to changes in a stemness gene network, revealing a potential effect on tumor stem cell reprograming.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFCCEbE4dt8bVg90H21EOLACvtfcHk0lhKm7X7cV-LjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCltrg%253D&md5=66f18cb85cdcb558e20cd213d791f4ac</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-17-0554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-17-0554%26sid%3Dliteratum%253Aachs%26aulast%3DAronchik%26aufirst%3DI.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DMalek%26aufirst%3DM.%26aulast%3DMavrommatis%26aufirst%3DK.%26aulast%3DBray%26aufirst%3DG.%2BL.%26aulast%3DFilvaroff%26aufirst%3DE.%2BH.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DBarnes%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DQiao%26aufirst%3DL.%26aulast%3DBeebe%26aufirst%3DL.%26aulast%3DElis%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DT.%26atitle%3DEfficacy%2520of%2520a%2520Covalent%2520ERK1%252F2%2520Inhibitor%252C%2520CC-90003%252C%2520in%2520KRAS-Mutant%2520Cancer%2520Models%2520Reveals%2520Novel%2520Mechanisms%2520of%2520Response%2520and%2520Resistance%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2019%26volume%3D17%26issue%3D2%26spage%3D642%26epage%3D654%26doi%3D10.1158%2F1541-7786.MCR-17-0554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span> </span><span class="NLM_article-title">A Phase I Clinical
Study
With Investigational Compound LTT462 in Adult Patients With Specific
Advanced Cancers</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT02711345" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02711345</a> (accessed June 1, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+Phase+I+Clinical%0AStudy%0AWith+Investigational+Compound+LTT462+in+Adult+Patients+With+Specific%0AAdvanced+Cancers.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02711345+%28accessed+June+1%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DA%2520Phase%2520I%2520Clinical%250AStudy%250AWith%2520Investigational%2520Compound%2520LTT462%2520in%2520Adult%2520Patients%2520With%2520Specific%250AAdvanced%2520Cancers" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span> </span><span class="NLM_article-title">First-in-Human Study
of KO-947 in Non-Hematological Malignancies</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03051035" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03051035</a> (accessed June 1, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+First-in-Human+Study%0Aof+KO-947+in+Non-Hematological+Malignancies.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03051035+%28accessed+June+1%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DFirst-in-Human%2520Study%250Aof%2520KO-947%2520in%2520Non-Hematological%2520Malignancies" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braithwaite, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths-Jones, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muench, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munck, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathuri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saini, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilsher, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onions, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4978</span>– <span class="NLM_lpage">4992</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00421</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00421" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps12lsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4978-4992&issue=11&author=T.+D.+Heightmanauthor=V.+Berdiniauthor=H.+Braithwaiteauthor=I.+M.+Buckauthor=M.+Cassidyauthor=J.+Castroauthor=A.+Courtinauthor=J.+E.+H.+Dayauthor=C.+Eastauthor=L.+Fazalauthor=B.+Grahamauthor=C.+M.+Griffiths-Jonesauthor=J.+F.+Lyonsauthor=V.+Martinsauthor=S.+Muenchauthor=J.+M.+Munckauthor=D.+Nortonauthor=M.+O%E2%80%99Reillyauthor=N.+Palmerauthor=P.+Pathuriauthor=M.+Readerauthor=D.+C.+Reesauthor=S.+J.+Richauthor=C.+Richardsonauthor=H.+Sainiauthor=N.+T.+Thompsonauthor=N.+G.+Wallisauthor=H.+Waltonauthor=N.+E.+Wilsherauthor=A.+J.+A.+Woolfordauthor=C.+W.+Murrayauthor=M.+Cookeauthor=D.+Cousinauthor=S.+Onionsauthor=J.+Shannonauthor=J.+Watts&title=Fragment-Based+Discovery+of+a+Potent%2C+Orally+Bioavailable+Inhibitor+That+Modulates+the+Phosphorylation+and+Catalytic+Activity+of+ERK1%2F2&doi=10.1021%2Facs.jmedchem.8b00421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2</span></div><div class="casAuthors">Heightman, Tom D.; Berdini, Valerio; Braithwaite, Hannah; Buck, Ildiko M.; Cassidy, Megan; Castro, Juan; Courtin, Aurelie; Day, James E. H.; East, Charlotte; Fazal, Lynsey; Graham, Brent; Griffiths-Jones, Charlotte M.; Lyons, John F.; Martins, Vanessa; Muench, Sandra; Munck, Joanne M.; Norton, David; O'Reilly, Marc; Palmer, Nick; Pathuri, Puja; Reader, Michael; Rees, David C.; Rich, Sharna J.; Richardson, Caroline; Saini, Harpreet; Thompson, Neil T.; Wallis, Nicola G.; Walton, Hugh; Wilsher, Nicola E.; Woolford, Alison J.-A.; Cooke, Michael; Cousin, David; Onions, Stuart; Shannon, Jonathan; Watts, John; Murray, Christopher W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4978-4992</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant activation of the MAPK pathway drives cell proliferation in multiple cancers.  Inhibitors of BRAF and MEK kinases are approved for the treatment of BRAF mutant melanoma, but resistance frequently emerges, often mediated by increased signaling through ERK1/2.  Here, we describe the fragment-based generation of ERK1/2 inhibitors that block catalytic phosphorylation of downstream substrates such as RSK but also modulate phosphorylation of ERK1/2 by MEK without directly inhibiting MEK.  X-ray crystallog. and biophys. fragment screening followed by structure-guided optimization and growth from the hinge into a pocket proximal to the C-α helix afforded highly potent ERK1/2 inhibitors with excellent kinome selectivity.  In BRAF mutant cells, the lead compd. suppresses pRSK and pERK levels and inhibits proliferation at low nanomolar concns.  The lead exhibits tumor regression upon oral dosing in BRAF mutant xenograft models, providing a promising basis for further optimization toward clin. pERK1/2 modulating ERK1/2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqstOOt0nyKg7Vg90H21EOLACvtfcHk0ljFDvCU_QuZvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps12lsLY%253D&md5=c2bd7c16be85e5f6af5525ce60272aa1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00421%26sid%3Dliteratum%253Aachs%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBraithwaite%26aufirst%3DH.%26aulast%3DBuck%26aufirst%3DI.%2BM.%26aulast%3DCassidy%26aufirst%3DM.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DCourtin%26aufirst%3DA.%26aulast%3DDay%26aufirst%3DJ.%2BE.%2BH.%26aulast%3DEast%26aufirst%3DC.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DGriffiths-Jones%26aufirst%3DC.%2BM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMuench%26aufirst%3DS.%26aulast%3DMunck%26aufirst%3DJ.%2BM.%26aulast%3DNorton%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DN.%26aulast%3DPathuri%26aufirst%3DP.%26aulast%3DReader%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%2BJ.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DSaini%26aufirst%3DH.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DWallis%26aufirst%3DN.%2BG.%26aulast%3DWalton%26aufirst%3DH.%26aulast%3DWilsher%26aufirst%3DN.%2BE.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%2BA.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCooke%26aufirst%3DM.%26aulast%3DCousin%26aufirst%3DD.%26aulast%3DOnions%26aufirst%3DS.%26aulast%3DShannon%26aufirst%3DJ.%26aulast%3DWatts%26aufirst%3DJ.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Potent%252C%2520Orally%2520Bioavailable%2520Inhibitor%2520That%2520Modulates%2520the%2520Phosphorylation%2520and%2520Catalytic%2520Activity%2520of%2520ERK1%252F2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D11%26spage%3D4978%26epage%3D4992%26doi%3D10.1021%2Facs.jmedchem.8b00421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">ClinicalTrials.gov</span>. <span> </span><span class="NLM_article-title">A Study
of ASN007 in
Patients With Advanced Solid Tumors</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03415126" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03415126</a> (accessed June 1, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov.+A+Study%0Aof+ASN007+in%0APatients+With+Advanced+Solid+Tumors.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03415126+%28accessed+June+1%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DA%2520Study%250Aof%2520ASN007%2520in%250APatients%2520With%2520Advanced%2520Solid%2520Tumors" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemington, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopcroft, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Gallay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, B.</span></span> <span> </span><span class="NLM_article-title">Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3438</span>– <span class="NLM_lpage">3450</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00267</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00267" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3438-3450&issue=8&author=R.+A.+Wardauthor=P.+Bethelauthor=C.+Cookauthor=E.+Daviesauthor=J.+E.+Debreczeniauthor=G.+Fairleyauthor=L.+Feronauthor=V.+Flemingtonauthor=M.+A.+Grahamauthor=R.+Greenwoodauthor=N.+Griffinauthor=L.+Hansonauthor=P.+Hopcroftauthor=T.+D.+Howardauthor=J.+Hudsonauthor=M.+Jamesauthor=C.+D.+Jonesauthor=C.+R.+Jonesauthor=S.+Lamontauthor=R.+Lewisauthor=N.+Lindsayauthor=K.+Robertsauthor=I.+Simpsonauthor=S.+St-Gallayauthor=S.+Swallowauthor=J.+Tangauthor=M.+Tongeauthor=Z.+Wangauthor=B.+Zhai&title=Structure-Guided+Discovery+of+Potent+and+Selective+Inhibitors+of+ERK1%2F2+from+a+Modestly+Active+and+Promiscuous+Chemical+Start+Point&doi=10.1021%2Facs.jmedchem.7b00267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point</span></div><div class="casAuthors">Ward, Richard A.; Bethel, Paul; Cook, Calum; Davies, Emma; Debreczeni, Judit E.; Fairley, Gary; Feron, Lyman; Flemington, Vikki; Graham, Mark A.; Greenwood, Ryan; Griffin, Nicola; Hanson, Lyndsey; Hopcroft, Philip; Howard, Tina D.; Hudson, Julian; James, Michael; Jones, Clifford D.; Jones, Christopher R.; Lamont, Scott; Lewis, Richard; Lindsay, Nicola; Roberts, Karen; Simpson, Iain; St-Gallay, Steve; Swallow, Steve; Tang, Jia; Tonge, Michael; Wang, Zhenhua; Zhai, Baochang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3438-3450</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are a no. of small-mol. inhibitors targeting the RAS/RAF/MEK/ERK signaling pathway that have either been approved or are in clin. development for oncol. across a range of disease indications.  The inhibition of ERK1/2 is of significant current interest, as cell lines with acquired resistance to BRAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition in preclin. models.  This article reports on authors' recent work to identify novel, potent, and selective reversible ERK1/2 inhibitors from a low-mol.-wt., modestly active, and highly promiscuous chem. start point, compd. I.  To guide and inform the evolution of this series, inhibitor binding mode information from X-ray crystal structures was crit. in the rapid exploration of this template to compd. II, which was active when tested in in vivo antitumor efficacy expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokuJLRaK0sLLVg90H21EOLACvtfcHk0lhMQSz4ST02uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7c%253D&md5=2ab5cd30f6a9c887a9a21010b492cb34</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00267%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DBethel%26aufirst%3DP.%26aulast%3DCook%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DE.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DFairley%26aufirst%3DG.%26aulast%3DFeron%26aufirst%3DL.%26aulast%3DFlemington%26aufirst%3DV.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DGriffin%26aufirst%3DN.%26aulast%3DHanson%26aufirst%3DL.%26aulast%3DHopcroft%26aufirst%3DP.%26aulast%3DHoward%26aufirst%3DT.%2BD.%26aulast%3DHudson%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BR.%26aulast%3DLamont%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DR.%26aulast%3DLindsay%26aufirst%3DN.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DSimpson%26aufirst%3DI.%26aulast%3DSt-Gallay%26aufirst%3DS.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhai%26aufirst%3DB.%26atitle%3DStructure-Guided%2520Discovery%2520of%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520ERK1%252F2%2520from%2520a%2520Modestly%2520Active%2520and%2520Promiscuous%2520Chemical%2520Start%2520Point%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D8%26spage%3D3438%26epage%3D3450%26doi%3D10.1021%2Facs.jmedchem.7b00267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">VanScyoc, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holdgate, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, W. H. J.</span></span> <span> </span><span class="NLM_article-title">Enzyme Kinetics and Binding Studies on Inhibitors of MEK Protein Kinase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">5017</span>– <span class="NLM_lpage">5027</span>, <span class="refDoi"> DOI: 10.1021/bi701811x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi701811x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksVSgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=5017-5027&issue=17&author=W.+S.+VanScyocauthor=G.+A.+Holdgateauthor=J.+E.+Sullivanauthor=W.+H.+J.+Ward&title=Enzyme+Kinetics+and+Binding+Studies+on+Inhibitors+of+MEK+Protein+Kinase&doi=10.1021%2Fbi701811x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Enzyme Kinetics and Binding Studies on Inhibitors of MEK Protein Kinase</span></div><div class="casAuthors">VanScyoc, Wendy S.; Holdgate, Geoffrey A.; Sullivan, Jane E.; Ward, Walter H. J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5017-5027</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the protein kinase, MEK1, is a potential approach for the treatment of cancer.  Inhibitors may act by prevention of activation (PoA), which involves interfering with phosphorylation of nonactivated MEK1 by the upstream kinase, B-RAF.  Modulation also may occur by inhibition of catalysis (IoC) during phosphorylation of the downstream substrate, ERK2, by activated MEK1.  Here, five MEK inhibitors are characterized in terms of binding affinity, PoA, and IoC.  The compds. are a butadiene (U-0126), an N-alkoxy amide (CI-1040), two CI-1040 analogs (an anthranilic acid and an N-alkyl amide), and a cyanoquinoline.  Some compds. give different mechanisms of inhibition (ATP-competitive, noncompetitive, or uncompetitive) in PoA compared to IoC or show a change in potency between the assays.  The inhibitors also exhibit different shifts in potency when either PoA or IoC is compared with binding to nonactivated MEK.  The inhibitor potency ranking, therefore, is dependent upon the assay format.  When the ATP concn. equals Km, IoC IC50 increases in the order CI-1040 ≈ cyanoquinoline ≤ anthranilic acid ≈ U-0126 < alkyl amide.  Conversely, the Kd from nonactivated MEK1 for four of the compds. varies between more than 6-fold lower and over 18-fold higher than this IC50, with U-0126 having the lowest Kd and CI-1040 having the highest.  In PoA when the ATP concn. equals Km, U-0126 has the lowest IC50, becoming more potent than CI-1040, the cyanoquinoline, and the anthranilic acid.  These observations have implications for understanding structure-activity relationships of MEK inhibitors and illustrate how assays can be designed to favor different compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmkJnmjsHeO7Vg90H21EOLACvtfcHk0lhMQSz4ST02uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksVSgsLo%253D&md5=88fa65b9c8e43e674b79208720e8d8fd</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fbi701811x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi701811x%26sid%3Dliteratum%253Aachs%26aulast%3DVanScyoc%26aufirst%3DW.%2BS.%26aulast%3DHoldgate%26aufirst%3DG.%2BA.%26aulast%3DSullivan%26aufirst%3DJ.%2BE.%26aulast%3DWard%26aufirst%3DW.%2BH.%2BJ.%26atitle%3DEnzyme%2520Kinetics%2520and%2520Binding%2520Studies%2520on%2520Inhibitors%2520of%2520MEK%2520Protein%2520Kinase%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26issue%3D17%26spage%3D5017%26epage%3D5027%26doi%3D10.1021%2Fbi701811x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafleur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevado, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caflisch, A.</span></span> <span> </span><span class="NLM_article-title">Kinase Selectivity Potential for Inhibitors Targeting the ATP Binding Site: A Network Analysis</span>. <i>Bioinformatics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1093/bioinformatics/btp650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1093%2Fbioinformatics%2Fbtp650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=19942586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2010&pages=198-204&issue=2&author=D.+Huangauthor=T.+Zhouauthor=K.+Lafleurauthor=C.+Nevadoauthor=A.+Caflisch&title=Kinase+Selectivity+Potential+for+Inhibitors+Targeting+the+ATP+Binding+Site%3A+A+Network+Analysis&doi=10.1093%2Fbioinformatics%2Fbtp650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis</span></div><div class="casAuthors">Huang, Danzhi; Zhou, Ting; Lafleur, Karine; Nevado, Cristina; Caflisch, Amedeo</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-204</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4803</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Small-mol. inhibitors targeting the ATP binding pocket of the catalytic domain of protein kinases have potential to become drugs devoid of (major) side effects, particularly if they bind selectively.  Here, the sequences of the 518 human kinases are first mapped onto the structural alignment of 116 kinases of known three-dimensional structure.  The multiple structure alignment is then used to encode the known strategies for developing selective inhibitors into a fingerprint.  Finally, a network anal. is used to partition the kinases into clusters according to similarity of their fingerprints, i.e., physico-chem. characteristics of the residues responsible for selective binding.  For each kinase the network anal. reveals the likelihood to find selective inhibitors targeting the ATP binding site.  Systematic guidelines are proposed to develop selective inhibitors.  Importantly, the network anal. suggests that the tyrosine kinase EphB4 has high selectivity potential, which is consistent with the selectivity profile of two novel EphB4 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQVQsrpqB_ILVg90H21EOLACvtfcHk0lhMQSz4ST02uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlGkug%253D%253D&md5=b6c63ccd4654219a56752f9cfc1356a3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtp650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtp650%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DLafleur%26aufirst%3DK.%26aulast%3DNevado%26aufirst%3DC.%26aulast%3DCaflisch%26aufirst%3DA.%26atitle%3DKinase%2520Selectivity%2520Potential%2520for%2520Inhibitors%2520Targeting%2520the%2520ATP%2520Binding%2520Site%253A%2520A%2520Network%2520Analysis%26jtitle%3DBioinformatics%26date%3D2010%26volume%3D26%26issue%3D2%26spage%3D198%26epage%3D204%26doi%3D10.1093%2Fbioinformatics%2Fbtp650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Free, S. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. W.</span></span> <span> </span><span class="NLM_article-title">A Mathematical Contribution to Structure-Activity Studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1964</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1021/jm00334a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00334a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADyaF2cXkt1OltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1964&pages=395-399&issue=4&author=S.+M.+Freeauthor=J.+W.+Wilson&title=A+Mathematical+Contribution+to+Structure-Activity+Studies&doi=10.1021%2Fjm00334a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A mathematical contribution to structure-activity studies</span></div><div class="casAuthors">Free, Spencer M., Jr.; Wilson, James W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">395-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A math. technique is suggested as a means of describing structure-activity relation of a series of chem. analogs.  The data requirements included specific side chain arrangements and performance characteristics of all analogs tested.  Two examples illustrate the use of the additive math. model where the performance characteristics are measures of biol. activity.  The results rank the structural changes per position by estg. the amt. of biol. response attributed to each change.  The estimates are both pos. and neg.  Several uses for the math. soln. are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRyTj3xI-aH7Vg90H21EOLACvtfcHk0ljYYPB-vLtPVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXkt1OltbY%253D&md5=88fabb64d7a5635506a11418a2744bd6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm00334a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00334a001%26sid%3Dliteratum%253Aachs%26aulast%3DFree%26aufirst%3DS.%2BM.%26aulast%3DWilson%26aufirst%3DJ.%2BW.%26atitle%3DA%2520Mathematical%2520Contribution%2520to%2520Structure-Activity%2520Studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1964%26volume%3D7%26issue%3D4%26spage%3D395%26epage%3D399%26doi%3D10.1021%2Fjm00334a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muresan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeberlein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Chemical Predictive Modelling to Improve Compound Quality</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1038/nrd4128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1038%2Fnrd4128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=24287782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGrtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=948-962&issue=12&author=J.+G.+Cummingauthor=A.+M.+Davisauthor=S.+Muresanauthor=M.+Haeberleinauthor=H.+Chen&title=Chemical+Predictive+Modelling+to+Improve+Compound+Quality&doi=10.1038%2Fnrd4128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical predictive modelling to improve compound quality</span></div><div class="casAuthors">Cumming, John G.; Davis, Andrew M.; Muresan, Sorel; Haeberlein, Markus; Chen, Hongming</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">948-962</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The 'quality' of small-mol. drug candidates, encompassing aspects including their potency, selectivity and ADMET (absorption, distribution, metab., excretion and toxicity) characteristics, is a key factor influencing the chances of success in clin. trials.  Importantly, such characteristics are under the control of chemists during the identification and optimization of lead compds.  Here, we discuss the application of computational methods, particularly quant. structure-activity relationships (QSARs), in guiding the selection of higher-quality drug candidates, as well as cultural factors that may have affected their use and impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4XwzW0wcxYbVg90H21EOLACvtfcHk0ljYYPB-vLtPVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGrtLjF&md5=e0a4265bb306ae5544d00f3c9e3e4050</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd4128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4128%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BG.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26aulast%3DMuresan%26aufirst%3DS.%26aulast%3DHaeberlein%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DChemical%2520Predictive%2520Modelling%2520to%2520Improve%2520Compound%2520Quality%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26issue%3D12%26spage%3D948%26epage%3D962%26doi%3D10.1038%2Fnrd4128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grohganz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löbmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priemel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarp Jensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rades, T.</span></span> <span> </span><span class="NLM_article-title">Amorphous Drugs and Dosage Forms</span>. <i>J. Drug Delivery Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1016/S1773-2247(13)50057-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.1016%2FS1773-2247%2813%2950057-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCqsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=403-408&issue=4&author=H.+Grohganzauthor=K.+L%C3%B6bmannauthor=P.+Priemelauthor=K.+Tarp+Jensenauthor=K.+Graeserauthor=C.+Strachanauthor=T.+Rades&title=Amorphous+Drugs+and+Dosage+Forms&doi=10.1016%2FS1773-2247%2813%2950057-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Amorphous drugs and dosage forms</span></div><div class="casAuthors">Grohganz, H.; Lobmann, K.; Priemel, P.; Jensen, K. Tarp; Graeser, K.; Strachan, C.; Rades, T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Delivery Science and Technology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">403-408</span>CODEN:
                <span class="NLM_cas:coden">JDDSAL</span>;
        ISSN:<span class="NLM_cas:issn">1773-2247</span>.
    
            (<span class="NLM_cas:orgname">Editions de Sante</span>)
        </div><div class="casAbstract">A review.  The transformation to an amorphous form is one of the most promising approaches to address the low soly. of drug compds., the latter being an increasing challenge in the development of new drug candidates.  However, amorphous forms are high energy solids and tend to recrystallize.  New formulation principles are needed to ensure the stability of amorphous drug forms.  The formation of solid dispersions is still the most investigated approach, but addnl. approaches are desirable to overcome the shortcomings of solid dispersions.  Spatial sepn. by either coating or the use of micro-containers has shown potential to prevent or delay recrystn.  Another recent approach is the formation of co-amorphous mixts. between either two drugs or one drug and one low mol. wt. excipient.  Mol. interactions between the two mols. provide an energy barrier that has to be overcome before single mols. are available for the formation of crystal nuclei, thus stabilizing the amorphous form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvjnM1tqLHyrVg90H21EOLACvtfcHk0ljYYPB-vLtPVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCqsrbN&md5=e51f9cbeed9dcd64f196d80fa10cf673</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2FS1773-2247%2813%2950057-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1773-2247%252813%252950057-8%26sid%3Dliteratum%253Aachs%26aulast%3DGrohganz%26aufirst%3DH.%26aulast%3DL%25C3%25B6bmann%26aufirst%3DK.%26aulast%3DPriemel%26aufirst%3DP.%26aulast%3DTarp%2BJensen%26aufirst%3DK.%26aulast%3DGraeser%26aufirst%3DK.%26aulast%3DStrachan%26aufirst%3DC.%26aulast%3DRades%26aufirst%3DT.%26atitle%3DAmorphous%2520Drugs%2520and%2520Dosage%2520Forms%26jtitle%3DJ.%2520Drug%2520Delivery%2520Sci.%2520Technol.%26date%3D2013%26volume%3D23%26issue%3D4%26spage%3D403%26epage%3D408%26doi%3D10.1016%2FS1773-2247%2813%2950057-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGinnity, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, R. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Human Pharmacokinetics, Therapeutic Dose and Exposure Predictions Using Marketed Oral Drugs</span>. <i>Current Drug Metabolism</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.2174/138920007780866799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=10.2174%2F138920007780866799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=17584017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsl2jtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=463-479&issue=5&author=D.+F.+McGinnityauthor=J.+Collingtonauthor=R.+P.+Austinauthor=R.+J.+Riley&title=Evaluation+of+Human+Pharmacokinetics%2C+Therapeutic+Dose+and+Exposure+Predictions+Using+Marketed+Oral+Drugs&doi=10.2174%2F138920007780866799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs</span></div><div class="casAuthors">McGinnity, D. F.; Collington, J.; Austin, R. P.; Riley, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-479</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In this article approaches to predict human pharmacokinetics (PK) are discussed and the capability of the exemplified methodologies to est. individual PK parameters and therapeutic dose for a set of marketed oral drugs has been assessed.  For a set of 63 drugs where the min. efficacious concn. (MEC) and human PK were known, the clin. dose was shown to be well predicted or in some cases over-estd. using a simple one-compartment oral PK model.  For a subset of these drugs, in vitro potency against the primary human targets was gathered, and compared to the obsd. MEC.  When cor. for plasma protein binding, the MEC of the majority of compds. was ≤ 3 fold over the resp. in vitro target potency value.  A series of in vitro and in vivo expts. were conducted to predict the human PK parameters.  Metabolic clearance was generally predicted well from human hepatocytes.  Interestingly, for this compd. set, allometry or glomerular filtration rate (GFR) ratio methods appeared to be applicable for renal CL even where CLrenal > GFR.  For ∼90% of compds. studied, the predicted CL using in vitro-in vivo (IVIV) extrapolation together with a CLrenal est., where appropriate, was within 2-fold of that obsd. clin.  Encouragingly vol. of distribution at steady state (Vss) estd. in preclin. species (rat and dog) when cor. for plasma protein binding, predicted human Vss successfully on the majority of occasions - 73% of compds. within 2-fold.  In this lab., absorption estd. from oral rat PK studies was lower than the obsd. human absorption for most drugs, even when soly. and permeability appeared not to be limiting.  Preliminary data indicate absorption in the dog may be more representative of human for compds. absorbed via the transcellular pathway.  Using predicted PK and MEC values estd. from in vitro potency assays there was a good correlation between predicted and obsd. dose.  This anal. suggests that for oral therapies, human PK parameters and clin. dose can be estd. from a consideration of data obtained from in vitro screens using human derived material and in vivo animal studies.  The benefits and limitations of this holistic approach to PK and dose prediction within the drug discovery process are exemplified and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdbfKDFLO_UrVg90H21EOLACvtfcHk0liWjGjVsnM9DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsl2jtL4%253D&md5=765bdc4b870b660e813e36ae3719ddb5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F138920007780866799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007780866799%26sid%3Dliteratum%253Aachs%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DCollington%26aufirst%3DJ.%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26atitle%3DEvaluation%2520of%2520Human%2520Pharmacokinetics%252C%2520Therapeutic%2520Dose%2520and%2520Exposure%2520Predictions%2520Using%2520Marketed%2520Oral%2520Drugs%26jtitle%3DCurrent%2520Drug%2520Metabolism%26date%3D2007%26volume%3D8%26issue%3D5%26spage%3D463%26epage%3D479%26doi%3D10.2174%2F138920007780866799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challinor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckersley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemington, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopcroft, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renshaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K.</span></span> <span> </span><span class="NLM_article-title">Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4790</span>– <span class="NLM_lpage">4801</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4790-4801&issue=11&author=R.+A.+Wardauthor=N.+Colcloughauthor=M.+Challinorauthor=J.+E.+Debreczeniauthor=K.+Eckersleyauthor=G.+Fairleyauthor=L.+Feronauthor=V.+Flemingtonauthor=M.+A.+Grahamauthor=R.+Greenwoodauthor=P.+Hopcroftauthor=T.+D.+Howardauthor=M.+Jamesauthor=C.+D.+Jonesauthor=C.+R.+Jonesauthor=J.+Renshawauthor=K.+Robertsauthor=L.+Snowauthor=M.+Tongeauthor=K.+Yeung&title=Structure-Guided+Design+of+Highly+Selective+and+Potent+Covalent+Inhibitors+of+ERK1%2F2&doi=10.1021%2Facs.jmedchem.5b00466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2</span></div><div class="casAuthors">Ward, Richard A.; Colclough, Nicola; Challinor, Mairi; Debreczeni, Judit E.; Eckersley, Kay; Fairley, Gary; Feron, Lyman; Flemington, Vikki; Graham, Mark A.; Greenwood, Ryan; Hopcroft, Philip; Howard, Tina D.; James, Michael; Jones, Clifford D.; Jones, Christopher R.; Renshaw, Jonathan; Roberts, Karen; Snow, Lindsay; Tonge, Michael; Yeung, Kay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4790-4801</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The RAS/RAF/MEK/ERK signaling pathway has been targeted with a no. of small mol. inhibitors in oncol. clin. development across multiple disease indications.  Importantly, cell lines with acquired resistance to B-RAF and MEK inhibitors have been shown to maintain sensitivity to ERK1/2 inhibition by small mol. inhibitors.  There are a no. of selective, noncovalent ERK1/2 inhibitors reported along with the promiscuous hypothemycin (and related analogs) that act via a covalent mechanism of action.  This article reports the identification of multiple series of highly selective covalent ERK1/2 inhibitors informed by structure-based drug design (SBDD).  As a starting point for these covalent inhibitors, reported ERK1/2 inhibitors and a chem. series identified via high-throughput screening were exploited.  These approaches resulted in the identification of selective covalent tool compds. for potential in vitro and in vivo studies to assess the risks and or benefits of targeting this pathway through such a mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLDLwUCW_ANrVg90H21EOLACvtfcHk0liWjGjVsnM9DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVChs7c%253D&md5=40b47d8671c966434434f056ac88b3a7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00466%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEckersley%26aufirst%3DK.%26aulast%3DFairley%26aufirst%3DG.%26aulast%3DFeron%26aufirst%3DL.%26aulast%3DFlemington%26aufirst%3DV.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHopcroft%26aufirst%3DP.%26aulast%3DHoward%26aufirst%3DT.%2BD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DJones%26aufirst%3DC.%2BR.%26aulast%3DRenshaw%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DK.%26aulast%3DSnow%26aufirst%3DL.%26aulast%3DTonge%26aufirst%3DM.%26aulast%3DYeung%26aufirst%3DK.%26atitle%3DStructure-Guided%2520Design%2520of%2520Highly%2520Selective%2520and%2520Potent%2520Covalent%2520Inhibitors%2520of%2520ERK1%252F2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D11%26spage%3D4790%26epage%3D4801%26doi%3D10.1021%2Facs.jmedchem.5b00466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NHP','PDB','5NHP'); return false;">PDB: 5NHP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SLG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SLG','PDB','6SLG'); return false;">PDB: 6SLG</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i46"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01295">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_86364"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01295?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01295</a>. <ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional data analyses, experimental information, compound molecular formula strings, and compound characterization (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_001.pdf">PDF</a>)</p></li><li><p class="inline">ERK2 biochemical, kM ATP IC50 (μM); ERK2 biochemical, high ATP IC50 (μM); cell MOA A375 pERK IC50 (μM); cell MOA A375 pRSK IC50 (μM) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_001.pdf">jm9b01295_si_001.pdf (508.06 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01295/suppl_file/jm9b01295_si_002.csv">jm9b01295_si_002.csv (1.29 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates and structure factors have been deposited in the Protein Data Bank under the accession code 6SLG. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01295&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01295%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01295" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a81e01fe732cd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
